



Bibliometric analysis of ongoing projects

9th report
August 2018

Copyright ©2018 Innovative Medicines Initiative

Prepared by Clarivate Analytics on behalf of IMI Programme Office
under a public procurement procedure document reference:
IMI2/INT/2015-01848

Disclaimer/Legal Notice

This document has been prepared solely for the Innovative Medicines Initiative (IMI). All contents may not be re-used (in whatever form and by whatever medium) by any third party without prior permission of the IMI.

Table of Contents

1	EXECUTIVE SUMMARY	5
2	INTRODUCTION	8
2.1	OVERVIEW	8
2.2	INNOVATIVE MEDICINES INITIATIVE (IMI) JOINT UNDERTAKING	8
2.3	CLARIVATE ANALYTICS	8
2.4	SCOPE OF THIS REPORT	9
3	DATA SOURCES, INDICATORS AND INTERPRETATION	10
3.1	BIBLIOMETRICS AND CITATION ANALYSIS	10
3.2	DATA SOURCE	10
3.3	METHODOLOGY	11
3.4	DATA COLLATION	12
4	CITATION ANALYSIS – IMI SUPPORTED PUBLICAITONS OVERALL	13
4.1	PUBLICATIONS FROM IMI-SUPPORTED PROJECTS	13
4.2	SHARE OF PAPERS RELATIVE TO OTHER PUBLICATION TYPES	15
4.3	TRENDS IN PUBLICATION OUTPUT	16
4.4	IN WHICH JOURNALS DO IMI PROJECT PUBLICATIONS APPEAR MOST FREQUENTLY?	18
4.5	WHICH RESEARCH FIELDS ACCOUNT FOR THE HIGHEST VOLUME OF IMI PROJECT PUBLICATIONS?	22
4.6	IMI RESEARCH FIELDS WITH HIGHEST VOLUME OF PUBLICATIONS BENCHMARKED AGAINST EU-28 PUBLICATIONS OF THE SAME FIELD	25
4.7	IS IMI PROJECT RESEARCH WELL-CITED?	26
5	CITATION ANALYSIS – AT IMI PROJECT LEVEL	27
5.1	TRENDS IN PUBLICATION OUTPUT BY IMI FUNDING CALL	27
5.2	SUMMARY BIBLIOMETRIC ANALYSES FOR IMI PROJECTS – CALL 1	30
5.3	SUMMARY BIBLIOMETRIC ANALYSES FOR IMI PROJECTS – CALL 2	31
5.4	SUMMARY BIBLIOMETRIC ANALYSES FOR IMI PROJECTS – CALL 3	34
5.5	SUMMARY BIBLIOMETRIC ANALYSES FOR IMI PROJECTS – CALL 4	36
5.6	SUMMARY BIBLIOMETRIC ANALYSES FOR IMI PROJECTS – CALL 5-11	38
5.7	SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 2 PROJECTS	41
6	COLLABORATION ANALYSIS FOR IMI RESEARCH	44
6.1	COLLABORATION ANALYSIS FOR IMI RESEARCH	44
6.2	COLLABORATION ANALYSIS BY IMI PROJECT	45
6.3	COLLABORATION METRICS FOR IMI RESEARCH.....	58
6.3.1	METRIC 1: FRACTION OF CROSS SECTOR COLLABORATIVE PUBLICATIONS	59
6.3.2	METRIC 2: FRACTION OF INTERNATIONALLY COLLABORATIVE PUBLICATIONS ..	60

6.3.3	METRIC 3: TOP COLLABORATING INSTITUTIONS PER PUBLICATION.....	61
6.4	COLLABORATION INDEX.....	64
7	BENCHMARKING ANALYSIS – IMI PROJECT RESEARCH AGAINST RESEARCH FROM SELECTED COMPARATORS	65
7.1	IDENTIFYING COMPARATORS	66
7.2	TRENDS IN OUTPUT: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS	67
7.2.1	TRENDS IN OUTPUT: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS.....	67
7.2.2	TRENDS IN FIELD NORMALISED CITATION IMPACT: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS	69
7.2.3	TRENDS IN JOURNAL NORMALISED CITATION IMPACT: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS	71
7.2.4	TRENDS IN RAW CITATION IMPACT: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS.....	72
7.2.5	TRENDS IN UNCITED RESEARCH: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS.....	73
7.2.6	TRENDS IN HIGHLY- CITED RESEARCH: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS	75
7.2.7	TRENDS IN OPEN-ACCESS RESEARCH: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS	76
7.3	SUMMARY OF BIBLIOMETRIC INDICATORS: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS	77
8	COLLABORATION NETWORK ANALYSIS BY IMI PROJECT	78
8.1	COLLABORATION PATTERNS ACROSS THE FIVE IMI PROJECTS WITH THE GREATEST PUBLICATION PRODUCTIVITY	79
8.2	COLLABORATION NETWORK GRAPHS BY IMI PROJECT	88
9	GEOGRAPHIC CLUSTERING ANALYSIS.....	94
	ANNEX 1: BIBLIOMETRICS AND CITATION ANALYSIS.....	105
	ANNEX 2: MEDICALLY RELATED JOURNAL CATEGORIES	116
	ANNEX 3: COLLABORATION INDEX FOR ALL IMI SUPPORTED RESEARCH PROJECTS	117
	ANNEX 4: BIBLIOGRAPHY OF HOT PAPERS AND HIGHLY-CITED PAPERS.....	119

1 EXECUTIVE SUMMARY

This report presents a bibliometric analysis of Innovative Medicine Initiative Joint Undertaking (IMI JU) project research published between 2010 and 2017, using citations as an index of research quality and co-authorship as an index of collaboration. This is the ninth report commissioned by IMI from Clarivate Analytics. The data show that IMI continues to perform well and rapidly expand its research effort.

The overall volume of IMI project research has increased rapidly since 2010, and the initiative continues to show an exceptionally high growth in publication output. This increase is expected as the number of funded projects has increased over time and as the projects funded early in the history of the program begin to publish. To date, IMI projects have produced 3,737 publications which have been matched to the Clarivate Web of Science™. This represents a 40% increase from the 2,686 publications matched to the Web of Science in Report 8, which covered IMI project research published between 2009 and 2016.

Around three quarters of IMI project research (73.3%) has been published in high impact journals, i.e. those journals in the highest quartile ranked by Journal Impact Factor. The average Journal Impact Factor of all IMI project publications was 5.83. IMI project research was wide-ranging – the research portfolio of IMI projects ranges from basic biological research to clinical practice. IMI project research has been published most frequently in the disciplines of Pharmacology & Pharmacy, Neurosciences and Biochemistry & Molecular Biology.

The quality of IMI project research (as indexed by citation impact) has been maintained while output has grown. The citation impact of IMI project research (1.98) was approximately twice the world average (1.00), which indicates the research was internationally influential. Between 2010 and 2017, the citation impact for IMI project papers was considerably higher (73.7%) than the European Union's (EU) average citation impact (1.14) in similar fields (journal categories). One quarter of papers from IMI projects were highly-cited - that is, the papers were in the world's top 10% of papers in that journal category and year of publication, when ranked by number of citations.

The output of individual IMI projects has also increased. BTCURE (Call 2) was the most prolific IMI project, with 573 publications as of this report. This is a 24.2% increase on the 461 publications attributed to BTCURE in Report 8. This growth is below the growth for all IMI projects in aggregate, but this is likely to be because the BTCURE project ended in the first quarter of 2017.

Projects funded by IMI were highly collaborative. Nearly two-thirds (59.7%) of all IMI project papers were coauthored by researchers affiliated with different sectors, more than three-quarters (83.3%) of involved collaboration between institutions and more than half (60.0%) of all IMI project papers were internationally collaborative. Collaborative IMI project research was internationally influential with a citation impact (2.80) well over twice the world average (1.0).

IMI's field-normalised citation impact (1.98) is on par with well-established funding bodies such as the Commonwealth Scientific and Industrial Research Organisation (CSIRO), the Medical Research Council (MRC) and the Wellcome Trust (WT) (1.55, 1.91 and 2.02 respectively). Its journal-normalised citation impact (1.29) and percentage of highly-cited papers (25%) are also similar to those of the comparator funders.

The collaborative research activity of the selected IMI projects has increased over time and involves a diverse range of institutions across multiple sectors and countries. It is also clear from the data that there is significant collaboration with institutions that were not formal participants in the IMI-supported projects, and that the involvement of such partners has grown with time.

Research in both Europe and North America tends to be clustered in major cities with an existing strong academic research base. It is also clear that the citation impact of the research IMI supports within these clusters is higher than the average national benchmarks. A relatively high percentage of IMI-supported research in the Spanish clusters in particular, is published in Open Access journals. Rates

of international collaboration (as indicated by co-authorship involving more than one country) are very high for the European clusters.

A more detailed summary of the key findings of this report (with cross-references to the relevant sections of this report) is presented below.

Summary of key findings

Since its first call for proposals in 2008, IMI has funded over 85 projects from a total of 23 funding calls, a further 4 calls are currently open for proposals. Of the calls, 11 were from IMI's first phase, which ran from 2008 to 2013, and the rest from its second phase, which was launched in 2014 and is still in progress. It may take several months for a project to progress from inception to the point where it has generated sufficient data for a publication. It may take further months or years until it has produced its most valuable results. Some of the IMI projects that are analysed here are still relatively young, and early bibliometric indicators may not fully reflect their eventual impact.

- IMI projects have published a total of 3,737 unique Web of Science publications (Figure 4.1.1). IMI project research continues to show substantial growth, with the research publication count increasing every year since its inception to 1,420 publications in 2017 (Figure 4.3.1).
- More IMI project publications appeared in *PLOS ONE* than in other journals (142 publications), followed by *Annals of the Rheumatic Diseases* (124 publications). All of the 20 journals in which IMI-funded project publish most frequently rank in the top quartile by Journal Impact Factor (Table 4.4.1).
- The highest Impact Factor journal in which IMI research was published is the *New England Journal of Medicine*, which has a Journal Impact Factor of 59.558. IMI project research published nine times in *Nature* and 8 times in *Science*, which have Journal Impact Factors of 38.138 and 34.661 respectively (Table 4.4.2).
- IMI project research was most frequently published in Pharmacology & Pharmacy journals (Figure 4.5.1). Of the 484 papers published in this field, 20.0% were highly-cited, 37.4% appeared in open access journals, and the average citation impact of these papers was 1.5 times the world average for the field to which they relate (Tables 4.5.2 and 4.5.3).
- IMI project research had a citation impact of at least equal to the European (EU-28) average in seven out of the 10 journal subject categories to which most IMI publications are assigned (Figure 4.6.1 and Table 4.6.1).
- A quarter (25%) of IMI papers were in the world's top 10% of most highly-cited papers in the relevant field and year of publication, suggesting very strong performance (Table 4.7.1).
- The citation impact of IMI project papers was nearly twice the world average (1.98) between 2010 and 2017. This indicates that the quality of IMI-associated research (as indicated by citation impact) has been maintained while output has continued to grow (Table 4.7.1).
- The number of publications from Call 1 increased from 2010 to 2013 to a peak of 172, before falling to less than 100 publications in 2017. Other early calls follow a similar pattern of initial growth followed by a decline (Figure 5.1.1).
- Research associated with three of the active projects in Call 1 (EUROPAIN, NEWMEDS, U-BIOPRED) received more than twice the world average number of citations for research published in the same field and year (Figure 5.2.1).
- IMI project research is collaborative across sectors, institutions and countries. More than half (59.7%) of IMI project papers were published by co-authors affiliated with more than one sector. More than three-quarters (83.3%) of IMI project papers involved collaboration between institutions. And more than half (60.0%) of all IMI project papers were internationally collaborative (Table 6.1.1). Cross sector collaboration has declined marginally since the last report, but all other types of collaboration measured have increased.
- BTCURE had the most cross-sector collaborative papers, 332 out of a total of 541 (61.4%), as well as the most internationally collaborative papers (313 out of 541) (Tables 6.2.1-6.2.3).

- IMI's research output grew faster (2918.2%) between 2010 and 2017 than any of the seven selected comparators (Table 7.2.1.2).
- IMI's citation impact of twice the world average was around the same as those of the MRC (1.91), CSIRO (1.55) and the WT (2.02) (Table 7.2.2.1).
- Of the five projects analysed, BTCURE and EU-AIMS had the largest proportional increases in the number of co-authoring institutions that were not formally part of the IMI-supported project (Figure 8.1.1).
- The largest geographic clusters of research supported by IMI in European are London (680 publications), Amsterdam (581), Stockholm (353), Paris (278) and Copenhagen (271). The largest clusters in North America are Boston (134), Toronto (132), Bethesda (74), New York (69) and Montreal (62) (Table 9.1 and Table 9.3).
- Typically, around 35-40% of EU-28 biomedical research involves international co-authorship whereas the lowest rate of international co-authorship for the European clusters analysed was 61.4% (Madrid). In addition, around two thirds of the European clusters have rates of international co-authorship of at least 75%. The North American clusters, as expected, have high rates of international collaboration because IMI is a European funding organisation (Table 9.1 and Table 9.3).

2 INTRODUCTION

2.1 OVERVIEW

The Innovative Medicines Initiative (IMI) Joint Undertaking has commissioned Clarivate Analytics to undertake a periodic evaluation of its research portfolio using bibliometric indicators.

The commissioned evaluation comprises a series of reports focusing on research publications produced by IMI funded researchers. This report is the ninth evaluation in the series.

2.2 INNOVATIVE MEDICINES INITIATIVE (IMI) JOINT UNDERTAKING

IMI's purpose is to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators.

IMI is a partnership between the EU and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI, as part of its second phase, has a budget of €3.3 billion for the period of 2014 to 2024. Half of this comes from the EU's research and innovation programme, Horizon 2020. The other half comes from large companies, mostly from the pharmaceutical sector; these do not receive any EU funding, but contribute to the projects 'in kind', for example by donating their researchers' time or providing access to research facilities or resources. The first phase of IMI had a budget of €2 billion equally shared between EU and EFPIA.

To date, IMI has announced 11 calls for proposals from its first phase and a further 16 calls for proposals under its second phase. The first funding call was announced in 2008 and the latest, was launched in July 2018. This report covers the research output (publications and papers) of a total of 60 projects from IMI phase one and 24 projects from IMI phase two.

2.3 CLARIVATE ANALYTICS

Clarivate Analytics, formerly the IP & Science business of Thomson Reuters, provides reporting and consultancy services within Research Analytics using customised analyses to bring together several indicators of research performance in such a way as to enable customers to rapidly make sense of and interpret a wide-range of data points to facilitate research strategy decision-making. We have extensive experience with databases on research inputs, activity and outputs and have developed innovative analytical approaches for benchmarking, interpreting and visualization of international, national and institutional research impact.

Clarivate Analytics' Research Analytics is a suite of products, services and tools that provide comprehensive research analysis, evaluation and management. For over half a century we have pioneered the world of citation indexing and analysis, helping to connect scientific and scholarly thought around the world. Today, academic and research institutions, governments, not-for-profits, funding agencies, and all others with a stake in research, need reliable, objective methods for managing and measuring performance.

Our consultants have up to 20 years of experience in research performance analysis and interpretation. In addition, the Clarivate regional Sales team provide effective on-site support to maximise the value of our work.

Visit [Clarivate Analytics](#) or our [Scientific & Academic Research Professional Services](#) team online for more information.

2.4 SCOPE OF THIS REPORT

The analyses and indicators presented in this report have been specified to provide an analysis of IMI research output for research management purposes:

- To provide bibliometric indicators to identify excellence in IMI-supported research and to benchmark this research, where possible, overall and at individual project level.
- To show that collaboration, at all levels (researcher, institutional and country), is being encouraged through the projects funded by IMI.

Outline of report

- Section 3 describes the data sources and methodology used in this report along with definitions of the indicators and guidelines to interpretation.
- Section 4 presents analyses of IMI project publications overall, including trends in publications, frequently used journals, and top research fields. Where possible IMI research is benchmarked to EU-28 research.
- Section 5 presents citation analyses of IMI publications at the call level, examining trends in publications, citation impact and outputs of individual project. Where possible the IMI projects are benchmarked to world output and overall IMI output.
- Section 6 presents collaboration analyses for IMI publications overall and at the project level, examining collaboration between different sectors and countries.
- Section 7 presents analysis of IMI publications, benchmarked to similar organisations. The organisations are: Commonwealth Scientific and Industrial Research Organization, Critical Path Institute, Foundation for the National Institutes of Health (NIH), Grand Challenges in Global Health, Indian Council of Medical Research, MRC, and the Wellcome Trust.
- Section 8 presents analysis of the collaborative networks that IMI research supports. These networks include institutions across multiple sectors and who may be direct participants in IMI projects or part of a wider network of co-authorship.
- Section 9 presents geographic clusters where IMI research activity occurs, including bibliometric data, the constituent institutions and top five journal subject categories within the clusters.

3 DATA SOURCES, INDICATORS AND INTERPRETATION

3.1 BIBLIOMETRICS AND CITATION ANALYSIS

Research evaluation is increasingly making wider use of bibliometric data and analyses. Bibliometrics is the analysis of data derived from publications and their citations. Publication of research outcomes is an integral part of the research process and is a universal activity. Consequently, bibliometric data have a currency across subjects, time and location that is found in few other sources of research-relevant data. The use of bibliometric analysis, allied to informed review by experts, increases the objectivity of, and confidence in, evaluation.

Research publications accumulate citation counts when they are referred to by more recent publications. Citations to prior work are a normal part of publication and reflect the value placed on a work by later researchers. Some papers get cited frequently and many remain uncited. Highly cited work is recognised as having a greater impact and Clarivate Analytics has shown that high citation rates are correlated with other qualitative evaluations of research performance, such as peer review.¹ This relationship holds across most science and technology areas and, to a limited extent, in social sciences and even in some humanities subjects.

Indicators derived from publication and citation data should always be used with caution. Some fields publish at faster rates than others and citation rates also vary. Citation counts must be carefully normalised to account for such variations by field. Because citation counts naturally grow over time, it is essential to account for growth by year. Normalisation is usually done by reference to the relevant global average for the field and for the year of publication.

Bibliometric indicators have been found to be more informative for core natural sciences, especially for basic science, than they are for applied and professional areas and for social sciences. In professional areas the range of publication modes used by leading researchers is likely to be diverse as they target a diverse, non-academic audience. In social sciences there is also a diversity of publication modes and citation rates are typically much lower than in natural sciences.

Bibliometrics work best with large data samples. As the data are disaggregated, so the relationship weakens. Average indicator values (e.g. of citation impact) for small numbers of publications can be skewed by single outlier values. At a finer scale, when analysing the specific outcome for individual departments, the statistical relationship is rarely a sufficient guide by itself. For this reason, bibliometrics are best used in support of, but not as a substitute for, expert decision processes. Well-founded analyses can enable conclusions to be reached more rapidly and with greater certainty, and are therefore an aid to management and to increased confidence among stakeholders, but they cannot substitute for review by well-informed and experienced peers.

3.2 DATA SOURCE

For the bibliometric analysis, data will be sourced from the databases underlying the Clarivate Analytics **Web of Science**, which gives access to conference proceedings, patents, websites, and chemical structures, compounds and reactions in addition to journals. It has a unified structure that integrates all data and search terms together and therefore provides a level of comparability not found in other databases. It is widely acknowledged to be the world's leading source of citation and bibliometric data.

The **Web of Science Core Collection** is part of the Web of Science and focuses on research published in journals and conferences in science, medicine, arts, humanities and social sciences. The authoritative, multidisciplinary content covers over 18,000 of the highest impact journals worldwide, including over 3,800 Open Access journals and over 170,000 conference proceedings. Coverage is

¹ Evidence Ltd. (2002) Maintaining Research Excellence and Volume: A report by Evidence Ltd to the Higher Education Funding Councils for England, Scotland and Wales and to Universities United Kingdom (UK). (Adams J, et al.) 48pp.

both current and retrospective in the sciences, social sciences, arts and humanities, in some cases back to 1900. Within the research community, these data are often still referred to by the acronym 'ISI'.² Clarivate Analytics has extensive experience with databases on research inputs, activity and outputs and has developed innovative analytical approaches for benchmarking and interpreting international, national and institutional research impact.

3.3 METHODOLOGY

Papers/publications: Clarivate Analytics abstracts publications including editorials, meeting abstracts and book reviews as well as research journal articles. The terms 'paper' and 'publication' are often used interchangeably to refer to printed and electronic outputs of many types. In this document the term 'paper' has been used exclusively to refer to substantive journal articles, reviews and some proceedings papers and excludes editorials, meeting abstracts or other types of publication. Papers are the subset of publications for which citation data are most informative and which are used in calculations of citation impact.

Citations: The citation count is the number of times that a citation has been recorded for a given publication since it was published. Not all citations are necessarily recorded since not all publications are indexed. The material indexed by Clarivate Analytics, however, is estimated to attract about 95% of global citations.

Citation impact: Citations per paper' is an index of academic or research impact (as compared with economic or social impact). It is calculated by dividing the sum of citations by the total number of papers in any given dataset (so, for a single paper, raw impact is the same as its citation count). Impact can be calculated for papers within a specific research field such as Clinical Neurology, or for a specific institution or group of institutions, or a specific country. Citation count declines in the most recent years of any time-period as papers have had less time to accumulate citations (papers published in 2007 will typically have more citations than papers published in 2010).

Field-normalised citation impact (nci_F): Citation rates vary between research fields and with time, consequently, analyses must take both field and year into account. In addition, the type of publication will influence the citation count. For this reason, only citation counts of papers (as defined above) are used in calculations of citation impact. The standard normalisation factor is the world average citations per paper for the year and journal category in which the paper was published. This normalisation is also referred to as 'rebasings' the citation count.

Mean normalised citation impact (mnci): The mean nci indicator for any specific dataset is calculated as the mean of the nci_F of all papers within that dataset.

Web of Science journal categories or Clarivate Analytics InCites: Essential Science IndicatorsSM fields: Standard bibliometric methodology uses journal category or ESI fields as a proxy for research fields. ESI fields aggregate data at a higher level than the journal categories – there are only 22 ESI research fields compared to 254 journal categories. Journals are assigned to one or more categories, and every article within that journal is subsequently assigned to that category. Papers from prestigious, 'multidisciplinary' and general medical journals such as *Nature*, *Science*, *The Lancet*, *The BMJ*, *The New England Journal of Medicine* and the *Proceedings of the National Academy of Sciences* (PNAS) are assigned to specific categories based on the journal categories of the references cited in the article.

² The origins of citation analysis as a tool that could be applied to research performance can be traced to the mid-1950s, when Eugene Garfield proposed the concept of citation indexing and introduced the Science Citation Index, the Social Sciences Citation Index and the Arts & Humanities Citation Index, produced by the Institute of Scientific Information – ISI (now Clarivate Analytics).

The selection procedures for the journals included in the citation databases are documented here <http://mjl.clarivate.com/>.³

Journal-normalised citation impact (nci_j): Another bibliometric indicator which can be very useful in small datasets is the journal-normalised citation impact, nci_j. This indicator is calculated from the citation impact relative to the specific journal in which the paper is published. For example, a paper published in the journal *Acta Biomaterialia* in 2005 that has been cited 189 times, would have an expected citation rate of 49.57 (the average number of citations per paper for this journal and publication year) and hence a nci_j of 6.3. This paper, therefore, has been cited more than expected for the journal.

3.4 DATA COLLATION

This analysis used a dataset comprising publications arising from IMI-supported projects. This contained publications associated with each IMI project identified using grant acknowledgments, title and abstract text search, as well as other parameters developed in conjunction with IMI staff. There are currently 86 active IMI projects. IMI staff validated the publications identified by this process and the list of projects to be analysed was provided by IMI staff.

³ Essential Science Indicators are defined by a unique grouping of journals with no journal being assigned to more than one field. These fields are focussed on the science, technology, engineering and medicine subjects and arts & humanities subjects are excluded. Customised analyses, however, can be designed to include these as an additional category.

4 CITATION ANALYSIS – IMI SUPPORTED PUBLICAITONS OVERALL

This Section analyses the volume and citation impact of publications arising from IMI-supported projects, and where possible, benchmarks this against similar European research.

The datasets analysed include IMI-supported publications identified in Clarivate Analytics Web of Science up to December 2017. The census point for inclusion of publications into the eighth report was 31st December 2016. Therefore, this report reflects changes in IMI activity between these points. Citation counts for all publications included previously have been updated to the end of 2017. Unless otherwise specified metrics are for all IMI-supported documents from all calls in IMI 1 and IMI 2, in aggregate.

When considering the analyses in this Section, earlier caveats regarding paper numbers should be borne in mind (Section 3).


4.1 PUBLICATIONS FROM IMI-SUPPORTED PROJECTS

Publications from IMI-supported projects were identified using bibliographic data supplied by IMI, and through specific keyword searches using funding acknowledgment data in Web of Science. The process of identifying publications from IMI-supported projects that have Clarivate Analytics citation data is outlined in Figure 4.1.1.

The IMI project dataset started with 2,686 publications which were previously identified as IMI publications. Separately, 1,420 new publications were identified as IMI-associated through keyword searches of funding acknowledgement text in Web of Science. The combination of these two datasets led to a total of 4,106 unique publication records associated with IMI-supported projects. Of these 4,106 publications that were matched to the databases underlying the Clarivate Analytics Web of Science, 369 were eliminated as they were either published in 2018 or could not be distinguished as IMI from a manual review of the dataset. Therefore, 3,737 Web of Science publications remained. Of the identified records 5 could not be assigned to a specific project.

The citation counts for this report were sourced from the citation databases which underlie Clarivate Analytics Web of Science and were extracted in March 2018. Normalised bibliometric indicators were calculated using standard methodology and the Clarivate Analytics National Science Indicators (NSI) database for 2017.

FIGURE 4.1.1 IDENTIFYING PUBLICATIONS FROM IMI-SUPPORTED PROJECTS WITH CLARIVATE ANALYTICS CITATION DATA




4.2 SHARE OF PAPERS RELATIVE TO OTHER PUBLICATION TYPES

FIGURE 4.2.1 CATEGORISATION OF IMI PROJECT RESEARCH BY DOCUMENT TYPE

Figure 4.2.1 shows the percentage of Web of Science publications from IMI-associated projects classified as papers (articles and reviews) relative to other document types. Papers are the subset of publications for which citation data are most informative and which are used in calculations of normalised citation impact.


IMI project research resulted in 3,737 unique Web of Science publications. Of these publications 95% were substantive articles or reviews with 187 documents not falling into these document types. These documents (classified as 'Other') comprised 50 editorials, 120 meeting abstracts, 10 letters, 4 corrections and 3 news items.



4.3 TRENDS IN PUBLICATION OUTPUT

Figure 4.3.1 shows the annual number of Web of Science publications arising from IMI projects between 2010 and 2017.

FIGURE 4.3.1 NUMBER OF WEB OF SCIENCE PUBLICATIONS FOR IMI PROJECTS BY YEAR, 2010-2017




IMI project research continued to show substantial growth with publication count increasing every year between 2010 and 2017:

- The percentage change in the output of IMI project-supported publications between 2016 and 2017 was 12.0%, compared with a growth of 19.6% between 2015 and 2016.
- While the percentage growth has decreased over time the number of publications continues to grow roughly linearly by an average of 132 per year.

Figure 4.3.2 shows the proportion of papers (articles and reviews) relative to other document types for IMI project research between 2010 and 2017.

FIGURE 4.3.2 CATEGORISATION OF WEB OF SCIENCE PUBLICATIONS FOR IMI PROJECTS BY YEAR AND DOCUMENT TYPE, 2010-2017



- IMI project research continued to generate a high proportion of papers relative to other document types. Articles accounted for around 80% of all publications, dropping 0.5% to 79.5% in 2017. Review papers accounted for approximately 20% of publications between 2010 and 2013 but fell after this point to 12.2% in 2017.

4.4 IN WHICH JOURNALS DO IMI PROJECT PUBLICATIONS APPEAR MOST FREQUENTLY?

The 20 journals in which IMI project publications appeared most frequently (ranked by number of publications) between 2010 and 2017, are listed in Table 4.4.1. Together, the 20 most frequently used journals account for 905 Web of Science publications - almost one-quarter (24.2%) of all IMI project publications.

IMI project publications appeared most frequently in *PLOS ONE* (142 publications), followed by *Annals of the Rheumatic Diseases* (124 publications). 18 of the 22 IMI publications in the *American Journal of Respiratory and Critical Care Medicine* (JIF = 13.12) were meeting abstracts and 4 were articles.

IMI continued to have a strong focus on Rheumatology, this category is represented three times in the top ten most frequent publishers of IMI research. However, the top 20 most frequent journals contain several in the multidisciplinary category, indicating a wider interest in IMI research.

Of the 20 journals in Table 4.4.1, all 20 were in the top quartile when ranked by Journal Impact Factor.

IMI project publications were published in a total of 925 journals, of which 604 were ranked in the top quartile (by Journal Impact Factor) of journals in their specific journal category. A total of 2,990 publications (80% of IMI project publications) were published in these well-regarded journals. The average Journal Impact Factor of all IMI project publications is 6.10.

The highest Impact Factor journal in which IMI project research was published is the *New England Journal of Medicine*, with a Journal Impact Factor of 59.558. IMI projects have published a total of nine publications (two since report 8) in *Nature*, which had a Journal Impact Factor of 38.138 and eight (two since report 8) in *Science* with a Journal Impact Factor of 34.661.

The 20 open access journals appearing most frequently (ranked by number of publications) in the IMI project publications dataset, 2010-2017, are listed in Table 4.4.3. This list is notably different to previous reports due to the re-indexing of a number of journals as newly open access. Clarivate Analytics is constantly adapting its database to be consistent with modern publishing practices, in this case giving improved insight on open access. Literature is now tagged at the publication level rather than the journal level, allowing journals to be associated with both open and closed access.

Of the top 20 open access journals in which IMI project research published most frequently, *Annals of the rheumatic diseases* had the highest impact factor (12.384). *PLOS ONE* is the open access journal with the highest number of IMI publications (142).

TABLE 4.4.1 JOURNALS IN WHICH IMI PROJECT PUBLICATIONS WERE PUBLISHED MOST FREQUENTLY, TOP 20 RANKED BY NUMBER OF WEB OF SCIENCE PUBLICATIONS, 2010-2017

Journal	Number of Web of Science Publications	Number of Papers	Journal Impact Factor (2017)	Web of Science Journal Categories	Quartile
<i>PLOS ONE</i>	142	142	3.057	MULTIDISCIPLINARY SCIENCES	Q1
<i>ANNALS OF THE RHEUMATIC DISEASES</i>	124	94	12.384	RHEUMATOLOGY	Q1
<i>SCIENTIFIC REPORTS</i>	77	77	5.228	MULTIDISCIPLINARY SCIENCES	Q1
<i>DIABETOLOGIA</i>	55	36	6.206	ENDOCRINOLOGY & METABOLISM	Q1
<i>ARTHRITIS RESEARCH & THERAPY</i>	44	44	3.979	RHEUMATOLOGY	Q1

Journal	Number of Web of Science Publications	Number of Papers	Journal Impact Factor (2017)	Web of Science Journal Categories	Quartile
<i>PAIN</i>	43	43	5.557	CLINICAL NEUROLOGY; NEUROSCIENCES; ANESTHESIOLOGY	Q1
<i>ARTHRITIS & RHEUMATOLOGY</i>	43	39	6.009	RHEUMATOLOGY	Q1
<i>PSYCHOPHARMACOLOGY</i>	41	41	3.54	NEUROSCIENCES; PSYCHIATRY; PHARMACOLOGY & PHARMACY	Q1
<i>JOURNAL OF ALZHEIMERS DISEASE</i>	37	37	3.92	NEUROSCIENCES	Q1
<i>EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES</i>	37	35	3.773	PHARMACOLOGY & PHARMACY	Q1
<i>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA</i>	32	32	9.423	MULTIDISCIPLINARY SCIENCES	Q1
<i>NATURE COMMUNICATIONS</i>	31	31	11.329	MULTIDISCIPLINARY SCIENCES	Q1
<i>MOLECULAR PHARMACEUTICS</i>	30	30	4.342	PHARMACOLOGY & PHARMACY; MEDICINE, RESEARCH & EXPERIMENTAL PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH;	Q1
<i>DRUG SAFETY</i>	29	28	3.206	PHARMACOLOGY & PHARMACY; TOXICOLOGY	Q1
<i>DIABETES</i>	29	24	8.784	ENDOCRINOLOGY & METABOLISM	Q1
<i>JOURNAL OF IMMUNOLOGY</i>	24	24	4.985	IMMUNOLOGY	Q1
<i>AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE</i>	22	4	13.118	CRITICAL CARE MEDICINE	Q1
<i>BIOINFORMATICS</i>	22	22	5.766	MATHEMATICAL & COMPUTATIONAL BIOLOGY; BIOTECHNOLOGY & APPLIED MICROBIOLOGY; STATISTICS & PROBABILITY; COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS; BIOCHEMICAL RESEARCH METHODS	Q1
<i>JOURNAL OF BIOLOGICAL CHEMISTRY</i>	22	22	4.258	BIOCHEMISTRY & MOLECULAR BIOLOGY	Q1
<i>NUCLEIC ACIDS RESEARCH</i>	21	21	9.202	BIOCHEMISTRY & MOLECULAR BIOLOGY	Q1

TABLE 4.4.2 JOURNALS IN WHICH IMI PROJECT PUBLICATIONS WERE PUBLISHED MOST FREQUENTLY, TOP 20 RANKED BY JOURNAL IMPACT FACTOR, 2010-2017

Journal	Number of Web of Science Publications	Number of Papers	Journal Impact Factor (2017)	Web of Science Journal Categories	Quartile
NEW ENGLAND JOURNAL OF MEDICINE	1	1	59.558	CLINICAL NEUROLOGY	Q1
NATURE REVIEWS DRUG DISCOVERY	5	1	47.12	BIOTECHNOLOGY & APPLIED MICROBIOLOGY; PHARMACOLOGY & PHARMACY	Q1
LANCET	2	2	44.002	MEDICINE, GENERAL & INTERNAL; PSYCHIATRY	Q1
NATURE BIOTECHNOLOGY	1	0	43.113	BIOTECHNOLOGY & APPLIED MICROBIOLOGY	Q1
NATURE REVIEWS IMMUNOLOGY	2	2	39.416	IMMUNOLOGY	Q1
NATURE REVIEWS MOLECULAR CELL BIOLOGY	1	1	38.602	CELL BIOLOGY	Q1
NATURE	9	9	38.138	MULTIDISCIPLINARY SCIENCES	Q1
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION	7	5	37.684	CARDIAC & CARDIOVASCULAR SYSTEMS; CLINICAL NEUROLOGY; RHEUMATOLOGY; MEDICINE, GENERAL & INTERNAL	Q1
CHEMICAL REVIEWS	2	2	37.369	CHEMISTRY, MULTIDISCIPLINARY	Q1
NATURE REVIEWS GENETICS	2	2	35.898	GENETICS & HEREDITY	Q1
SCIENCE	8	7	34.661	MULTIDISCIPLINARY SCIENCES	Q1
NATURE REVIEWS CANCER	1	1	34.244	ONCOLOGY	Q1
CHEMICAL SOCIETY REVIEWS	1	1	34.090	CHEMISTRY, MULTIDISCIPLINARY	Q1
NATURE GENETICS	9	6	31.616	GENETICS & HEREDITY	Q1
PHYSIOLOGICAL REVIEWS	1	1	30.924	PHYSIOLOGY	Q1
NATURE MEDICINE	5	5	30.357	BIOCHEMISTRY & MOLECULAR BIOLOGY; CELL BIOLOGY; MEDICINE, RESEARCH & EXPERIMENTAL	Q1
NATURE REVIEWS NEUROSCIENCE	2	2	29.298	NEUROSCIENCES	Q1
CELL	1	1	28.710	CELL BIOLOGY; CELL BIOLOGY	Q1
NATURE CHEMISTRY	1	1	27.893	CHEMISTRY, MULTIDISCIPLINARY	Q1
LANCET ONCOLOGY	1	1	26.509	ONCOLOGY	Q1


TABLE 4.4.3 OPEN ACCESS JOURNALS IN WHICH IMI PROJECT PUBLICATIONS WERE PUBLISHED MOST FREQUENTLY, TOP 20 RANKED BY NUMBER OF WEB OF SCIENCE PUBLICATIONS, 2010-2017

Open Access Journal	Number of Web of Science Publications	Number of Papers	Journal Impact Factor (2017)	Web of Science Journal Categories
<i>PLOS ONE</i>	142	142	3.057	MULTIDISCIPLINARY SCIENCES
<i>SCIENTIFIC REPORTS</i>	77	77	5.228	MULTIDISCIPLINARY SCIENCES
<i>ARTHRITIS RESEARCH & THERAPY</i>	44	44	3.979	RHEUMATOLOGY
<i>ARTHRITIS & RHEUMATOLOGY</i>	36	36	6.009	RHEUMATOLOGY
<i>NATURE COMMUNICATIONS</i>	31	31	11.329	MULTIDISCIPLINARY SCIENCES
<i>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA</i>	31	31	9.423	MULTIDISCIPLINARY SCIENCES
<i>DIABETOLOGIA</i>	27	27	6.206	ENDOCRINOLOGY & METABOLISM
<i>ANNALS OF THE RHEUMATIC DISEASES</i>	26	25	12.384	RHEUMATOLOGY
<i>DIABETES</i>	22	22	8.784	ENDOCRINOLOGY & METABOLISM
<i>NUCLEIC ACIDS RESEARCH</i>	21	21	9.202	BIOCHEMISTRY & MOLECULAR BIOLOGY
<i>BIOINFORMATICS</i>	20	20	5.766	MATHEMATICAL & COMPUTATIONAL BIOLOGY; BIOTECHNOLOGY & APPLIED MICROBIOLOGY; STATISTICS & PROBABILITY; COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS; BIOCHEMICAL RESEARCH METHODS
<i>JOURNAL OF BIOLOGICAL CHEMISTRY</i>	20	20	4.258	BIOCHEMISTRY & MOLECULAR BIOLOGY
<i>JOURNAL OF IMMUNOLOGY</i>	20	20	4.985	IMMUNOLOGY
<i>ARTHRITIS AND RHEUMATISM</i>	19	19	8.955	RHEUMATOLOGY
<i>JOURNAL OF ALZHEIMERS DISEASE</i>	19	19	3.920	NEUROSCIENCES
<i>ANTIMICROBIAL AGENTS AND CHEMOTHERAPY</i>	18	17	4.415	MICROBIOLOGY; PHARMACOLOGY & PHARMACY
<i>EUROPEAN JOURNAL OF IMMUNOLOGY</i>	16	15	4.179	IMMUNOLOGY
<i>JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY</i>	16	16	4.919	PHARMACOLOGY & PHARMACY
<i>INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES</i>	15	15	3.257	CHEMISTRY, MULTIDISCIPLINARY
<i>TRANSLATIONAL PSYCHIATRY</i>	15	15	5.538	PSYCHIATRY

4.5 WHICH RESEARCH FIELDS ACCOUNT FOR THE HIGHEST VOLUME OF IMI PROJECT PUBLICATIONS?

Figure 4.5.1 shows the top ten Web of Science journal categories⁴ rank by numbers of publications associated with IMI project research⁵. IMI 1 calls 5-11 have a lower number of publications relative to calls 1-4 and for clarity of presentation these publications are shown as one group in Figure 4.5.1. Likewise, IMI 2 has far fewer publications compared to IMI 1 and so all IMI 2 calls are aggregated in one group in Figure 4.5.1.

FIGURE 4.5.1 TOP TEN WEB OF SCIENCE JOURNAL CATEGORIES IN WHICH IMI PROJECT RESEARCH WERE PUBLISHED, 2010-2017



- IMI projects generated more publications in Pharmacology & Pharmacy than in other journal categories, followed by Neurosciences and Biochemistry & Molecular Biology.
- Since the last report, Immunology has overtaken Clinical Neurology in terms of number of publications, and Multidisciplinary Chemistry and Cell Biology have overtaken Genetic & Heredity, which is no longer in the top ten Web of Science journal categories.
- The majority of publications (93.3%) in Rheumatology were from the call 2 project BTCURE.
- The publications assigned to Neurosciences and Psychiatry were predominantly from calls 1 and 3.

⁴ Journals can be associated with more than one Web of Science category.

⁵ It should be noted that there are 130 publications which are associated with multiple IMI calls.

Table 4.5.1 shows the same data as Figure 4.5.1. It provides the number of publications assigned to each of the top ten Web of Science journal categories in which IMI project research is published. Table 4.5.2 and Table 4.5.3 provide the citation impact, percentage of highly-cited and percentage of publications in open access journals for the IMI project research in the top ten journal categories.

TABLE 4.5.1 NUMBER OF PUBLICATIONS BY IMI 1 CALL AND IMI 2 FOR THE TOP TEN WEB OF SCIENCE JOURNAL CATEGORIES IN WHICH IMI PROJECT RESEARCH WAS PUBLISHED, 2010-2017

Journal Category	Number of publications by IMI 1 Call												Not assigned
	1	2	3	4	5	6	7	8	9	10	11	IMI 2	
Pharmacology & Pharmacy	175	56	71	152	5	11	4	2	13	0	7	3	13
Neurosciences	243	1	142	50	0	0	0	19	3	0	4	3	0
Biochemistry & Molecular Biology	82	58	34	53	19	28	0	12	1	0	51	9	11
Rheumatology	1	304	3	0	0	0	0	13	0	0	5	0	0
Immunology	15	134	56	1	0	1	4	12	3	12	11	9	1
Clinical Neurology	128	0	44	32	0	0	0	5	0	0	6	2	0
Psychiatry	106	0	98	5	0	0	0	1	0	0	1	1	0
Endocrinology & Metabolism	100	15	34	43	0	0	0	1	2	0	1	15	0
Chemistry, Multidisciplinary	25	22	9	79	22	6	0	4	1	0	8	1	1
Cell Biology	27	51	17	28	1	2	0	5	0	0	11	24	2

TABLE 4.5.2 FIELD NORMALISED, JOURNAL NORMALISED AND RAW CITATION IMPACT OF PAPERS IN TOP TEN WEB OF SCIENCE JOURNAL CATEGORIES IN WHICH IMI PROJECT RESEARCH WAS PUBLISHED, 2010-2017

Journal category	Number of Papers	Citation Impact		
		Normalised at field level (nci _F)	Normalised at journal level (nci _J)	Raw citation impact
Pharmacology & Pharmacy	484	1.54	1.18	10.31
Neurosciences	445	1.81	1.29	20.74
Biochemistry & Molecular Biology	343	1.93	1.44	14.77
Rheumatology	287	2.07	1.06	16.38
Immunology	247	1.56	1.17	13.36
Clinical Neurology	200	3.09	1.44	27.30
Psychiatry	198	2.29	1.12	19.59
Endocrinology & Metabolism	181	1.44	0.99	12.72
Chemistry, Multidisciplinary	176	1.56	1.36	16.10
Cell Biology	170	1.79	1.45	14.21

TABLE 4.5.3 TOP TEN WEB OF SCIENCE JOURNAL CATEGORIES IN WHICH IMI PROJECT RESEARCH WAS PUBLISHED, WITH PERCENTAGE OF PUBLICATIONS IN OPEN ACCESS JOURNALS, AND PERCENTAGE OF HIGHLY-CITED PAPERS, 2010-2017

Journal Category	Number of Web of Science publications	% of Open Access publications	Number of papers	% of Highly Cited Papers
Pharmacology & Pharmacy	503	37.4%	484	20.0%
Neurosciences	460	49.1%	445	29.2%
Biochemistry & Molecular Biology	344	63.1%	343	21.6%
Rheumatology	325	53.9%	287	29.3%
Immunology	253	58.9%	247	23.5%
Clinical Neurology	214	41.1%	200	39.5%
Psychiatry	208	51.0%	198	26.8%
Endocrinology & Metabolism	206	64.1%	181	17.1%
Chemistry, Multidisciplinary	177	41.2%	176	23.9%
Cell Biology	171	73.1%	170	30.0%

- There is a step change in the percentage of papers seen in open access journals compared to the previous reports. This step is likely not representative of a real difference in publishing behaviour, but a result of increased resolution as Clarivate Analytics has improved its ability to identify open access publications through its collaboration with ImpactStory.⁶
- IMI project research was most frequently published in Pharmacology & Pharmacy journals. Of the 503 papers published in this field, 20.0% were highly-cited.
- There were 214 publications (200 papers) in Clinical Neurology; this category has the highest percentage of highly cited papers (39.5%).
- The percentage of publications in open access journals was highest in Cell biology (73.1%).

⁶ Easing Access to Open Access: Clarivate Analytics partners with Impactstory: <https://clarivate.com/blog/easing-access-to-open-access-clarivate-analytics-partners-with-impactstory/>

4.6 IMI RESEARCH FIELDS WITH HIGHEST VOLUME OF PUBLICATIONS BENCHMARKED AGAINST EU-28 PUBLICATIONS OF THE SAME FIELD

Figure 4.6.1 shows the citation impact of the top ten Web of Science journal categories in which IMI project research was published. These data are benchmarked against the same journal categories for EU-28 research papers. Table 4.6.1, expands on this figure and shows the percentage of publications for each journal category for IMI and EU-28.

FIGURE 4.6.1 TOP TEN WEB OF SCIENCE JOURNAL CATEGORIES IN WHICH IMI PROJECT RESEARCH WAS PUBLISHED, BENCHMARKED AGAINST EU-28 PAPERS IN THE SAME JOURNAL CATEGORIES, 2010-2017




TABLE 4.6.1 CITATION IMPACT AND PERCENTAGE OF PAPERS IN TOP TEN WEB OF SCIENCE JOURNAL CATEGORIES IN WHICH IMI PROJECT RESEARCH WAS PUBLISHED, BENCHMARKED AGAINST EU-28 PAPERS IN THE SAME JOURNAL CATEGORIES, 2010-2017

Journal category	% of IMI papers	% of EU-28 papers	Citation impact normalised at field level	
			IMI papers	EU-28
Pharmacology & Pharmacy	13.6%	2.3%	1.18	1.04
Neurosciences	12.5%	3.0%	1.29	1.20
Biochemistry & Molecular Biology	9.7%	4.0%	1.44	1.19
Rheumatology	8.1%	0.5%	1.06	1.23
Immunology	7.0%	1.7%	1.17	1.17
Clinical Neurology	5.6%	2.1%	1.44	1.18
Psychiatry	5.6%	1.5%	1.12	1.14
Endocrinology & Metabolism	5.1%	1.5%	0.99	1.11
Chemistry, Multidisciplinary	5.0%	3.0%	1.36	1.14
Cell Biology	4.8%	2.0%	1.45	1.30

- IMI project research had a higher citation impact in most of the fields it is most frequently published in than the EU-28 papers published in the same research fields (as determined by journal subject categories) except for Rheumatology, Psychiatry and Endocrinology and Metabolism.
- The journal category in which IMI-supported papers had the highest citation impact was Cell Biology (1.45).
- The journal category with the highest citation impact for EU-28 papers was Cell Biology (1.30).

4.7 IS IMI PROJECT RESEARCH WELL-CITED?

The number of citations a paper receives (also known as its citation impact) is at least partly determined by the field to which it relates. Typically, papers published in disciplines such as biomedical research receive more citations than papers published in subjects such as engineering, even if the papers are published in the same year. All citation impact data presented in this report are therefore normalised, or rebased, to the relevant world average to allow comparison between years and fields.

Table 4.7.1 and 4.7.2 present summary results for all IMI publications and papers.

TABLE 4.7.1 SUMMARY CITATION ANALYSIS FOR IMI SUPPORTED RESEARCH PAPERS, 2010-2017

	Number of Papers	Citation Impact		Average Percentile	% Highly cited papers
		Normalised at field level (nci _F)	Normalised at journal level (nci _J)		
IMI projects	3,550	1.98	1.29	38.68	25.0%

TABLE 4.7.2 SUMMARY OF IMI SUPPORTED RESEARCH PUBLICATIONS, 2010-2017

	Number of Publications	% Publications in Open access journals	Number of papers	Citations	Raw citation impact
IMI Projects	3,737	52.2%	3,550	52,362	14.75

SUMMARY OF KEY FINDINGS

- The citation impact of IMI project papers was 1.98 for the 7-year period, 2010-2017 (almost twice the world average of 1.0). This indicates the quality of IMI-associated research (as indicated by citation impact) had been maintained while output had continued to grow.
- The citation impact of IMI project papers was 60% higher than the EU's average citation impact (1.17)^{7,8} relative to the world baseline between 2010 and 2017, in the same group of journal categories.
- Almost a quarter (24.3%) of IMI papers were highly-cited, that is, they were in the world's top 10% of most highly-cited papers in the relevant journal category and year of publication.

⁷ EU-28 grouping of countries: Clarivate Analytics National Science Indicators 2017 database; similar research has been defined as including the same journal categories as in the IMI project dataset.


⁸ For this analysis, only papers are considered since only these publication types have normalised citation impact data (see Section 3).

5 CITATION ANALYSIS – AT IMI PROJECT LEVEL

5.1 TRENDS IN PUBLICATION OUTPUT BY IMI FUNDING CALL

Figure 5.1.1 shows the number of Web of Science publications between 2010 and 2017 for IMI group by call. Call 1-4 are shown separately. Calls 5-11 are more recent and consequently have fewer publications, they are therefore shown in aggregate in Figure 5.1.2. Likewise, IMI 2 has far fewer publications compared than IMI 1 and so all IMI 2 calls are aggregated into a single group in Figure 4.5.1. Table 5.1.1 presents summary bibliometric data for IMI 1 calls 1-11 and IMI 2, including number of publications, numbers of papers, and citation impact.

FIGURE 5.1.1 NUMBER OF WEB OF SCIENCE PUBLICATIONS BY YEAR AND FUNDING CALL 2010-2017



- The number of publications from call 1 increased from 2010 to a peak of 172 in 2013.
- In 2015 and 2016, call 2 had the highest number of publications (173 and 200, respectively) but fell below call 4 in 2017 (155 publications), which exhibits a steep growth profile between 2013 and 2016.
- Calls 1 - 4 grow approximately linearly for 3 - 4 years from first publications, followed by a short plateau and call 1 has started to show a shallow decline over the period 2016 – 2017.

FIGURE 5.1.2 NUMBER OF WEB OF SCIENCE PUBLICATIONS BY YEAR AND FUNDING CALL 2010-2017




TABLE 5.1.1 SUMMARY BIBLIOMETRIC ANALYSES OF IMI PROJECTS AGGREGATED BY FUNDING CALL, 2010-2017

IMI Call	Number of Publications ⁹	% Publications in Open access journals	Number of Papers	Raw citation impact	Citation Impact Normalised at field level (nci _f)	Normalised at journal level (nci _j)
1	957	49.9%	912	20.71	1.83	1.20
2	926	62.2%	883	16.60	1.99	1.23
3	569	58.6%	529	14.01	2.05	1.20
4	553	46.4%	544	10.38	2.08	1.41
5	75	46.7%	75	5.63	1.33	1.07
6	99	51.5%	98	7.11	1.39	1.03
7	38	60.5%	33	2.82	2.97	1.70
8	86	57.0%	76	5.43	1.29	1.03
9	87	39.1%	80	5.21	2.72	2.47
10	17	70.6%	17	3.24	1.13	1.25
11	267	61.0%	251	5.97	2.51	1.37
IMI 2	88	70.0%	76	2.04	1.66	0.74
Unassigned	63	60.0%	61	7.09	1.37	1.07

- IMI call 1 generated the highest number of Web of Science publications (957), and papers (912). Of the 957 publications in call 1, around half (49.9%) were published in open access journals. The publications generated by IMI 1 call 1 also had the highest raw citation impact (20.71).


⁹ Publications can be associated with more than one call.

- Papers assigned to call 7 had the highest average field normalised citation impact (2.97), though it should be noted this is an average for only 33 papers.

5.2 SUMMARY BIBLIOMETRIC ANALYSES FOR IMI PROJECTS – CALL 1

Figure 5.2.1 presents an analysis of IMI-supported research published by IMI 1, call 1 projects. Only projects with at least 10 papers and one highly-cited paper over the time period (2010-2017) are shown. The number of papers, average citation impact and share of highly-cited papers are compared. The area of the 'bubble' is proportional to the share of highly-cited papers. The solid horizontal line indicates the average citation impact for all IMI project papers.

FIGURE 5.2.1 PAPER NUMBERS, AVERAGE CITATION IMPACT AND SHARE OF HIGHLY-CITED RESEARCH FOR SELECTED IMI PROJECTS – CALL 1, 2010-2017



The data in Figure 5.2.1 shows that:

- The average citation impact of all projects with at least 10 publications was above the world average (1.0) and the percentage of highly-cited research was above the world average (10%). This shows excellent research performance of IMI-associated research.
- Research associated with three of the projects that had at least 10 publications (NEWMEDS, EUROPAIN, U-BIOPRED) in call 1 was cited more than twice the world average.
- Of the 11 projects in call 1, three (NEWMEDS, EUROPAIN, U-BIOPRED) had papers with an average citation impact greater than the average citation impact of all IMI project papers (1.98).

Table 5.2.1 shows citation impact normalised against world average values and expands on the data shown in Figure 5.2.1. Table 5.2.2 shows the raw citation impact and the percentage of publications in open access papers by project for call 1 publications.

TABLE 5.2.1 SUMMARY CITATION INDICATORS FOR IMI PROJECTS IN CALL 1, 2010-2017

Project	Number of Papers	Citation Impact			% Highly cited papers
		Normalised at field level (nci _f)	Normalised at journal level (nci _j)	Average Percentile	
eTOX	84	1.74	1.48	33.66	25.00%
EUROPAIN	154	2.39	1.46	27.89	31.82%
IMIDIA	124	1.70	1.18	32.88	22.58%
INNODIA	17	1.16	0.91	70.87	11.76%
MARCAR	48	1.20	0.93	40.49	16.67%
NEWMEDS	171	2.27	1.18	33.15	28.65%
Pharma-Cog	65	1.55	1.00	42.08	15.38%
PROTECT	94	1.07	1.04	39.96	11.70%
SAFE-T	15	1.64	1.53	29.35	20.00%
SUMMIT	96	1.31	0.88	47.20	15.63%
U-BIOPRED	54	2.48	1.34	25.27	37.04%
Overall (IMI projects)	3550	1.98	1.26	35.77	25.55%

TABLE 5.2.2 BIBLIOMETRIC INDICATORS FOR IMI PROJECTS IN CALL 1, 2010-2017

Project	Number of Publications	Number of Papers	% Publications in Open access journals	Citations	Raw citation impact
eTOX	86	84	59.3%	1799	21.37
EUROPAIN	154	154	35.1%	4119	26.75
IMIDIA	127	124	78.0%	2666	21.50
INNODIA	19	17	36.8%	28	1.65
MARCAR	49	48	79.6%	693	14.38
NEWMEDS	173	171	50.3%	5285	30.88
Pharma-Cog	69	65	26.1%	1294	19.91
PROTECT	95	94	38.9%	1018	10.83
SAFE-T	17	15	29.4%	194	12.93
SUMMIT	99	96	65.7%	1346	14.02
U-BIOPRED	79	54	26.6%	1334	24.54


- Of the projects in call 1, IMIDIA had the highest number of publications in open access journals (99), and MARCAR had the highest percentage of publications in open access journals (79.6%).
- There is a step change in the percentage of papers seen in open access journals compared to the previous reports. This is likely not representative of a real difference in publishing behaviour, but a result of increased resolution as Clarivate Analytics has improved its coverage of open access publications.¹⁰

¹⁰ Easing Access to Open Access: Clarivate Analytics partners with Impactstory: <https://clarivate.com/blog/easing-access-to-open-access-clarivate-analytics-partners-with-impactstory/>

5.3 SUMMARY BIBLIOMETRIC ANALYSES FOR IMI PROJECTS – CALL 2

Figure 5.3.1 presents an analysis of IMI-supported research published by IMI 1, call 2 projects. Only projects with at least 10 papers and one highly-cited paper over the time period (2010-2017) are shown. The number of papers, average citation impact and share of highly-cited papers are compared. The area of the ‘bubble’ is proportional to the share of highly-cited papers. The solid horizontal line indicates the average citation impact for all IMI project papers.

FIGURE 5.3.1 PAPER NUMBERS, AVERAGE CITATION IMPACT AND SHARE OF HIGHLY-CITED RESEARCH



FOR SELECTED IMI PROJECTS – CALL 2, 2010-2017

The data in Figure 5.3.1 shows that:

- The average citation impact of most call 2 projects was above world average. RAPP-ID had a citation impact very close to world average (1.01).
- BTCURE was by far the most prolific IMI call 2 project with 541 papers at the end of 2017. The citation impact of this research was twice the world average (1.96).
- Research associated with EBOVAC1 was very well-cited with a citation impact of well over three times (3.70) the world average. It should be noted that this project only published 11 papers by the end of 2017.
- QUIC-CONCEPT, Open PHACTS and Onco Track were also very well-cited with a citation impact of more than twice the world average; 2.74, 2.69 and 2.66 respectively.
- Four of the nine projects in this call had an average citation impact greater than the citation impact of all IMI project papers, and Preduct was exactly at the IMI average.

Table 5.3.1 shows citation impact normalised against world average values for call 2 and is an expansion of the data used in Figure 5.3.1. Table 5.3.2 shows raw citation impact and the percentage of open access papers by project for call 2 publications.

TABLE 5.3.1 SUMMARY CITATION INDICATORS FOR IMI PROJECTS IN CALL 2, 2010-2017

Project	Number of Papers	Citation Impact			% Highly cited papers
		Normalised at field level (nci _F)	Normalised at journal level (nci _J)	Average Percentile	
BTCure	541	1.96	1.13	34.40	27.54%
DDMoRe	58	0.71	0.71	62.27	6.90%
EBOVAC1	11	3.70	1.43	32.76	36.36%
EHR4CR	16	1.19	1.31	48.07	12.50%
Onco Track	50	2.66	1.33	27.12	40.00%
Open PHACTS	68	2.69	1.77	44.65	22.06%
Preduct	34	1.98	1.47	38.18	32.35%
Quic-Concept	80	2.74	1.70	38.37	33.75%
RAPP-ID	36	1.01	1.00	42.97	8.33%
Overall (IMI projects)	3550	1.98	1.26	35.77	25.55%

TABLE 5.3.2 BIBLIOMETRIC INDICATORS FOR IMI PROJECTS IN CALL 2, 2010-2017


Project	Number of Publications	Number of papers	% Publications in Open access journals	Citations	Raw citation impact
BTCure	573	541	59.2%	9098	16.72
DDMoRe	61	58	63.9%	327	5.60
EBOVAC1	13	11	100.0%	68	6.09
EHR4CR	16	16	75.0%	124	7.75
Onco Track	53	50	58.5%	1664	33.26
Open PHACTS	71	68	84.5%	1496	19.43
Preduct	36	34	77.8%	445	13.09
Quic-Concept	80	80	61.3%	1826	22.82
RAPP-ID	36	36	50.0%	396	11.00

- Among the projects with at least 10 publications, BTCURE was the project with the highest number of open access publications (339), but all of EBOVAC1's 13 publications were open access.

5.4 SUMMARY BIBLIOMETRIC ANALYSES FOR IMI PROJECTS – CALL 3

Figure 5.4.1 presents an analysis of research published by IMI 1, call 3 projects. Only projects with at least ten papers and one highly-cited paper over the time period (2010-2017) are shown. The number of papers, average citation impact and share of highly-cited papers are compared. The area of the 'bubble' is proportional to the share of highly-cited papers. The solid horizontal line indicates the average citation impact for all IMI project papers.

FIGURE 5.4.1 PAPER NUMBERS, AVERAGE CITATION IMPACT AND SHARE OF HIGHLY-CITED RESEARCH FOR SELECTED IMI PROJECTS – CALL 3, 2010-2017



The data in Figure 5.4.1 shows that:

- The average citation impact of all projects in this call was above world average.
- EU-AIMS was by far the most prolific call 3 project with 255 papers by the end of 2017. The citation impact of this research was more than twice the world average (2.36).
- Research associated with DIRECT was also very well-cited with a citation impact that was over three times the world average (3.22).
- Two of the six projects in call 3 had an average citation impact greater than the citation impact of all IMI related projects.

Table 5.4.1 shows citation impact normalised against world average values for IMI call 3 projects and is an expansion of the data shown in Figure 5.4.1. Table 5.4.2 shows raw citation impact and the percentage of open access papers by project for call 3 publications.

TABLE 5.4.1 SUMMARY CITATION INDICATORS FOR IMI PROJECTS IN CALL 3, 2010-2017

Project	Number of Papers	Citation Impact		Average Percentile	% Highly cited papers
		Normalised at field level (nci _f)	Normalised at journal level (nci _j)		
ABIRISK	48	1.49	1.17	45.48	18.75%
BioVacSafe	46	1.55	1.18	37.71	30.43%
DIRECT	34	3.22	1.21	46.85	26.47%
EU-AIMS	255	2.36	1.22	34.17	33.33%
MIP-DILI	75	1.85	1.45	38.85	28.00%
PreDiCT-TB	70	1.31	0.91	47.45	14.29%
Overall (IMI projects)	3550	1.98	1.26	35.77	25.55%

TABLE 5.4.2 SUMMARY BIBLIOMETRIC INDICATORS FOR IMI PROJECTS IN CALL 3, 2010-2017


Project	Number of Publications	Number of papers	% Publications in Open access journals	Citations	Raw citation impact
ABIRISK	57	48	42.1%	617	12.85
BioVacSafe	48	46	68.8%	728	15.80
DIRECT	49	34	51.0%	556	16.35
EU-AIMS	262	255	59.2%	4851	18.88
MIP-DILI	82	75	48.8%	626	8.27
PreDiCT-TB	70	70	78.6%	598	8.54

- Among the projects with at least 10 publications, EU-AIMS was the project with the highest number of publications in open access journals (44) but PreDiCT-TB had the highest percentage of publications in open access journals (26.4%).

5.5 SUMMARY BIBLIOMETRIC ANALYSES FOR IMI PROJECTS – CALL 4

Table 5.5.1 presents an analysis of research published by IMI 1, call 4 projects. Only projects with at least ten papers and one highly-cited paper over the time period (2010-2017) are shown. The number of papers, average citation impact and share of highly-cited papers are compared. The area of the 'bubble' is proportional to the share of highly-cited papers. The solid horizontal line indicates the average citation impact for all IMI project papers.

FIGURE 5.5.1 PAPER NUMBERS, AVERAGE CITATION IMPACT AND SHARE OF HIGHLY-CITED RESEARCH FOR SELECTED IMI PROJECTS – CALL 4, 2010-2017



The data in Figure 5.5.1 shows that:

- The average citation impact of all projects in this call is above world average.
- EMIF produced the highest number of papers in call 4, with 155 to the end of 2017.
- Research associated with EMIF and eTRICKS was very well-cited with citation impacts of 2.80 and 2.71, respectively.
- Three of the seven projects in this call had an average citation impact greater than the citation impact of all IMI related projects.

Table 5.5.1 presents indicators where citation impact has been normalised against world average values and is an expansion of the data used in Figure 5.5.1. Table 5.5.2 shows raw citation impact and the percentage of open access papers by project for call 4 publications.

TABLE 5.5.1 SUMMARY BIBLIOMETRIC INDICATORS FOR IMI PROJECTS IN CALL 4, 2010-2016

Project	Number of Papers	Citation Impact		Average Percentile	% Highly cited papers
		Normalised at field level (nci _F)	Normalised at journal level (nci _J)		
CHEM21	102	1.73	1.38	40.27	16.67%
COMPACT	54	1.89	1.45	40.41	24.07%
EMIF	155	2.80	1.45	38.13	33.55%
eTRIKS	22	2.71	2.27	26.32	54.55%
K4DD	35	2.01	1.33	34.67	28.57%
ORBITO	106	1.60	1.28	46.73	19.81%
STEMBANCC	71	1.73	1.33	45.14	19.72%
Overall (IMI projects)	3550	1.98	1.26	35.77	25.55%

TABLE 5.5.2 BIBLIOMETRIC INDICATORS FOR IMI PROJECTS IN CALL 4, 2010-2017


Project	Number of Publications	Number of Papers	% Publications in Open access journals	Citations	Raw citation impact
CHEM21	105	102	25.7%	1310	12.83
COMPACT	54	54	31.5%	586	10.85
EMIF	160	155	67.5%	1954	12.60
eTRIKS	22	22	77.3%	225	10.23
K4DD	35	35	57.1%	245	7.00
ORBITO	107	106	19.6%	836	7.86
STEMBANCC	71	71	66.2%	596	8.39

- EMIF has the highest number of citations (1954) and has a citation impact just lower than CHEM21 which has the highest.
- EMIF is the project with the highest number of publications (108) in open access journals and eTRICKS has the highest percentage in open access journals (77.3%)

5.6 SUMMARY BIBLIOMETRIC ANALYSES FOR IMI PROJECTS – CALL 5-11

Figure 5.6.1 presents an analysis of IMI-supported research published by IMI 1, call 5-11 projects. Only projects with at least ten papers and one highly-cited paper over the time period analysed (2010-2017) are shown. The number of papers, average citation impact and share of highly-cited papers are compared. The area of the 'bubble' is proportional to the share of highly-cited papers. The solid horizontal line indicates the average citation impact for all IMI project papers.

FIGURE 5.6.1 PAPER NUMBERS, AVERAGE CITATION IMPACT AND SHARE OF HIGHLY-CITED RESEARCH FOR SELECTED IMI PROJECTS – CALL 5-11, 2010-2017



The data in Figure 5.6.1 shows that:

- Research associated with CANCER-ID was very well-cited with a citation impact of more than three and a half times the world average (3.66), and 49.18% of papers that are highly-cited.

Table 5.6.1 presents indicators where citation impact has been normalised against world average values and is an expansion of the data used in Figure 5.6.1. Table 5.6.2 shows raw citation impact and the percentage of open access papers by project for call 5-11 publications.

TABLE 5.6.1 SUMMARY BIBLIOMETRIC INDICATORS FOR IMI PROJECTS IN CALL 5-11, 2010-2017

Project	Number of Papers	Citation Impact		Average Percentile	% Highly cited papers
		Normalised at field level (nci _F)	Normalised at journal level (nci _J)		
AETIONOMY	32	1.06	0.77	53.69	18.75%
APPROACH	16	3.23	1.63	40.39	25.00%
CANCER-ID	61	3.66	1.66	24.11	49.18%
COMBACTE-CARE	15	2.37	2.01	35.52	20.00%
COMBACTE-MAGNET	19	1.97	1.51	55.09	21.05%
COMBACTE-NET	14	0.75	0.44	74.73	7.14%
DRIVE-AB	16	2.03	1.18	40.98	31.25%
ELF	75	1.33	1.07	44.26	20.00%
ENABLE	12	1.65	1.37	31.19	25.00%
FLUCOP	17	1.13	1.25	47.55	11.76%
GETREAL	26	3.35	1.86	33.28	34.62%
iPiE	16	1.60	1.68	49.44	18.75%
PRECISESADS	22	1.43	0.88	41.93	22.73%
SPRINTT	44	3.03	2.85	26.72	45.45%
TRANSLOCATION	84	1.50	1.13	40.14	23.81%
ULTRA-DD	109	2.11	1.17	47.17	24.77%
ZAPI	21	2.30	1.22	52.35	33.33%
Overall (IMI projects)	3550	1.98	1.26	35.77	25.55%

TABLE 5.6.2 BIBLIOMETRIC INDICATORS FOR IMI PROJECTS IN CALL 5-11, 2010-2017

Project	Number of Publications	Number of Papers	% Open access journals	Citations	Raw citation impact
AETIONOMY	33	32	63.6%	130	4.06
APPROACH	17	16	70.6%	113	7.06
CANCER-ID	69	61	56.5%	638	10.36
COMBACTE-CARE	16	15	37.5%	45	3.00
COMBACTE-MAGNET	22	19	54.5%	43	2.11
COMBACTE-NET	15	14	60.0%	9	0.64
DRIVE-AB	20	16	45.0%	141	8.56
ELF	75	75	46.7%	422	5.63
ENABLE	12	12	75.0%	101	8.42
FLUCOP	17	17	70.6%	55	3.24
GETREAL	31	26	58.1%	77	2.65
iPiE	16	16	50.0%	32	2.00
PRECISESADS	29	22	34.5%	188	8.55
SPRINTT	45	44	35.6%	242	5.48
TRANSLOCATION	84	84	50.0%	695	8.27


Project	Number of Publications	Number of Papers	% Open access journals	Citations	Raw citation impact
ULTRA-DD	110	109	62.7%	579	5.30
ZAPI	22	21	72.7%	125	5.86

- ENABLE has the highest percentage (75.0%) of publications in open access journals with a raw citation impact of 8.42, second highest in calls 5-7 in the range 2010-2017.
- ULTRA-DD has the highest number of publications (110) but TRANSLOCATION has the most citations (695).

5.7 SUMMARY BIBLIOMETRIC ANALYSES FOR IMI 2 PROJECTS

Figure 5.7.1 shows trends in publication output of IMI 2 funding call projects. Table 5.7.1 presents summary bibliometric data for IMI 2 calls, including the number of publications, the number of papers, and the average citation impact.

FIGURE 5.7.1 NUMBER OF WEB OF SCIENCE PUBLICATIONS BY YEAR AND FUNDING CALL 2015-2017 FOR IMI 2 PROJECTS



- IMI 2 projects from call 2 generated the greatest number of publications from 2015-2017.

TABLE 5.7.1 SUMMARY BIBLIOMETRIC ANALYSES OF IMI 2 PROJECTS AGGREGATED BY FUNDING CALL, 2015-2017

IMI Call	Number of Publications ¹¹	% Publications in Open access journals	Number of Papers	Raw citation impact	Citation Impact Normalised at field level (ncif)	Normalised at journal level (ncij)
1	18	38.9%	16	1.19	1.20	0.93
2	29	77.4%	27	3.34	1.92	0.93
3	8	62.5%	7	3.43	2.45	0.54
4	2	0.0%	2	2.00	0.67	0.36
5	16	70.6%	14	0.73	0.88	0.56
6	7	57.1%	3	0.00	0.00	0.00
7	4	75.0%	3	5.00	5.68	0.70
8	1	0.0%	1	3.00	4.46	1.24
9	3	66.7%	3	1.00	1.37	0.17

- Call 2 has the highest number of publications and the highest proportion in open access journals.

¹¹ Publications can be associated with more than one call.

Figure 5.6.1 and Table 5.7.3 present an analysis of IMI-supported research published by IMI 2 projects. Table 5.7.2 presents indicators where citation impact has been normalised against world average values. Table 5.7.3 shows raw citation impact and percentage of open access journals by project for IMI 2 publications.

TABLE 5.7.2 SUMMARY BIBLIOMETRIC INDICATORS FOR IMI 2 PROJECTS, 2015-2017

Project	Number of Papers	Citation Impact		Average Percentile	% Highly cited papers
		Normalised at field level (ncif)	Normalised at journal level (ncij)		
ADAPTED	1	1.62	0.56	22.21	0.0%
ADAPT-SMART	2	0.67	0.36	63.37	0.0%
AMYPAD	1	0.00	0.00	100.00	0.0%
BEAT-DKD	10	1.00	0.72	67.51	10.0%
BigData@Heart	0	0.00	0.00	0.00	0.0%
EBODAC	1	0.00	0.00	100.00	0.0%
Ebola+	1	4.46	1.24	4.80	100.0%
EbolaMoDRAD	10	0.68	0.86	71.94	0.0%
EBOVAC1	11	3.70	1.43	32.76	36.4%
EBOVAC2	2	0.00	0.00	100.00	0.0%
FILODIAG	1	0.00	0.00	100.00	0.0%
HARMONY	1	0.00	0.00	100.00	0.0%
IMPRIND	2	8.52	1.05	50.16	50.0%
INNODIA	16	1.20	0.93	71.50	12.5%
PHAGO	3	0.54	0.19	74.07	0.0%
PREFER	0	0.00	0.00	0.00	0.0%
PRISM	1	0.00	0.00	100.00	0.0%
RADAR-CNS	2	0.23	0.09	82.79	0.0%
RHAPSODY	4	4.17	0.89	30.59	50.0%
ROADMAP	1	0.00	0.00	100.00	0.0%
RTCure	3	1.37	0.17	68.27	33.3%
TransQST	1	0.00	0.00	100.00	0.0%
TRISTAN	1	0.00	0.00	100.00	0.0%
VSV-EBOVAC	4	2.04	0.69	32.17	50.0%
Overall (IMI projects)	3550	1.98	1.26	35.77	25.5%

TABLE 5.7.3 BIBLIOMETRIC INDICATORS FOR IMI 2 PROJECTS, 2015-2017

Project	Number of Publications	Number of Papers	% Open access journals	Citations	Raw citation impact
ADAPTED	1	1	100.0%	1	1.00
ADAPT-SMART	2	2	0.0%	4	2.00
AMYPAD	1	1	100.0%	0	0.00
BEAT-DKD	10	10	60.0%	9	0.90
BigData@Heart	1	0	0.0%	0	0.00
EBODAC	1	1	100.0%	0	0.00
Ebola+	1	1	0.0%	3	3.00
EbolaMoDRAD	10	10	50.0%	7	0.70
EBOVAC1	13	11	100.0%	68	6.09
EBOVAC2	2	2	100.0%	0	0.00
FILODIAG	1	1	100.0%	0	0.00
HARMONY	3	1	66.7%	1	0.00
IMPRiND	2	2	100.0%	15	7.50
INNODIA	18	16	38.9%	19	1.19
PHAGO	3	3	100.0%	1	0.33
PREFER	2	0	50.0%	1	0.00
PRISM	1	1	100.0%	0	0.00
RADAR-CNS	2	2	50.0%	1	0.50
RHAPSODY	5	4	60.0%	23	5.57
ROADMAP	3	1	33.3%	0	0.00
RTCure	3	3	66.7%	3	1.00
TransQST	1	1	100.0%	0	0.00
TRISTAN	1	1	100.0%	0	0.00
VSV-EBOVAC	4	4	50.0%	23	5.75

- INNODIA has the highest number of papers (16) but EBOVAC1 has the highest number of citations (68), with a raw citation impact of 6.09.
- Very low paper counts make it difficult to draw firm conclusions from average citation impact indicators. However, the IMPRiND project had the highest field normalised citation impact (8.52) followed by Ebola+ (4.46).

6 COLLABORATION ANALYSIS FOR IMI RESEARCH

6.1 COLLABORATION ANALYSIS FOR IMI RESEARCH

International research collaboration is a rapidly growing aspect of research activity.¹² The reasons for this have not been fully clarified but include increasing access to facilities, resources, knowledge, people and expertise. In addition, international collaboration has been shown to be associated with an increase in the number of citations received by research papers, although this does depend upon the partner countries involved.¹³ Co-authorship is likely to be a good indicator of collaboration, although there will be collaborations that do not result in co-authored papers, and co-authored papers which may have required limited collaboration. Alternative data-based approaches, for example using information about co-funding or international exchanges, have limitations in terms of both comprehensiveness and validity.

In this report, co-authorship is used as a measure of collaboration. Table 6.1.1 compares the output and citation impact of IMI project papers that are co-authored between different sectors, institutions and countries. In this analysis the sectors are defined as academic, corporate, government, medical, or other¹⁴. A paper is defined as cross-sector if the listed addresses are for organisations from more than one sector. For example, if a paper has addresses corresponding to the University of Copenhagen and the company Novartis, it would be classified as cross-sector. If a paper has addresses corresponding to the University of Cambridge and Utrecht University, it would be classified as single-sector since both addresses are academic institutions. A paper is defined as cross-institution if more than one institution is listed in the addresses. A paper is defined as international if more than one country is listed in the addresses, or domestic if a single country is listed.

The data in Table 6.1.1 show that IMI project research is collaborative at the sector, institution and country level.

TABLE 6.1.1 CROSS-SECTOR, CROSS-INSTITUTION AND INTERNATIONAL OUTPUT – IMI PROJECT RESEARCH, 2010-2016

	Number of papers	Percentage of Papers	Citation impact (normalised at field level)
Cross-sector	2117	59.7%	2.72
Single-sector	1428	40.3%	2.09
Cross-institution	2954	83.3%	2.64
Single-institution	591	16.7%	1.77
International	2126	60.0%	2.80
Domestic	1419	40.0%	1.97

- Over half (59.7%) of all IMI project papers were published by researchers affiliated with different sectors.
- More than three-quarters (83.3%) of IMI project papers involved collaboration between institutions.
- More than half (60%) of all IMI project papers were internationally collaborative.

¹² Adams J (2013). Collaborations: the fourth age of research. *Nature*, 497, 557-560.

¹³ Adams, J., Gurney, K., & Marshall, S. (2007). Patterns of international collaboration for the UK and leading partners. A report by *Evidence Ltd* to the UK Office of Science and Innovation. 27pp.

¹⁴ These sectors are: academic, corporate, medical, government, or other. Medical includes hospitals and institutions that provide information to patients such as the American Cancer Society. Government includes state or federally funded research institutions such as NIH or the World Health Organization (WHO). Other includes any other research institutions.

- Collaborative IMI project research was internationally influential with a citation impact well over twice the world average (1.0). Collaborative IMI research also had more of an impact than non-collaborative IMI project research.

6.2 COLLABORATION ANALYSIS BY IMI PROJECT

In this section, the collaboration of IMI research is presented at the more granular level of individual projects. Table 6.2.1 shows the number, percentage and citation impact of IMI-supported research papers with authors from more than one country. Table 6.2.2 shows number, percentage, and citation impact of IMI-supported research papers with authors from more than one institution. Table 6.2.3 shows number, percentage and citation impact of IMI-supported research papers with authors from more than one sector. This section also presents maps of international collaboration for the five IMI projects with the highest number of publications. The projects included are BTCURE, EU-AIMS, NEWMEDS, EUROPAIN, and IMIDIA. The countries with the most frequent collaboration are shaded purple, those with little collaboration in white, and those with no collaboration in grey.

It should be noted that the last column in Table 6.2.1-6.2.3 does not show the citation impact of all papers for that project, rather it is the citation impact of those papers involving collaboration of the type being analysed. Therefore, in Table 6.2.1, the last column contains the citation impact of only the internationally collaborative papers for each project. Similarly, the last column in Table 6.2.2 contains only the citation impact of the papers from more than one institution, and in Table 6.2.3, the last column contains only the citation impact of cross sector papers.

The key findings of this section are:

- BTCURE had the highest number of papers with authors from more than one country, institution and sector (Table 6.1.1-6.2.3). This may be due to BTCURE having the highest overall number of papers.
- EU-AIMS had the second highest number of papers with authors from more than one country, institution and sector (Table 6.1.1-6.2.3).
- The majority of collaborative papers from the top five projects were co-authored with researchers from the United States (USA) and Europe (Figure 6.2.1-6.2.5).
- For BTCURE, there were also substantial collaborations with China, and Japan (Figure 6.2.1). EU-AIMS also had substantial collaborations with Canada and China (Figure 6.2.2), and NEWMEDS also had substantial collaborations with Canada (Figure 6.2.3).

TABLE 6.2.1 NUMBER, PERCENTAGE AND CITATION IMPACT¹⁵ OF IMI-SUPPORTED RESEARCH PAPERS WITH AUTHORS FROM MORE THAN ONE COUNTRY, 2010-2017

Project	Number of papers	Number of internationally collaborative papers	Percentage of internationally collaborative papers	Citation impact (normalised at field level)
BTCure	541	313	57.9%	2.16
EU-AIMS	255	181	71.0%	2.50
NEWMEDS	171	109	63.7%	2.35
EMIF	155	112	72.3%	3.29
EUROPAIN	154	62	40.3%	2.94
IMIDIA	124	69	55.6%	1.96
ULTRA-DD	109	81	74.3%	2.10
ORBITO	106	60	56.6%	1.64
CHEM21	102	36	35.3%	2.29
SUMMIT	96	62	64.6%	1.53
PROTECT	94	69	73.4%	1.18
TRANSLOCATION	84	49	58.3%	1.68
eTOX	84	34	40.5%	1.62
Quic-Concept	80	55	68.8%	3.27
ELF	75	41	54.7%	1.32
MIP-DILI	75	40	53.3%	1.99
STEMBANCC	71	38	53.5%	1.90
PreDiCT-TB	70	40	57.1%	1.59
Open PHACTS	68	42	61.8%	2.60
Pharma-Cog	65	53	81.5%	1.73
CANCER-ID	61	29	47.5%	5.07
DDMoRe	58	36	62.1%	0.70
U-BIOPRED	54	35	64.8%	3.22
COMPACT	54	25	46.3%	1.85
Onco Track	50	24	48.0%	3.06
ABIRISK	48	22	45.8%	1.52
MARCAR	48	23	47.9%	1.51
BioVacSafe	46	21	45.7%	1.48
SPRINTT	44	28	63.6%	3.27
COMBACTE	39	15	38.5%	1.56
RAPP-ID	36	17	47.2%	0.98
K4DD	35	20	57.1%	2.55
Preduct	34	24	70.6%	1.96
DIRECT	34	24	70.6%	3.39
AETIONOMY	32	15	46.9%	1.10
GETREAL	26	23	88.5%	2.86
ND4BB	24	13	54.2%	1.46
PRO-active	24	20	83.3%	2.51
PRECISESADS	22	17	77.3%	1.52

¹⁵ The last column is the citation impact of only the internationally collaborative papers.

Project	Number of papers	Number of internationally collaborative papers	Percentage of internationally collaborative papers	Citation impact (normalised at field level)
eTRIKS	22	21	95.5%	2.84
ZAPI	21	15	71.4%	2.36
COMBACTE-MAGNET	19	14	73.7%	2.10
INNODIA	17	13	76.5%	1.48
FLUCOP	17	13	76.5%	1.42
APPROACH	16	15	93.8%	3.45
DRIVE-AB	16	10	62.5%	2.07
iPiE	16	3	18.8%	0.91
EHR4CR	16	11	68.8%	1.42
SAFE-T	15	9	60.0%	2.01
COMBACTE-CARE	15	13	86.7%	2.50
COMBACTE-NET	14	8	57.1%	1.27
ENABLE	12	5	41.7%	1.14
EBOVAC1	11	7	63.6%	4.95
EbolaMoDRAD	10	6	60.0%	1.13
EBiSC	10	8	80.0%	1.29
BEAT-DKD	10	7	70.0%	0.82
ADVANCE	7	6	85.7%	1.49
EPAD	6	5	83.3%	1.60
WEB-RADR	5	5	100.0%	3.21
VSV-EBOVAC	4	3	75.0%	1.93
RHAPSODY	4	3	75.0%	1.89
Structural Genomic Consortium	3	2	66.7%	0.00
PHAGO	3	3	100.0%	0.54
RTCure	3	0	0.0%	0.00
iABC	3	2	66.7%	3.19
SafeSciMET	3	3	100.0%	1.52
RADAR-CNS	2	2	100.0%	0.23
IMPRiND	2	1	50.0%	17.05
EUPATI	2	2	100.0%	1.01
Eu2P	2	1	50.0%	0.00
EBOVAC2	2	2	100.0%	0.00
ADAPT-SMART	2	1	50.0%	1.33
TransQST	1	1	100.0%	0.00
TRISTAN	1	1	100.0%	0.00
ADAPTED	1	1	100.0%	1.62
AMYPAD	1	0	0.0%	0.00
EBODAC	1	1	100.0%	0.00
Ebola+	1	1	100.0%	4.46
EMTRAIN	1	1	100.0%	0.16
FILODIAG	1	0	0.0%	0.00
HARMONY	1	1	100.0%	0.00
Pharmatrain	1	1	100.0%	0.00

Project	Number of papers	Number of internationally collaborative papers	Percentage of internationally collaborative papers	Citation impact (normalised at field level)
PRISM	1	0	0.0%	0.00
ROADMAP	1	1	100.0%	0.00
PREFER	0	0	0.0%	0.00
BigData@Heart	0	0	0.0%	0.00

TABLE 6.2.2 NUMBER, PERCENTAGE AND CITATION IMPACT¹⁶ OF IMI-SUPPORTED RESEARCH PAPERS WITH AUTHORS FROM MORE THAN ONE INSTITUTION, 2010-2017

Project	Number of papers	Number of papers from more than one institution	Percentage of papers from more than one institution	Citation impact (normalised at field level)
BTCure	541	437	80.8%	2.06
EU-AIMS	255	239	93.7%	2.38
NEWMEDS	171	155	90.6%	2.34
EMIF	155	143	92.3%	2.97
EUROPAIN	154	99	64.3%	2.68
IMIDIA	124	100	80.6%	1.79
ULTRA-DD	109	101	92.7%	2.10
ORBITO	106	79	74.5%	1.53
CHEM21	102	58	56.9%	1.94
SUMMIT	96	79	82.3%	1.40
PROTECT	94	93	98.9%	1.07
TRANSLOCATION	84	65	77.4%	1.51
eTOX	84	57	67.9%	2.07
Quic-Concept	80	68	85.0%	3.05
ELF	75	54	72.0%	1.27
MIP-DILI	75	58	77.3%	1.72
STEMBANCC	71	55	77.5%	1.87
PreDiCT-TB	70	58	82.9%	1.43
Open PHACTS	68	59	86.8%	3.02
Pharma-Cog	65	63	96.9%	1.57
CANCER-ID	61	55	90.2%	3.85
DDMoRe	58	47	81.0%	0.64
U-BIOPRED	54	47	87.0%	2.67
COMPACT	54	41	75.9%	1.76
Onco Track	50	44	88.0%	2.89
ABIRISK	48	43	89.6%	1.56
MARCAR	48	34	70.8%	1.32
BioVacSafe	46	34	73.9%	1.51
SPRINTT	44	32	72.7%	3.43
COMBACTE	39	32	82.1%	1.41
RAPP-ID	36	26	72.2%	0.98
K4DD	35	30	85.7%	2.22
DIRECT	34	32	94.1%	3.06
Prelect	34	28	82.4%	1.84
AETIONOMY	32	32	100.0%	1.06
GETREAL	26	26	100.0%	3.35
ND4BB	24	21	87.5%	1.27
PRO-active	24	24	100.0%	2.17
PRECISESADS	22	22	100.0%	1.43

¹⁶ The last column in is only the citation impact of the papers from more than one institution.

Project	Number of papers	Number of papers from more than one institution	Percentage of papers from more than one institution	Citation impact (normalised at field level)
eTRIKS	22	22	100.0%	2.71
ZAPI	21	18	85.7%	1.99
COMBACTE-MAGNET	19	16	84.2%	2.32
FLUCOP	17	15	88.2%	1.28
INNODIA	17	16	94.1%	1.23
APPROACH	16	16	100.0%	3.23
DRIVE-AB	16	12	75.0%	2.16
iPiE	16	13	81.3%	1.67
EHR4CR	16	16	100.0%	1.19
SAFE-T	15	15	100.0%	1.64
COMBACTE-CARE	15	15	100.0%	2.37
COMBACTE-NET	14	12	85.7%	0.87
ENABLE	12	11	91.7%	1.38
EBOVAC1	11	11	100.0%	3.70
BEAT-DKD	10	10	100.0%	1.00
EBiSC	10	9	90.0%	1.43
EbolaMoDRAD	10	9	90.0%	0.75
ADVANCE	7	6	85.7%	1.49
EPAD	6	6	100.0%	1.33
WEB-RADR	5	5	100.0%	3.21
VSV-EBOVAC	4	3	75.0%	1.93
RHAPSODY	4	3	75.0%	1.89
SafeSciMET	3	3	100.0%	1.52
iABC	3	3	100.0%	2.13
RTCure	3	1	33.3%	0.00
PHAGO	3	3	100.0%	0.54
Structural Genomic Consortium	3	3	100.0%	0.00
ADAPT-SMART	2	2	100.0%	0.67
EBOVAC2	2	2	100.0%	0.00
Eu2P	2	2	100.0%	1.96
EUPATI	2	2	100.0%	1.01
IMPRiND	2	1	50.0%	17.05
RADAR-CNS	2	2	100.0%	0.23
ROADMAP	1	1	100.0%	0.00
PRISM	1	1	100.0%	0.00
Pharmatrain	1	1	100.0%	0.00
HARMONY	1	1	100.0%	0.00
FILODIAG	1	1	100.0%	0.00
EMTRAIN	1	1	100.0%	0.16
Ebola+	1	1	100.0%	4.46
EBODAC	1	1	100.0%	0.00
AMYPAD	1	1	100.0%	0.00
ADAPTED	1	1	100.0%	1.62

Project	Number of papers	Number of papers from more than one institution	Percentage of papers from more than one institution	Citation impact (normalised at field level)
TRISTAN	1	1	100.0%	0.00
TransQST	1	1	100.0%	0.00
PREFER	0	0	0.0%	0.00
BigData@Heart	0	0	0.0%	0.00

TABLE 6.2.3 NUMBER, PERCENTAGE AND CITATION IMPACT¹⁷ OF IMI-SUPPORTED RESEARCH PAPERS WITH AUTHORS FROM MORE THAN ONE SECTOR, 2010-2017

Project	Number of papers	Number of cross sector papers	Percentage of cross sector papers	Citation impact (normalised at field level)
BTCure	541	332	61.4%	2.17
EU-AIMS	255	171	67.1%	2.43
NEWMEDS	170	108	63.5%	2.38
EMIF	155	123	79.4%	2.64
EUROPAIN	154	78	50.6%	2.82
IMIDIA	124	64	51.6%	2.03
ULTRA-DD	109	63	57.8%	2.72
ORBITO	106	57	53.8%	1.77
CHEM21	102	21	20.6%	2.39
SUMMIT	96	68	70.8%	1.36
PROTECT	94	92	97.9%	1.07
TRANSLOCATION	84	30	35.7%	1.54
eTOX	84	24	28.6%	1.78
Quic-Concept	80	56	70.0%	2.22
ELF	75	27	36.0%	1.34
MIP-DILI	75	52	69.3%	1.79
STEMBANCC	71	38	53.5%	2.02
PreDiCT-TB	70	39	55.7%	1.31
Open PHACTS	68	41	60.3%	3.15
Pharma-Cog	65	56	86.2%	1.69
CANCER-ID	61	46	75.4%	4.10
DDMoRe	58	33	56.9%	0.71
COMPACT	54	8	14.8%	3.55
U-BIOPRED	54	41	75.9%	2.87
Onco Track	50	28	56.0%	2.86
ABIRISK	48	31	64.6%	1.51
MARCAR	48	21	43.8%	1.37
BioVacSafe	46	20	43.5%	1.46
SPRINTT	43	22	51.2%	3.42
COMBACTE	39	23	59.0%	1.65
RAPP-ID	36	11	30.6%	0.99
K4DD	35	16	45.7%	1.97
DIRECT	34	24	70.6%	2.12
Predect	34	24	70.6%	4.23
AETIONOMY	32	20	62.5%	1.43
GETREAL	26	21	80.8%	3.65
PRO-active	24	24	100.0%	2.17
ND4BB	23	11	47.8%	1.31
eTRIKS	22	15	68.2%	3.26

¹⁷ The last column is only citation impact of cross sector papers.

Project	Number of papers	Number of cross sector papers	Percentage of cross sector papers	Citation impact (normalised at field level)
PRECISESADS	22	15	68.2%	1.55
ZAPI	21	12	57.1%	2.68
COMBACTE-MAGNET	18	12	66.7%	2.31
FLUCOP	17	16	94.1%	1.20
INNODIA	17	9	52.9%	1.41
DRIVE-AB	16	10	62.5%	2.12
APPROACH	16	11	68.8%	2.63
iPiE	16	9	56.3%	0.64
EHR4CR	16	14	87.5%	1.22
COMBACTE-CARE	15	15	100.0%	2.37
SAFE-T	15	15	100.0%	1.64
COMBACTE-NET	14	12	85.7%	0.87
ENABLE	12	4	33.3%	1.30
EBOVAC1	11	6	54.5%	5.77
EBiSC	10	5	50.0%	1.77
EbolaMoDRAD	10	4	40.0%	0.82
BEAT-DKD	10	6	60.0%	0.79
ADVANCE	7	4	57.1%	1.85
EPAD	6	5	83.3%	1.60
WEB-RADR	5	3	60.0%	3.37
RHAPSODY	4	1	25.0%	11.02
VSV-EBOVAC	4	2	50.0%	2.89
PHAGO	3	2	66.7%	0.00
RTCure	3	1	33.3%	0.00
SafeSciMET	3	3	100.0%	1.52
Structural Genomic Consortium	3	2	66.7%	0.00
iABC	3	2	66.7%	3.19
IMPRiND	2	0	0.0%	0.00
ADAPT-SMART	2	2	100.0%	0.67
EUPATI	2	2	100.0%	1.01
Eu2P	2	1	50.0%	0.00
RADAR-CNS	2	1	50.0%	0.45
EBOVAC2	2	1	50.0%	0.00
EMTRAIN	1	1	100.0%	0.16
ROADMAP	1	1	100.0%	0.00
Pharmatrain	1	1	100.0%	0.00
PRISM	1	0	0.0%	0.00
FILODIAG	1	1	100.0%	0.00
AMYPAD	1	0	0.0%	0.00
Ebola+	1	1	100.0%	4.46
TransQST	1	1	100.0%	0.00
TRISTAN	1	0	0.0%	0.00
ADAPTED	1	0	0.0%	0.00

Project	Number of papers	Number of cross sector papers	Percentage of cross sector papers	Citation impact (normalised at field level)
EBODAC	1	0	0.0%	0.00
PREFER	0	0	0.0%	0.00
HARMONY	0	0	0.0%	0.00
BigData@Heart	0	0	0.0%	0.00

FIGURE 6.2.1 INTERNATIONAL COLLABORATION BY COUNTRY, FOR IMI PROJECT: BTCURE, 2010-2017




FIGURE 6.2.2 INTERNATIONAL COLLABORATION BY COUNTRY, FOR IMI PROJECT: EU-AIMS, 2010-2017




FIGURE 6.2.3 INTERNATIONAL COLLABORATION BY COUNTRY, FOR IMI PROJECT: NEWMEDS, 2010-2017




FIGURE 6.2.4 INTERNATIONAL COLLABORATION BY COUNTRY, FOR IMI PROJECT: EUROPAIN, 2010-2017





FIGURE 6.2.5 INTERNATIONAL COLLABORATION BY COUNTRY, FOR IMI PROJECT: IMIDIA, 2010-2017



6.3 COLLABORATION METRICS FOR IMI RESEARCH

This section of the report analyses the types of collaboration that occurred within each IMI project publication and examines the intensity of collaborations within each project. In common with other metrics based on publications and citations, the indicators we present here work best with larger sample sizes. Indicators based on small numbers of publications will be less informative than those calculated for larger bodies of work. Therefore, the analysis presented in this section is for projects with at least 20 publications published between 2010 and 2017. The results for all projects are shown in Annex 3.


Three metrics were used to evaluate the collaborative nature of IMI projects:

- Metric 1 – Fraction of publications with co-authors affiliated to institutions in different sectors. The institutions affiliated with each author on a publication within the dataset were manually assigned by Clarivate Analytics to the relevant sector. Author affiliations were obtained through Web of Science.
- Metric 2 – Percentage of internationally collaborative publications. The country location of each author was determined using author addresses extracted in the Web of Science.
- Metric 3 – Intensity of collaboration. Pairs of collaborating institutions were identified for each IMI project publication and the intensity of each pair was assessed. The collaboration intensities of the pairs of institutions for each IMI project were averaged.
- The collaboration index is a sum of all three metrics.

6.3.1 METRIC 1: FRACTION OF CROSS SECTOR COLLABORATIVE PUBLICATIONS

The sectors involved in each IMI project publication were used to classify each publication as “within one sector” or “cross sector”. Figure 6.3.1.1 shows the total number of publications for each project. Projects are ordered by the number of cross sector collaborative publications. Only projects with more than 20 associated publications are shown. The dark blue bars represent the number of publications or fraction of publications that include at least one cross sector collaboration. The fraction of publications in each project that involve cross-sector collaborations is referred to in the diagram by the abbreviation “X-Sector Score”.

FIGURE 6.3.1.1 FRACTION OF CROSS-SECTOR COLLABORATIVE PUBLICATIONS BY PROJECT, 2010-2017




BTCURE had the greatest number of cross-sector collaborative publications, 347 out of 572. PRO-active, Protect and PHARMA-COG had the highest percentage of cross-sector collaborative publications (96.8%, 96.2% and 84.1% respectively).

6.3.2 METRIC 2: FRACTION OF INTERNATIONALLY COLLABORATIVE PUBLICATIONS

Author names and affiliations were extracted from the Web of Science for all IMI project publications. The number of countries in the author affiliations for each publication was counted and used to classify the publication as “more than two countries”, “two countries” or “within one country”.

Figure 6.3.2.1 below shows the total number of publications for each project. Projects are ordered by the number of publications with author affiliations from more than one country. The bar colours reflect the fraction of publications that include international collaboration. Only projects with more than 20 associated publications are shown. The International Score was calculated by weighting each publication that involved only two countries by 0.75 and each publication that involved more than two countries by 1.00. The sum of the weighted publications was then divided by the total number of publications.

FIGURE 6.3.2.1 FRACTION OF INTERNATIONALLY COLLABORATIVE PUBLICATIONS BY PROJECT, 2010-2017




BTCURE had the most internationally collaborative publications involving two or more countries (326 out of 573), with an International Score of 0.49. eTRICKS, GETREAL and PRO-active, had the highest International Score (0.85, 0.80 and 0.76 respectively).

6.3.3 METRIC 3: TOP COLLABORATING INSTITUTIONS PER PUBLICATION


Metric 3 focuses on the most frequently collaborating institutions and the number of those institutions involved in publications associated with each project. Figure 6.3.3.1 shows the top ten 10 collaborating institutions pairs and the total number of collaborating publications for each pair. Figure 6.3.3.2 shows the number of collaborating institutions for each institution. Figure 6.3.3.3 shows the distribution of metric 3 scores for each project.

FIGURE 6.3.3.1 THE TEN MOST PRODUCTIVE PAIRS OF COLLABORATING INSTITUTIONS, 2010-2017



The institutions that collaborated most frequently on IMI project publications were the Karolinska Institute and the Karolinska University Hospital.


FIGURE 6.3.3.2 THE TEN MOST DIVERSE COLLABORATIVE INSTITUTIONS, 2010-2017



Karolinska Institute has collaborated with 1,173 different institutions within the IMI project publications.

The top 50 most diverse collaborating institutions were used to assign each project a score (metric 3). For each project, the number of publications affiliated with the top 50 collaborating institutions was calculated, publications were counted more than once if they were affiliated with more than one top 50 institution. This value was then divided by the total number of publications for that project. If the result was greater than or equal to one, the value of metric three for that project was set to one. If the result was less than one, then metric was set to that value. For example, for BTCure the summed count of publications affiliated with the top 50 institutions was 1,440, and it published a total of 595 publications, so the result for metric 3 was 2.42 and this was consequently set to 1.0.

FIGURE 6.3.3.3 METRIC 3 SCORE DISTRIBUTION, 2010-2017



6.4 COLLABORATION INDEX

Metrics 1 and 2 (described above) measure different types of collaboration diversity. The first measures the fraction of publications that involve cross sector collaborations, and the second measures the fraction of publications that involve international collaborations. Metric 3 is based on the average number of top collaborating institutions per publication within each project. We compute a “collaboration index” across IMI projects as the sum of all three of the metrics described above (Table 6.4.1). PROTECT had the highest overall collaboration index score (2.61) followed by Pharma-Cog (2.57). For most projects the Collaboration Index is lower than in last years report as in this report if Metric 3 was greater than or equal to one, the value was set to one.

TABLE 6.4.1 SUMMARY SCORE FOR COLLABORATION METRICS, TOTAL NUMBER PUBLICATIONS, AND CITATION IMPACT FOR IMI PROJECTS, 2010-2017

Project	X-sector Score	International score	Metric 3	Collaboration Index	Total Papers publications	Citation impact (field normalised)
BTCure	0.61	0.49	1.00	2.10	573	1.86
EU-AIMS	0.66	0.64	1.00	2.30	262	2.32
NEWMEDS	0.63	0.57	1.00	2.20	173	2.25
EMIF	0.79	0.63	1.00	2.42	160	2.72
EUROPAIN	0.51	0.35	1.00	1.86	154	2.39
IMIDIA	0.52	0.48	1.00	2.00	127	1.66
ULTRA-DD	0.58	0.65	1.00	2.23	110	2.10
ORBITO	0.54	0.48	1.00	2.02	107	1.59
CHEM21	0.22	0.27	0.59	1.08	105	1.69
SUMMIT	0.71	0.60	1.00	2.31	99	1.27
PROTECT	0.97	0.64	1.00	2.61	95	1.06
eTOX	0.29	0.37	0.38	1.04	86	1.72
TRANSLOCATION	0.36	0.49	0.32	1.17	84	1.50
MIP-DILI	0.68	0.42	1.00	2.10	82	1.70
Quic-Concept	0.70	0.58	1.00	2.28	80	2.74
U-BIOPRED	0.81	0.63	1.00	2.44	79	1.72
ELF	0.36	0.50	1.00	1.86	75	1.33
Open PHACTS	0.62	0.58	1.00	2.20	71	2.68
STEMBANCC	0.54	0.45	1.00	1.99	71	1.73
PreDiCT-TB	0.56	0.48	1.00	2.04	70	1.31
CANCER-ID	0.74	0.37	1.00	2.11	69	3.27
Pharma-Cog	0.84	0.73	1.00	2.57	69	1.46
DDMoRe	0.57	0.52	1.00	2.09	61	0.69
ABIRISK	0.63	0.37	1.00	2.00	57	1.26
COMPACT	0.15	0.39	1.00	1.54	54	1.89
Onco Track	0.55	0.41	1.00	1.96	53	2.51
DIRECT	0.73	0.65	1.00	2.38	49	2.23
MARCAR	0.43	0.40	1.00	1.83	49	1.18
BioVacSafe	0.46	0.42	1.00	1.88	48	1.49
SPRINTT	0.52	0.56	0.43	1.51	45	2.99
COMBACTE	0.61	0.35	1.00	1.96	41	1.52
Preduct	0.69	0.63	1.00	2.32	36	1.87
RAPP-ID	0.31	0.38	0.65	1.34	36	1.01

Project	X-sector Score	International score	Metric 3	Collaboration Index	Total Papers publications	Citation impact (field normalised)
K4DD	0.46	0.49	1.00	1.95	35	2.01
AETIONOMY	0.64	0.44	1.00	2.08	33	1.02
GETREAL	0.80	0.80	1.00	2.60	31	3.36
PRECISESADS	0.66	0.68	1.00	2.34	29	1.08
PRO-active	0.96	0.76	1.00	2.72	26	2.00
ND4BB	0.48	0.46	0.46	1.40	24	1.15
COMBACTE-MAGNET	0.67	0.70	1.00	2.37	22	1.87
eTRIKS	0.68	0.85	1.00	2.53	22	2.71
ZAPI	0.59	0.65	1.00	2.24	22	2.31

7 BENCHMARKING ANALYSIS – IMI PROJECT RESEARCH AGAINST RESEARCH FROM SELECTED COMPARATORS

This section of the report analyses the output and citation impact of IMI project research benchmarked against research associated with other selected Public-Private Partnerships, and funders of biomedical research across Europe, Asia and North America.

The publications funded by each comparator were identified using specific keyword searches of the funding acknowledgment data provided by authors and extracted in Web of Science. This is the same process by which IMI project publications have been identified. Authors may not always acknowledge their sources of funding and may not always do so correctly. Therefore, the coverage of the datasets used in these analyses may not be complete and may not be entirely accurate; however, the sample represented by these datasets is sufficient to allow a comparison to be made.

7.1 IDENTIFYING COMPARATORS

The seven funders listed in Table 7.1.1 were used as comparators for IMI in this report. They are the same comparators as in the previous report (2017). Each of them had sufficient publications to allow a robust analysis.

TABLE 7.1.1 SUMMARY OF INFORMATION OF IMI-SELECTED COMPARATORS, 2010-2017

Comparator	Publications (2010-2017)	Papers (2010-2017)	Country	Region
Critical Path (C-Path)	346	340	USA	North America
Commonwealth Scientific and Industrial Research Organization (CSIRO) ¹⁸	614	611	Australia	Australia
Foundation for the National Institutes of Health (FNIH)	2,355	2,315	USA	North America
Grand Challenges in Global Health (GCGH)	796	796	USA	North America
Indian Council of Medical Research (ICMR)	9,061	8,984	India	Asia
Medical Research Council (MRC)	40,856	40,161	UK	Europe
Wellcome Trust (WT)	51,744	48,763	UK	Europe

¹⁸ The total publications for CSIRO between 2010 and 2017 was 14,504; the dataset used for analysis has been reduced to include only medically related publications. A list of Web of Science journal categories which capture medically related publications is given in Annex 2.

7.2 TRENDS IN OUTPUT: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS

This section of the report analyses trends in the performance of IMI project research and the selected comparators.

7.2.1 TRENDS IN OUTPUT: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS

The output of IMI and the comparators varies widely (some produced many papers and some relatively few), therefore a visual comparison of absolute paper counts would not provide an understanding of their growth relative to one another. To provide a more easily interpretable comparison, Figure 7.2.1.1 shows the the organisation's papers published in each year as a percentage of the total number of papers published between 2010 and 2017. Table 7.2.1.1 shows the same data as in Figure 7.2.1.1. Table 7.2.1.2 gives the number of papers per year for IMI and the selected comparators.

FIGURE 7.2.1.1 TRENDS IN OUTPUT – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2017

Share of output




TABLE 7.2.1.1 SHARE OF OUPUT – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2017

Year	IMI	CSIRO	C-Path	FNIH	GCGH	ICMR	MRC	WT
2010	0.7%	8.8%	5.9%	7.8%	17.5%	8.8%	11.1%	10.5%
2011	2.7%	11.8%	9.7%	8.0%	18.2%	10.2%	11.9%	10.9%
2012	6.5%	11.9%	11.2%	10.1%	15.6%	11.2%	12.4%	12.0%
2013	10.4%	12.6%	10.3%	11.5%	13.2%	12.9%	12.8%	12.8%
2014	13.2%	14.7%	11.5%	13.7%	14.1%	14.2%	12.2%	12.6%
2015	19.5%	15.5%	18.8%	15.9%	9.9%	13.7%	13.0%	13.7%
2016	22.4%	13.6%	12.6%	14.7%	6.4%	14.8%	13.1%	13.9%
2017	24.6%	11.0%	20.0%	18.3%	5.2%	14.2%	13.5%	13.6%

TABLE 7.2.1.2 NUMBER OF PAPERS – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2017

Year	IMI	CSIRO	C-Path	FNIH	GCGH	ICMR	MRC	WT
2010	26	54	20	180	139	790	4441	5136
2011	97	72	33	186	145	913	4772	5321
2012	231	73	38	234	124	1006	4961	5837
2013	370	77	35	267	105	1160	5152	6232
2014	467	90	39	316	112	1277	4919	6151
2015	691	95	64	368	79	1230	5224	6681
2016	796	83	43	341	51	1334	5260	6761
2017	872	67	68	423	41	1274	5432	6644
Total	3,550	611	340	2,315	796	8,984	40,161	48,763

- Except GCGH, both IMI and the other comparators had a generally upward trend in papers published between 2010 and 2017.
- In contrast to other, more established funders, IMI had a steady increase in papers since 2010. The papers that were published in the last two years, 2016 and 2017, account for nearly half the total.

7.2.2 TRENDS IN FIELD NORMALISED CITATION IMPACT: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS

As discussed in Section 3, citations accumulate over time at a rate that is dependent upon the field of research. Therefore, it is standard bibliometric practice to normalise citation counts for these two factors. In this report, nci_F has been calculated by dividing the citations received by each publication by the world average citations per publication for the relevant year and field. Figure 7.2.2.1 shows the nci_F of IMI and the comparators between 2010 and 2017. Table 7.2.2.1 has the same data as in Figures 7.2.2.1 and 7.2.2.1.

FIGURE 7.2.2.1 TRENDS IN NCI_F – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2017




TABLE 7.2.2.1 NCI_F – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2017

Year	IMI	CSIRO	C-Path	FNIH	GCGH	ICMR	MRC	WT
2010	3.38	3.42	4.68	2.27	1.84	0.76	1.88	2.10
2011	1.86	1.90	0.99	2.63	1.89	0.85	1.91	2.08
2012	2.08	1.37	1.21	1.85	1.61	0.79	2.03	2.08
2013	1.76	1.27	1.47	1.89	1.73	0.79	1.92	1.89
2014	2.00	1.44	1.05	1.92	1.73	0.82	1.85	1.93
2015	1.74	1.32	1.17	1.86	1.63	0.79	1.87	2.04
2016	1.78	0.96	0.83	1.59	2.47	0.77	1.91	2.06
2017	1.92	1.24	1.74	1.61	2.34	0.81	1.86	1.98
AVG	1.98	1.55	1.44	1.89	1.83	0.80	1.91	2.02

- In 2012 and 2014, IMI had the highest citation impact (2.08 and 2.00 respectively) of the funding organisations analysed.
- The citation impact of MRC and the WT were stable at around twice the world average between 2010 and 2017, indicating highly-cited, internationally significant research.

- The exceptionally high citation impact of IMI, CSIRO and C-Path project research in 2010 was driven by a small number of highly-cited papers.

7.2.3 TRENDS IN JOURNAL NORMALISED CITATION IMPACT: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS

As discussed in Section 3, an alternative indicator to nci_f is nci_j . This is calculated by dividing the number of citations a paper received by the average for the year and the journal in which the paper is published. Figure 7.2.3.1 shows the nci_j of IMI and the comparators between 2010 and 2017. Table 7.2.3.1 shows the same data as in Figure 7.2.3.1.

FIGURE 7.2.3.1 TRENDS IN NCI_j – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2017




TABLE 7.2.3.1 NCI_j – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2017

Year	IMI	CSIRO	C-Path	FNIH	GCGH	ICMR	MRC	WT
2010	1.97	2.30	0.85	1.34	1.24	1.05	1.13	1.19
2011	1.32	1.39	0.85	1.45	1.24	1.06	1.18	1.18
2012	1.42	1.13	1.19	1.37	1.16	1.00	1.17	1.18
2013	1.11	1.27	1.05	1.30	1.26	0.96	1.18	1.15
2014	1.18	1.20	0.96	1.36	1.36	1.02	1.15	1.16
2015	1.31	1.15	1.04	1.28	1.17	1.02	1.13	1.21
2016	1.28	0.83	0.90	1.12	1.76	0.92	1.18	1.23
2017	1.15	1.21	1.52	1.19	2.11	0.96	1.13	1.20
AVG	1.29	1.27	1.10	1.29	1.32	0.99	1.16	1.19

- IMI had the joint third highest nci_j (1.29).
- The nci_j of the ICMR, MRC and WT remained relatively stable, while that of CSIRO and GCGH showed greater variability. This is to be expected given the smaller number of papers funded by CSIRO and GCGH, and their growth relative to the output of more established research institutions like the MRC and Wellcome Trust.

7.2.4 TRENDS IN RAW CITATION IMPACT: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS

The raw (un-normalised) citation impact of a group of papers is calculated by dividing the sum of citations by the total number of papers. This indicator must be used with caution as it is not normalised to field or year. Figure 7.2.4.1 shows the average raw citation impact of IMI and the comparators between 2010 and 2017. Table 7.2.4.1 has the same data as in Figure 7.2.4.1.

FIGURE 7.2.4.1 TRENDS IN RAW CITATION IMPACT – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2017




TABLE 7.2.4.1 RAW CITATION IMPACT – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2017

Year	IMI	CSIRO	C-Path	FNIH	GCGH	ICMR	MRC	WT
2010	78.88	71.50	99.40	58.23	47.68	17.41	52.51	53.34
2011	44.77	34.96	21.18	57.45	44.50	16.00	43.35	44.56
2012	41.71	23.51	18.97	30.71	30.44	12.95	39.41	39.93
2013	25.35	16.65	29.31	25.95	26.24	10.80	29.40	29.67
2014	23.34	14.14	11.97	19.22	17.13	8.62	21.68	22.79
2015	13.45	9.07	7.39	13.14	11.49	5.54	13.91	15.26
2016	6.80	2.95	3.47	5.53	8.57	2.62	7.01	7.90
2017	1.55	0.81	1.41	1.12	1.49	0.54	1.38	1.47
AVG	14.75	19.33	16.53	20.97	28.81	8.45	25.17	25.31

- The raw citation impact of all organisations decreased from 2010 to 2017. This is expected as more recent publications have had less time to accumulate citations, and the raw citation impact is not normalised.
- In 2017 IMI's raw citation impact was the highest among the comparator group (1.55).

7.2.5 TRENDS IN UNCITED RESEARCH: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS

Most publication datasets will include papers which have no citations. Figure 7.2.5.1 shows the percentage of uncited papers between 2010 and 2017 for IMI and the selected comparators. Table 7.2.5.1 has the same data as in Figure 7.2.5.1.

FIGURE 7.2.5.1 TRENDS IN UNCITED PAPERS – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2017




TABLE 7.2.5.1 PERCENTAGE OF UNCITED PAPERS – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2017

Year	IMI	CSIRO	C-Path	FNIH	GCGH	ICMR	MRC	WT
2010	0.0%	0.0%	5.0%	0.0%	0.0%	3.8%	0.4%	0.7%
2011	0.0%	2.8%	0.0%	1.1%	0.0%	2.6%	0.7%	0.9%
2012	0.0%	2.7%	2.6%	0.4%	0.8%	3.4%	0.6%	1.0%
2013	1.1%	1.3%	5.7%	1.1%	1.9%	4.7%	1.3%	1.5%
2014	1.7%	3.3%	7.7%	1.6%	0.9%	5.8%	1.5%	2.0%
2015	3.6%	4.2%	3.1%	1.6%	2.5%	11.7%	3.6%	4.3%
2016	8.7%	13.3%	16.3%	14.7%	9.8%	26.6%	11.1%	11.2%
2017	50.6%	50.7%	61.8%	56.7%	48.8%	68.2%	52.4%	53.4%
Total	15.4%	9.3%	17.1%	13.3%	3.9%	17.6%	9.6%	10.1%

- A little over one sixth of papers published from IMI project research were uncited. The proportion of uncited research is similar to the comparators, except GCGH. Less than 4% of GCGH papers were uncited overall between 2010 and 2017.
- No IMI project papers published between 2010 and 2012 are uncited. Its share of uncited research in the most recent year, 2017, is among the lowest of the comparators.
- The similar trends in uncited papers indicate the similar citation life-cycle for biomedical research funded across all the benchmarking organisations. More recent publications are less likely to be cited than older publications. Therefore, the higher percentage of uncited papers in

most recent years should not be taken as evidence that these articles are more likely to remain uncited.

7.2.6 TRENDS IN HIGHLY- CITED RESEARCH: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS

As discussed in Section 3, highly-cited work is recognised as having a greater impact, and Clarivate Analytics correlates this with other qualitative evaluations of research performance, such as peer review. For institutional research evaluation, we have found that the world’s top 10% of most highly-cited papers is often a suitable definition of highly-cited work. Therefore, if more than 10% of an entity’s publications are in the top 10% of the world’s most highly-cited papers, then it has performed better than expected. Figure 7.2.6.1 shows the percentage of highly-cited papers between 2010 and 2017 for IMI and the selected comparators. Table 7.2.6.1 has the same data as in Figure 7.2.6.1.

FIGURE 7.2.6.1 TRENDS IN HIGHLY CITED PAPERS – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2017




TABLE 7.2.6.1 PERCENTAGE OF HIGHLY CITED PAPERS – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2017

Year	IMI	CSIRO	C-Path	FNIH	GCGH	ICMR	MRC	WT
2010	34.6%	13.0%	15.0%	42.2%	30.2%	5.4%	28.0%	25.1%
2011	27.8%	29.2%	6.1%	41.9%	33.1%	6.7%	25.8%	24.8%
2012	31.6%	23.3%	13.2%	26.5%	24.2%	6.5%	27.0%	26.1%
2013	27.3%	15.6%	8.6%	27.3%	27.6%	6.4%	27.0%	26.0%
2014	27.8%	26.7%	15.4%	29.1%	24.1%	7.4%	26.9%	27.3%
2015	26.3%	16.8%	15.6%	27.2%	24.1%	5.4%	25.4%	27.3%
2016	25.3%	8.4%	11.6%	19.6%	27.5%	5.6%	24.6%	25.3%
2017	21.2%	9.0%	17.6%	16.5%	26.8%	4.9%	16.7%	17.3%
Total	25.6%	18.0%	13.5%	26.7%	27.6%	6.0%	25.0%	24.9%

- Approximately one quarter of papers published by IMI and most of the comparators between 2010 and 2017 were highly cited. ICMR and C-Path were notable exceptions.
- In 2012, IMI had the highest share of highly-cited papers in the group. In 2010, 2014 and 2016 IMI had the second highest proportion of highly-cited papers.

7.2.7 TRENDS IN OPEN ACCESS RESEARCH: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS

Figure 7.2.7.1 shows the percentage of IMI publications that were published as open access between 2010 and 2017 for IMI and the selected comparators. Table 7.2.7.1 shows the same data as in Figure 7.2.7.1.

FIGURE 7.2.7.1 TRENDS IN OPEN ACCESS PUBLICATIONS – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2017




TABLE 7.2.7.1 PERCENTAGE OF OPEN ACCESS PUBLICATIONS – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2017

Year	IMI	CSIRO	C-Path	FNIH	GCGH	ICMR	MRC	WT
2010	42.3%	33.3%	35.0%	83.3%	74.1%	32.0%	68.6%	80.5%
2011	55.7%	30.6%	45.5%	82.3%	77.9%	33.3%	68.7%	80.9%
2012	55.4%	47.9%	28.9%	79.1%	71.0%	33.7%	71.6%	82.8%
2013	57.3%	44.2%	40.0%	75.7%	75.2%	35.5%	76.1%	85.6%
2014	52.7%	46.7%	38.5%	83.5%	80.4%	37.7%	80.1%	86.9%
2015	60.6%	41.1%	56.3%	81.5%	87.3%	34.5%	81.4%	87.5%
2016	60.2%	42.2%	55.8%	67.7%	80.4%	34.7%	84.6%	87.9%
2017	54.6%	43.3%	38.2%	57.4%	80.5%	29.0%	80.8%	84.0%
Total	57.0%	41.6%	43.5%	74.6%	77.4%	33.9%	76.8%	84.7%

- The majority of organisations, including IMI, have more than 40% of open access publications.
- WT has the highest percentage of open access publications in all years between 2010 and 2017 in the group. Overall, it had over three-quarters of publication available via open access 2010 and 2017, while C-Path only had about a third of such publication.
- There is a step change increase in the percentage of publication seen in open access journals compared to the previous reports. This step is likely not representative of a real difference in publishing behaviour, but a result of increased resolution as Clarivate Analytics adapts its database to be consistent with modern publishing practices.

7.3 SUMMARY OF BIBLIOMETRIC INDICATORS: IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS

Even though IMI is a ‘young’ funding agency, its performance is on par with well-established funding bodies like the MRC and Wellcome Trust, as indicated by its citation impact, and percentage of highly-cited papers (Table 7.3.1).

TABLE 7.3.1 SUMMARY OF BIBLIOMETRIC INDICATORS – IMI PROJECT RESEARCH COMPARED WITH SELECTED COMPARATORS, 2010-2017

	Number of papers	Citation impact (normalised at field level)	Percentage of uncited papers	Percentage of highly-cited papers
IMI	3,550	1.98	15.4%	25.6%
CSIRO	611	1.55	9.3%	18.0%
C-Path	340	1.44	17.1%	13.5%
FNIH	2,315	1.89	13.3%	26.7%
GCGH	796	1.83	3.9%	27.6%
ICMR	8,984	0.80	17.6%	6.0%
MRC	40,161	1.91	9.6%	25.0%
WT	48,763	2.02	10.1%	24.9%

8 COLLABORATION NETWORK ANALYSIS BY IMI PROJECT

This section of the report analyses changes in institutional collaborations on IMI projects over time. The projects analysed are BTCURE (Call 2), EU-AIMS (Call 3), EUROPAIN (Call 1), IMIDIA (Call 1), and NEWMEDS (Call 1). In this report, co-authorship of publications is used as an index of collaborative research; where two institutions appear together in the authors address list on a publication this is recorded as an instance of collaboration. These five projects generated the greatest number of publications among the IMI projects from 2010 to 2017. Changes in collaborations are compared across two time periods, 2010-2013 and 2014-2017 – this allows changes in collaboration between the periods initially after the project commenced to be compared with patterns of collaboration once the projects had matured.

Network graphs for each project and period are shown in Section 8.2. The nodes of the network graphs represent unified institutions appearing in the author address lists of publications (including all the institutions that are participating in the project¹⁹). The number of papers co-authored between institutions is represented by the thickness of the line linking them. Graph nodes are coloured according to their corresponding sector. As in the section 6 collaboration analysis, the sectors assigned to the institutions are academic, corporate, government, medical, or other¹⁴. The top ten collaborative institutions are labeled, where the font size is linearly proportional to the number of collaborations it has. The graphs show the amount of change in collaborations from period 1 to period 2.

The numbers of publications co-published by institutions and the network graphics illustrating these linkages show that the collaborative research activity of the selected IMI projects has increased over time. These collaborations involve a range of institutions across multiple sectors and countries. It is also clear from the data that there is significant collaboration with institutions that were not formal participants in the IMI-supported projects and that the involvement of such partners has grown with time.

The results of this section have not been normalised since many factors, known and unknown, may affect the occurrence of publication collaborations. It is important, however, to keep in mind while reviewing the results some of the context that may be affecting publication collaborations for these five projects. Table 8.1 provides the start and end date as well as the total funding support for each of the five projects. All projects were supported between 5 to 6 years. BTCURE and EU-AIMS received substantially more funding than the other three projects.

TABLE 8.1 OVERVIEW OF THE FIVE IMI PROJECTS WITH GREATEST PUBLICATION OUTPUT¹⁹

PROJECT	START DATE	END DATE	TOTAL FUNDING SUPPORT
BTCURE	1/4/2011	31/03/2017	€39,371,092
EU-AIMS	1/4/2012	31/03/2018	€37,480,613
EUROPAIN	1/10/2009	30/09/2015	€22,550,083
IMIDIA	1/4/2011	30/09/2015	€27,447,009
NEWMEDS	1/9/2009	28/02/2015	€24,849,675

¹⁹ Information about IMI's ongoing projects including the participants of those projects is available on its website: <https://www.imi.europa.eu/content/ongoing-projects>.

8.1 COLLABORATION PATTERNS ACROSS THE FIVE IMI PROJECTS WITH THE GREATEST PUBLICATION PRODUCTIVITY

In this subsection the changes from period 1 (2010-2013) to period 2 (2014-2017) in the number and types of institutions contributing to IMI publications as well as the changes in the number of publication collaborations between sectors are reviewed.

Table 8.1.1 tabulates for each of the five projects the number of institutions that were IMI participants by sector.

- The BTCURE project had the largest number of academia, corporate and medical institutions (17, 10 and 6, respectively) as IMI participants among these five projects.
- EU-AIMS had the largest number of government institutions (3) as IMI participants.

TABLE 8.1.1 NUMBER OF IMI PARTICIPATING ORGANIZATIONS¹⁹

SECTOR	BTCURE	EU-AIMS	EUROPAIN	NEWMEDS	IMIDIA
ACADEMIA	17	14	11	8	8
CORPORATE	10	5	6	8	9
GOVERNMENT	0	3	0	0	0
MEDICAL	6	4	3	1	1
OTHER	2	1	0	0	1

Academia institutions include universities and other institutions that focus on a combination of education and research such as Kings College London and the Karolinska Institute. Corporate institutions are commercial institutions such as pharmaceutical companies (use chemical materials to create medicines) and biotechnology companies (use live organisms to create medicines) such as AstraZeneca and Janssen Biotechnology Company. Government institutions, often an appointed commission, are a part of a government that is responsible for the oversight and administration of specific functions such as the United States Department of Health and Human Services, Deutsches Rheuma-Forschungszentrum, and The European Medicines Agency. Medical institutions include hospitals and patient-care institutions such as CHU Montpellier and the Central Institute of Mental Health Mannheim. Other institutions include institutions that either have reach across multiple sectors such as CSIC or those that do not align with one of the other sector categorizations such as the non-governmental, non-profit association the Max Planck Society.

Among the institutions co-authoring IMI publications, the academic and medical sectors had the greatest changes in the number of non-IMI participating institutions across the five projects.

Table 8.1.2 provides the number of institutions by sector for all five projects. The unshaded and grey shaded rows provide the information for the IMI participating and non-IMI participating institutions respectively. Only non-participating medical institutions in the NEWMEDS project were fewer in the second period compared to the first.

Table 8.1.2 THE NUMBER OF ORGANIZATIONS BY SECTOR AND PROJECT IN TWO PERIODS P1 (2010-2013) AND P2 (2014-2017) FOR PARTICIPATING AND NON-PARTICIPATING INSTITUTIONS

SECTOR	STATUS	BTCURE		EU-AIMS		EUROPAIN		NEWMEDS		IMIDIA	
		P1	P2	P1	P2	P1	P2	P1	P2	P1	P2
ACADEMIA	IMI participating	10	17	3	14	6	9	3	8	5	8
	IMI non-participating	54	308	73	264	33	81	74	162	47	81
CORPORATE	IMI participating	1	10	1	5	1	6	4	8	1	8
	IMI non-participating	7	25	5	14	2	12	4	20	1	6
GOVERNMENT	IMI participating	0	0	1	3	0	0	0	0	0	0
	IMI non-participating	1	19	5	16	3	5	2	10	0	1
MEDICAL	IMI participating	1	6	3	4	1	3	1	1	0	1
	IMI non-participating	34	208	15	99	19	42	70	47	11	27
OTHER	IMI participating	1	2	0	1	0	0	0	0	0	1
	IMI non-participating	6	35	3	21	3	5	5	8	1	6

Figure 8.1.1 graphs the number of collaborating institutions for period 1 and period 2 for the academic sector. Note that these data do not include multiple instances of collaboration between the same two institutions.

- For all five projects either all or nearly all of the IMI participating academic institutions contributed to publications during period 2.
- All five projects had an increase in the number of IMI participating and non-IMI participating academic institutions from period 1 to period 2.
 - BTCURE and EU-AIMS had the largest increases from period 1 to period 2 in the number of non-IMI participating academic institutions that contributed to IMI publications (+254 and +191, respectively or 4.7 and 2.6 times more of these collaborations in period 2 compared to period 1, respectively).
 - EU-AIMS had the largest change in participating institutions between period 1 and period 2 (11 or 4.7 times)

FIGURE 8.1.1 NUMBER OF COLLABORATING INSTITUTIONS FROM THE **ACADEMIC** SECTOR IN PERIOD 1 (2010-2013) AND IN PERIOD 2 (2014-2017)




Figure 8.1.2 graphs the number of collaborating institutions for both periods for the medical sector. Note that these data do not include multiple instances of collaboration between the same two institutions.

- IMIDIA had no contributions from IMI participating institutions
- All projects except NEWMEDS had an increase in the number of non-IMI participating medical institutions contributing to IMI publications.
- BTCURE and EU-AIMS had the largest increase in the number of non-IMI participating medical institutions from period 1 to period 2 (+174 and +84, respectively which corresponds to 6.1 and 6.6 times more collaborations in period 2).

FIGURE 8.1.2 NUMBER OF COLLABORATING INSTITUTIONS FROM THE **MEDICAL** SECTOR IN PERIOD 1 (2010-2013) AND IN PERIOD 2 (2014-2017)




Table 8.1.3 provides data on the number of cross (and self) collaborations between sectors. The numbers represent the number of publications so, in many cases, include multiple collaborations between the same institutions.

- EU-AIMS had the largest increase in publication collaborations between academia institutions (+4,145).
- EU-AIMS also had the largest increase in collaborations between academia and medical institutions (+1,268).
- NEWMEDS had a decrease in publication collaborations between academia and medical institutions (-105).

TABLE 8.1.3 THE NUMBER PUBLICATION COLLABORATIONS BY SECTOR IN P1 (2010-20113) AND P2 (2014-2017)

SECTOR 1	SECTOR 2	BTCURE		EU-AIMS		EUROPAIN		NEWMEDS		IMIDIA	
		P1	P2	P1	P2	P1	P2	P1	P2	P1	P2
ACADEMIA	ACADEMIA	1731	2663	6519	7982	526	823	2509	3099	374	462
	CORPORATE	18	58	24	48	28	57	96	182	5	43
	GOVERNMENT	8	56	88	140	3	13	45	84	0	1
	MEDICAL	335	576	379	819	76	115	541	509	71	87
	OTHER	20	94	43	64	3	0	23	11	0	7
CORPORATE	CORPORATE	3	11	4	15	9	49	60	79	2	12
	GOVERNMENT	1	2	2	4	0	1	8	8	0	0
	MEDICAL	24	61	14	46	19	43	107	96	9	17
	OTHER	3	8	0	8	1	1	4	1	1	2
GOVERNMENT	GOVERNMENT	0	3	11	10	1	1	1	4	0	0
	MEDICAL	4	13	48	89	1	3	3	10	0	0
	OTHER	0	6	2	5	0	0	0	0	0	0
MEDICAL	MEDICAL	512	1045	153	272	77	76	1349	252	9	14
	OTHER	30	70	15	33	9	1	76	6	1	0
OTHER	OTHER	5	19	2	8	0	0	1	0	0	1

Figure 8.1.3 to Figure 8.1.6 graphs the change in the number of publication collaborations from period 1 to period 2 for collaborations between academia and academia institutions, academia and corporate institutions, academia and government institutions, academia and medical institutions, and academia and other institutions.

FIGURE 8.1.3 CHANGE IN THE NUMBER OF PUBLICATION COLLABORATIONS FROM PERIOD 1 TO PERIOD 2 BETWEEN **ACADEMIA** INSTITUTIONS AND INSTITUTIONS FROM EACH OF THE FIVE SECTORS




Figure 8.1.4 graphs the change in the number of publication collaborations from period 1 to period 2 for collaborations between corporate and academia institutions, corporate and corporate institutions, corporate and government institutions, corporate and medical institutions, and corporate and other institutions.

- NEWMEDS had the largest increase in corporate - academic collaborations (+86) but had a small decrease in corporate - medical collaborations
- EUROPAIN had the largest increase in corporate – corporate collaborations (+40).

FIGURE 8.1.4 CHANGE IN THE NUMBER OF PUBLICATION COLLABORATIONS FROM PERIOD 1 TO PERIOD 2 BETWEEN **CORPORATE** INSTITUTIONS AND INSTITUTIONS FROM EACH OF THE FIVE SECTORS




Figure 8.1.5 graphs the change in the number of publication collaborations from period 1 to period 2 for collaborations between government and academia institutions, government and corporate institutions, government and government institutions, government and medical institutions, and government and other institutions.

- EU-AIMS had the largest increase in collaborations between government and academia institutions (+52) and in collaborations between government and medical institutions (+41).

FIGURE 8.1.5 CHANGE IN THE NUMBER OF PUBLICATION COLLABORATIONS FROM PERIOD 1 TO PERIOD 2 BETWEEN **GOVERNMENT** INSTITUTIONS AND INSTITUTIONS FROM EACH OF THE FIVE SECTORS





Figure 8.1.6 graphs the change in the number of publication collaborations from period 1 to period 2 for collaborations between medical and academia institutions, medical and corporate institutions, medical and government institutions, medical and medical institutions, and medical and other institutions.

- BTCURE had the largest increase in collaborations between medical institutions (+241)
- NEWMEDS had a large decrease in the number of medical – medical collaborations (-1097)

FIGURE 8.1.6 CHANGE IN THE NUMBER OF PUBLICATION COLLABORATIONS FROM PERIOD 1 TO PERIOD 2 BETWEEN **MEDICAL** INSTITUTIONS AND INSTITUTIONS FROM EACH OF THE FIVE SECTORS



8.2 COLLABORATION NETWORK GRAPHS BY IMI PROJECT

Figures 8.2.1 to 8.2.10 show network graphs of collaborative publication for each project in two periods, period 1 (2010-2013) and period 2 (2014-2017). The network nodes represent distinct unified institutions and are coloured according to the sector to which the institution belongs. The top ten collaborative institutions for each project are titled and the font size is linearly proportional to the number of collaborations with other institutions (including repeated collaborations). An edge denotes collaboration between institutions and is represented by a line, where the line weighting is linearly proportional to number of shared publications. Each network is independently scaled so the font sizes and line weights are not comparable between figures. The network diameter is the shortest distance between the two most distant nodes in the network.

In all five projects collaboration activity increased between period 1 and period 2. Below is an overview of some statistics for the graphed projects in period 2:

- BTCURE has three non-academic institutions in the top ten. It has 314 nodes, 2732 edges and a network diameter of 5.
- EU-AIMS has only academic institutions in the top ten and is the largest network. There are 6228 edges connecting the 423 institutions.
- EUROPAIN is the smallest network with 140 nodes but it has 1179 edges and a network diameter of 6, the largest of the five graphed.
- NEWMEDS has 246 nodes which are connected by 4895 edges (nearly twice that of BTCURE but with fewer nodes). The graph shows a regular array of institutions with many low weight edges linking them.
- IMIDIA is the second smallest network with 143 nodes but has 681 edges, the fewest of the five graphed.

FIGURE 8.2.1 COLLABORATION NETWORK ANALYSIS: BTCURE PERIOD 1 (2010-2013)




FIGURE 8.2.2 COLLABORATION NETWORK ANALYSIS: BTCURE PERIOD 2 (2014-2017)




FIGURE 8.2.3 COLLABORATION NETWORK ANALYSIS: EU-AIMS PERIOD 1 (2010-2013)




FIGURE 8.2.4 COLLABORATION NETWORK ANALYSIS: EU-AIMS PERIOD 2 (2014-2017)




FIGURE 8.2.5 COLLABORATION NETWORK ANALYSIS: EUROPAIN PERIOD 1 (2010-2013)




FIGURE 8.2.6 COLLABORATION NETWORK ANALYSIS: EUROPAIN PERIOD 2 (2014-2017)




Figure 8.2.7 COLLABORATION NETWORK ANALYSIS: NEWMEDS PERIOD 1 (2010-2013)




FIGURE 8.2.8 COLLABORATION NETWORK ANALYSIS: NEWMEDS PERIOD 2 (2014-2017)




FIGURE 8.2.9 COLLABORATION NETWORK ANALYSIS: IMIDIA PERIOD 1 (2010-2013)





FIGURE 8.2.10 COLLABORATION NETWORK ANALYSIS: IMIDIA PERIOD 2 (2014-2017)



9 GEOGRAPHIC CLUSTERING ANALYSIS

This Section of the report analyses where IMI project research is taking place. It provides data on geographic clusters where IMI research activity occurs, including bibliometric data and it identifies the constituent institutions within the clusters.

Substantive clusters of research activity were identified in Europe and North America. While IMI project research also involves institutions in other parts of the world, publication rates for other geographies were low. This analysis, therefore, focuses on Europe and North America and we have identified the 36 and 15 geographic clusters respectively with the highest output within a 20km radius.

The clusters in both Europe and North America tend to focus on major cities with an existing strong academic research base. The largest European clusters are London (680 publications), Amsterdam (580), Stockholm (353), Copenhagen (271) and Cambridge (194). The largest clusters in North America are Boston (134), Toronto (132), Bethesda (74), New York (69) and Montreal (62). It is also clear that the citation impact of the research IMI supports within these clusters is higher than the average national benchmark. A relatively high percentage of IMI supported research, in the Spanish clusters in particular, is published in Open Access journals. It should be noted that in previous sections the Open Access status of a publication was determined per publication, regardless of the journal, here we report publications from Open Access journals.

Rates of international collaboration are very high for most clusters. Around 35-40% of EU-28 biomedical research typically involves international co-authorship whereas the lowest rate of international co-authorship for the European clusters analysed was 61.4% (Madrid). In addition, around two thirds of the European clusters have rates of international co-authorship of at least 75%. High rates of international collaboration are to be expected for the North American clusters because IMI is a European funding organisation.

The clusters are visualised as maps in Figure 9.1 and 9.2. Both maps are scaled separately so that the most intensive areas of output are shaded red and the lowest areas of output are blue. This means that the same colour shading is not comparable between maps. Tables 9.1 to 9.4 show the research publication outputs of the individual clusters along with bibliometric indicators of their research performance. The citations metrics in Tables 9.2 and 9.4 are shaded green when the performance of a cluster of IMI-supported research outperforms the national average performance for biomedical research.

The institutions that constitute the top five clusters within each of the European and North American regions are shown in Tables 9.5 and 9.6 respectively. The five journal subject categories in which the top five clusters published most frequently within each of the European and North American regions are shown in Tables 9.7 and 9.8 respectively.

FIGURE 9.1 MAP SHOWING EUROPEAN GEOGRAPHIC CLUSTERS OF IMI PROJECT RESEARCH, 2010-2017




FIGURE 9.2 MAP SHOWING NORTH AMERICAN GEOGRAPHIC CLUSTERS OF IMI PROJECT RESEARCH, 2010-2017




TABLE 9.1 OUTPUT AND RESEARCH PERFORMANCE OF EUROPEAN GEOGRAPHIC CLUSTERS OF IMI PROJECT RESEARCH, 2010-2017

Cluster	Publications	Papers	Percentage publications open access	Raw Citation Impact	Percentage of internationally collaborative publications
London (UK)	680	651	15.8%	19.20	82.1%
Amsterdam (Netherlands)	581	542	12.9%	19.04	75.2%
Stockholm (Sweden)	353	337	17.2%	18.42	73.7%
Paris (France)	278	267	14.6%	18.91	82.4%
Copenhagen (Denmark)	271	258	15.9%	13.68	74.9%
Cambridge (UK)	194	183	24.0%	20.72	89.2%
Oxford (UK)	190	180	21.1%	15.47	81.1%
Barcelona (Spain)	169	161	24.8%	15.29	68.0%
Berlin (Germany)	167	159	15.1%	17.01	72.5%
Basel (Switzerland)	156	149	17.4%	14.48	92.9%
Mannheim (Germany)	154	151	13.2%	25.91	84.4%
Geneva (Switzerland)	142	131	13.0%	22.94	82.4%
Manchester (UK)	135	119	16.8%	15.37	84.4%
Rome (Italy)	129	117	19.7%	15.15	74.4%
Uppsala (Sweden)	126	119	10.9%	10.60	71.4%
Beerse (Belgium)	120	117	12.8%	11.25	75.8%
Erlangen (Germany)	115	114	7.9%	22.83	68.7%
Vienna (Austria)	105	103	16.5%	12.13	70.5%
Groningen (Netherlands)	103	101	5.9%	21.41	75.7%
Molndal (Sweden)	102	95	12.6%	13.91	89.2%
Munich (Germany)	97	90	17.8%	20.56	78.4%
Hamburg (Germany)	96	90	16.7%	12.84	77.1%
Milan (Italy)	86	82	12.2%	16.49	86.0%
Maastricht (Netherlands)	86	84	16.7%	32.44	87.2%
Nijmegen (Netherlands)	84	82	18.3%	24.80	83.3%
Nottingham (UK)	80	75	9.3%	11.56	92.5%
Frankfurt (Germany)	77	74	9.5%	10.88	87.0%
Helsinki (Finland)	72	72	18.1%	14.86	90.3%
Madrid (Spain)	70	67	25.4%	14.80	61.4%
Leuven (Belgium)	69	65	20.0%	21.39	76.8%
Lausanne (Switzerland)	60	59	20.3%	27.93	73.3%
Bonn (Germany)	56	54	27.8%	22.02	78.6%
Marseille (France)	55	49	22.4%	13.38	87.3%
Granada (Spain)	42	36	36.1%	18.79	66.7%
Lille (France)	37	34	14.7%	13.35	94.6%

TABLE 9.2 RESEARCH PERFORMANCE OF EUROPEAN GEOGRAPHIC CLUSTERS OF IMI PROJECT RESEARCH COMPARED TO NATIONAL BENCHMARKS, 2010-2017

Cluster	Field normalised citation impact		Journal normalised citation impact		Percentage of highly-cited papers	
	Cluster	National	Cluster	National	Cluster	National
London (UK)	2.61	1.4	1.42	1.13	32.26%	15.63%
Amsterdam (Netherlands)	2.54	1.56	1.36	1.18	30.63%	17.97%
Stockholm (Sweden)	2.50	1.44	1.32	1.13	30.27%	15.79%
Paris (France)	2.45	1.23	1.31	1.06	30.34%	13.33%
Copenhagen (Denmark)	1.86	1.59	1.11	1.21	22.09%	17.98%
Cambridge (UK)	2.86	1.4	1.25	1.13	32.24%	15.63%
Oxford (UK)	3.05	1.4	1.59	1.13	33.89%	15.63%
Barcelona (Spain)	2.17	1.18	1.55	1.06	27.33%	12.56%
Berlin (Germany)	2.19	1.28	1.36	1.11	32.70%	14.21%
Basel (Switzerland)	1.87	1.62	1.45	1.21	28.86%	18.6%
Mannheim (Germany)	2.76	1.28	1.20	1.11	34.44%	14.21%
Geneva (Switzerland)	2.59	1.62	1.33	1.21	29.77%	18.6%
Manchester (UK)	2.66	1.4	1.39	1.13	36.13%	15.63%
Rome (Italy)	2.62	1.25	1.67	1.15	33.33%	13.46%
Uppsala (Sweden)	1.58	1.44	1.18	1.13	21.85%	15.79%
Beerse (Belgium)	2.28	1.45	1.62	1.18	24.79%	16.1%
Erlangen (Germany)	2.48	1.28	1.37	1.11	35.09%	14.21%
Vienna (Austria)	1.60	1.39	1.06	1.17	20.39%	15.26%
Groningen (Netherlands)	3.00	1.56	1.25	1.18	31.68%	17.97%
Molndal (Sweden)	2.89	1.44	2.00	1.13	42.11%	15.79%
Munich (Germany)	2.78	1.28	1.30	1.11	32.22%	14.21%
Hamburg (Germany)	2.60	1.28	1.05	1.11	27.78%	14.21%
Milan (Italy)	2.46	1.25	1.08	1.15	30.49%	13.46%
Maastricht (Netherlands)	4.34	1.56	2.41	1.18	51.19%	17.97%
Nijmegen (Netherlands)	2.88	1.56	1.43	1.18	32.93%	17.97%
Nottingham (UK)	2.54	1.4	1.12	1.13	28.00%	15.63%
Frankfurt (Germany)	2.48	1.28	1.47	1.11	36.49%	14.21%
Helsinki (Finland)	2.55	1.4	1.34	1.13	31.94%	14.65%
Madrid (Spain)	2.12	1.18	1.07	1.06	22.39%	12.56%
Leuven (Belgium)	3.54	1.45	1.87	1.18	44.62%	16.1%
Lausanne (Switzerland)	2.64	1.62	1.38	1.21	32.20%	18.6%
Bonn (Germany)	2.15	1.28	1.22	1.11	27.78%	14.21%
Marseille (France)	2.19	1.23	1.10	1.06	30.61%	13.33%
Granada (Spain)	2.44	1.18	0.80	1.06	22.22%	12.56%
Lille (France)	2.03	1.23	1.00	1.06	29.41%	13.33%

TABLE 9.3 OUTPUT AND RESEARCH PERFORMANCE OF NORTH AMERICAN GEOGRAPHIC CLUSTERS OF IMI PROJECT RESEARCH, 2010-2017

Cluster	Publications	Papers	Percentage publications open access	Raw Citation Impact	Percentage of internationally collaborative publications
Boston (USA)	134	131	16.79%	39.66	98.51%
Toronto (Canada)	132	131	15.27%	19.77	91.67%
Bethesda (USA)	74	74	14.86%	28.22	97.30%
New York (USA)	69	68	10.29%	21.45	98.55%
Montreal (Canada)	62	62	17.74%	17.18	100.00%
Burlington (USA)	42	42	9.52%	14.38	100.00%
San Francisco (USA)	40	40	20.00%	52.48	100.00%
Indianapolis (USA)	39	38	5.26%	20.41	97.44%
Baltimore (USA)	35	35	11.43%	24.54	100.00%
Chapel Hill (USA)	29	28	28.57%	30.41	93.10%
Ann Arbor (USA)	25	25	12.00%	18.16	100.00%
La Jolla (USA)	22	22	36.36%	31.14	100.00%
Seattle (USA)	22	22	13.64%	48.77	100.00%
Los Angeles (USA)	21	21	0.00%	49.10	95.24%
Titusville (USA)	15	14	7.14%	11.67	86.67%

TABLE 9.4 RESEARCH PERFORMANCE OF NORTH AMERICAN GEOGRAPHIC CLUSTERS OF IMI PROJECT RESEARCH COMPARED TO NATIONAL BENCHMARKS, 2010-2017

Cluster	Field normalised citation impact		Journal normalised citation impact		Percentage of highly-cited papers	
	Cluster	National	Cluster	National	Cluster	National
Boston (USA)	4.17	1.32	1.78	1.06	16.79%	14.99%
Toronto (Canada)	2.46	1.32	1.24	1.08	15.27%	14.17%
Bethesda (USA)	3.63	1.32	1.50	1.06	14.86%	14.99%
New York (USA)	2.11	1.32	1.05	1.06	10.29%	14.99%
Montreal (Canada)	1.96	1.32	1.14	1.08	17.74%	14.17%
Burlington (USA)	2.00	1.32	1.00	1.06	9.52%	14.99%
San Francisco (USA)	5.82	1.32	1.63	1.06	20.00%	14.99%
Indianapolis (USA)	2.88	1.32	1.36	1.06	5.26%	14.99%
Baltimore (USA)	5.08	1.32	1.61	1.06	11.43%	14.99%
Chapel Hill (USA)	5.19	1.32	1.92	1.06	28.57%	14.99%
Ann Arbor (USA)	3.70	1.32	1.03	1.06	12.00%	14.99%
La Jolla (USA)	5.12	1.32	1.79	1.06	36.36%	14.99%
Seattle (USA)	4.58	1.32	1.66	1.06	13.64%	14.99%
Los Angeles (USA)	2.99	1.32	0.82	1.06	0.00%	14.99%
Titusville (USA)	1.00	1.32	1.61	1.06	7.14%	14.99%

TABLE 9.5 INSTITUTIONS CONSTITUTING EUROPEAN GEOGRAPHIC CLUSTERS OF IMI PROJECT RESEARCH, 2010-2017

Cluster	Country	Institutions	Publications
London	United Kingdom	Kings College London	263
		Imperial College London	182
		University College London	139
		GlaxoSmithKline	109
		London School of Hygiene & Tropical Medicine	28
		Guy's & St Thomas' NHS Foundation Trust	25
		Queen Mary University London	23
		Birkbeck University London	22
		South London & Maudsley NHS Trust	18
		European Med Agcy	15
		Royal Brompton Hosp	14
		Med & Healthcare Prod Regulatory Agcy	9
		University of London	9
		EMA	6
		MRC Social Genet & Dev Psychiat SGDP Ctr	6
		Royal Brompton & Harefield NHS Fdn Trust	6
		South London & Maudsley NHS Fdn	6
		St Georges University London	6
		Heptares Therapeut	5
		London School Economics & Political Science	5
Amsterdam	Netherlands	Leiden University	190
		Vrije Universiteit Amsterdam	150
		Utrecht Univ	141
		Erasmus University Rotterdam	93
		University of Amsterdam	91
		Utrecht Univ Med Ctr	56
		Acad Med Ctr	10
		Netherlands National Institute for Public Health & the Environment	10
		Jan van Breemen Res Inst Reade	6
Stockholm	Sweden	Karolinska Institutet	321
		Karolinska Univ Hosp	111
		Stockholm City Council	20
		Stockholm University	17
		AstraZeneca	16
		Royal Institute of Technology	15
Paris	France	Institut National de la Sante et de la Recherche Medicale (Inserm)	131
		Universite Paris Saclay (ComUE)	80
		Univ Paris Descartes	75
		Univ Paris Sud	63
		CEA	44
		Univ Sorbonne Paris Cite-USPC ComUE	42
		Centre National de la Recherche Scientifique (CNRS)	37
		Hopital Universitaire Pitie-Salpetriere - APHP	37
		Univ Paris Diderot	32

Cluster	Country	Institutions	Publications
		Hopital Universitaire Cochin - APHP	27
		Inst Pasteur Paris	24
		Le Reseau International des Instituts Pasteur (RIIP)	24
		Sanofi France	22
		Assistance Publique Hopitaux Paris (APHP)	21
		Univ Paris 06	16
		Hopital Universitaire Europeen Georges-Pompidou - APHP	10
		Orsay Hosp	9
		Hopital Universitaire Necker-Enfants Malades - APHP	8
		Institut de Recherches Internationales Servier	8
		PSL Research University Paris	6
		University of Versailles Saint-Quentin-En-Yvelines	6
		Hop Univ Ambroise-Pare APHP	4
		Inst Ecol Environment	4
		Museum Natl Histoire Nat	2
		Sanofi-Aventis	1
		Servier	1
Copenhagen	Denmark	University of Copenhagen	123
		Lund University	70
		Lundbeck Corporation	38
		Skane University Hospital	38
		Technical University of Denmark	35
		Steno Diabet Ctr	19
		Novo Nordisk	18
		Novo Nordisk Foundation	10
		Statens Serum Inst	5

TABLE 9.6 INSTITUTIONS CONSTITUTING NORTH AMERICAN GEOGRAPHIC CLUSTERS OF IMI PROJECT RESEARCH, 2010-2017

Cluster	Country	Institutions	Publications
Boston	USA	Harvard University	111
		VA Boston Healthcare System	50
		Harvard Univ Medical Affiliates	35
		Broad Institute	29
		Pfizer	16
		Boston University	12
		Dana-Farber Cancer Institute	11
		Boston Child Hosp	9
		Massachusetts Gen Hosp	7
		NIH National Heart Lung & Blood Institute (NHLBI)	6
		US Dept Hlth Human Services	4
		Framingham Heart Study	3
		Massachusetts Institute of Technology (MIT)	1
		Toronto	Canada
Struct Genom Consortium	39		
Hospital for Sick Children (SickKids)	28		
Univ Toronto Affiliates	19		
Princess Margaret Canc Ctr	17		
Centre for Addiction & Mental Health - Canada	7		
Univ Hlth Network Toronto	5		
Lunenfeld Tanenbaum Res Inst	1		
Mt Sinai Hosp Toronto	1		
Bethesda	USA	Natl Inst Hlth USA	47
		US Dept Hlth Human Services	23
		NIH National Heart Lung & Blood Institute (NHLBI)	14
		AstraZeneca	7
		NIH National Institute of Mental Health (NIMH)	6
		NIH National Institute on Aging (NIA)	6
		NIH Natl Canc Inst	4
		Natl Inst Allergy Infectious Dis (NIAID)	3
New York	USA	Pfizer	23
		Columbia University	22
		New York University	16
		Northwell Health	7
		Albert Einstein College of Medicine	6
Montreal	Canada	University of Montreal	46
		McGill University	36

TABLE 9.7 FIVE JOURNAL SUBJECT CATEGORIES IN WHICH EUROPEAN GEOGRAPHIC CLUSTERS OF IMI PROJECT RESEARCH PUBLISHED MOST FREQUENTLY, 2010-2017

Cluster	Country	Journal Subject Category	Publications
London	United Kingdom	NEUROSCIENCES	166
		PSYCHIATRY	101
		PHARMACOLOGY & PHARMACY	77
		CLINICAL NEUROLOGY	72
		BIOCHEMISTRY & MOLECULAR BIOLOGY	44
Amsterdam	Netherlands	RHEUMATOLOGY	105
		PHARMACOLOGY & PHARMACY	85
		NEUROSCIENCES	54
		IMMUNOLOGY	50
		PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH	43
Stockholm	Sweden	RHEUMATOLOGY	77
		NEUROSCIENCES	46
		IMMUNOLOGY	45
		CLINICAL NEUROLOGY	36
		BIOCHEMISTRY & MOLECULAR BIOLOGY	27
Paris	France	NEUROSCIENCES	64
		PSYCHIATRY	33
		PHARMACOLOGY & PHARMACY	31
		ENDOCRINOLOGY & METABOLISM	20
		CLINICAL NEUROLOGY	19
Copenhagen	Denmark	ENDOCRINOLOGY & METABOLISM	42
		PHARMACOLOGY & PHARMACY	42
		NEUROSCIENCES	33
		CLINICAL NEUROLOGY	32
		ANESTHESIOLOGY	31

TABLE 9.8 FIVE JOURNAL SUBJECT CATEGORIES in which North American GEOGRAPHIC CLUSTERS OF IMI PROJECT RESEARCH published most frequently, 2010-2017

Cluster	Country	Journal Subject Category	Publications
Boston	USA	GENETICS & HEREDITY	19
		NEUROSCIENCES	17
		RHEUMATOLOGY	15
		ENDOCRINOLOGY & METABOLISM	14
		BIOCHEMISTRY & MOLECULAR BIOLOGY	11
Toronto	Canada	PSYCHIATRY	32
		BIOCHEMISTRY & MOLECULAR BIOLOGY	31
		NEUROSCIENCES	29
		CHEMISTRY, MEDICINAL	15
		GENETICS & HEREDITY	13
Bethesda	USA	PHARMACOLOGY & PHARMACY	17
		PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH	15
		TOXICOLOGY	14
		GENETICS & HEREDITY	11
		BIOCHEMISTRY & MOLECULAR BIOLOGY	9
New York	USA	PHARMACOLOGY & PHARMACY	29
		NEUROSCIENCES	15
		PSYCHIATRY	14
		PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH	13
		TOXICOLOGY	10
Montreal	Canada	PSYCHIATRY	26
		NEUROSCIENCES	24
		PSYCHOLOGY, DEVELOPMENTAL	8
		BIOCHEMISTRY & MOLECULAR BIOLOGY	6
		GENETICS & HEREDITY	6

ANNEX 1: BIBLIOMETRICS AND CITATION ANALYSIS

Bibliometrics are about publications and their citations. The academic field emerged from 'information science' and now usually refers to the methods used to study and index texts and information.

Publications cite other publications. These citation links grow into networks, and their numbers are likely to be related to the significance or impact of the publication. The meaning of the publication is determined from keywords and content. Citation analysis and content analysis have therefore become a common part of bibliometric methodology. Historically, bibliometric methods were used to trace relationships amongst academic journal citations. Now, bibliometrics are important in indexing research performance.

Bibliometric data have particular characteristics of which the user should be aware, and these are considered here.

Journal papers (publications, sources) report research work. Papers refer to or 'cite' earlier work relevant to the material being reported. New papers are cited in their turn. Papers that accumulate more citations are thought of as having greater 'impact', which is interpreted as significance or influence on their field. Citation counts are therefore recognised as a measure of impact, which can be used to index the excellence of the research from a particular group, institution or country.

The origins of citation analysis as a tool that could be applied to research performance can be traced to the mid-1950s, when Eugene Garfield proposed the concept of citation indexing and introduced the Science Citation Index, the Social Sciences Citation Index and the Arts & Humanities Citation Index, produced by the Institute of Scientific Information (now Clarivate Analytics).²⁰

We can count citations, but they are only 'indicators' of impact or quality – not metrics. Most impact indicators use average citation counts from groups of papers, because some individual papers may have unusual or misleading citation profiles. These outliers are diluted in larger samples.

Data source

The data we use come from the Clarivate Analytics Web of Science databases which give access not only to journals but also to conference proceedings, books, patents, websites, and chemical structures, compounds and reactions. It has a unified structure that integrates all data and search terms together and therefore provides a level of comparability not found in other databases. It is widely acknowledged to be the world's leading source of citation and bibliometric data. The Clarivate Analytics Web of Science Core Collection is part of the Web of Science, and focuses on research published in journals and conferences in science, medicine, arts, humanities and social sciences.

The Web of Science was originally created as an awareness and information retrieval tool but it has acquired an important primary use as a tool for research evaluation, using citation analysis and bibliometrics. Data coverage is both current and retrospective in the sciences, social sciences, arts and humanities, in some cases back to 1900. Within the research community this data source was previously referred to by the acronym 'ISI'.

Unlike other databases, the Web of Science and underlying databases are selective, that is: the journals abstracted are selected using rigorous editorial and quality criteria. The authoritative, multidisciplinary content covers over 12,000 of the highest impact journals worldwide, including Open Access journals, and over 150,000 conference proceedings. The abstracted journals encompass the majority of significant, frequently cited scientific reports and, more importantly, an even greater proportion of the scientific research output which is cited. This selective process ensures that the citation counts remain

²⁰ Garfield, E (1955) Citation Indexes for Science – New dimension in documentation through association of ideas. *Science*: 122, 108-111.

relatively stable in given research fields and do not fluctuate unduly from year to year, which increases the usability of such data for performance evaluation.

Clarivate Analytics has extensive experience with databases on research inputs, activity and outputs and has developed innovative analytical approaches for benchmarking and interpreting international, national and institutional research impact.

Database categories

The source data can be grouped in various classification systems. Most of these are based on groups of journals that have a relatively high cross-citation linkage and naturally cluster together. Custom classifications use subject maps in third-party data such as the OECD categories set out in the Frascati manual.

Clarivate Analytics frequently uses the broader field categories in the InCites: Essential Science Indicators *system* and the finer journal categories in the Web of Science. There are 22 fields in Essential Science Indicators and 254 fields in Web of Science. In either case, our bibliometric analyses draw on the full range of data available in the underlying database, so analyses in our reports will differ slightly from anything created 'on the fly' from data in the web interface.

The lists of journal categories in these systems are attached at the end of this document.

Most analyses start with an overall view across the data, then move to a view across broad categories and only then focus in at a finer level in the areas of greatest interest to policy, programme or organisational purpose.

Assigning papers to addresses

A paper is assigned to each country and each organisation whose address appears at least once for any author on that paper. One paper counts once and only once for each assignment, however many address variants occur for the country or organisation. No weighting is applied.

For example, a paper has five authors, thus:

Author	Organisation	Country		
Gurney, KA	Univ Leeds	UK	Counts for Univ Leeds	Counts for UK
Adams, J	Univ Leeds	UK	No gain for Univ Leeds	No gain for UK
Kochalko, D	Univ C San Diego	USA	Counts for UCSD	Counts for USA
Munshi, S	Gujarat Univ	India	Counts for Gujarat Univ	Counts for India
Pendlebury, D	Univ Oregon	USA	Counts for Univ Oregon	No gain for USA

So this one paper with five authors would be included once in the tallies for each of four universities and once in the tallies for each of three countries.

Work carried out within Clarivate Analytics, and research published elsewhere, indicates that fractional weighting based on the balance of authors by organisation and country makes little difference to the conclusions of an analysis at an aggregate level. Such fractional analysis can introduce unforeseen errors in the attempt to create a detailed but uncertain assignment. Partitioning credit would make a greater difference at a detailed, group level but the analysis can then be manually validated.


Citation counts

A publication accumulates citation counts when it is referred to by more recent publications. Some papers get cited frequently and many get cited rarely or never, so the distribution of citations is highly skewed.

Why are many papers never cited? Certainly some papers remain uncited because their content is of little or no impact, but that is not the only reason. It might be because they have been published in a journal not read by researchers to whom the paper might be interesting. It might be that they represent important but 'negative' work reporting a blind alley to be avoided by others. The publication may be a commentary in an editorial, rather than a normal journal article and thus of general rather than research interest. Or it might be that the work is a 'sleeping beauty' that has yet to be recognised for its significance.

Other papers can be very highly cited: hundreds, even thousands of times. Again, there are multiple reasons for this. Most frequently cited work is being recognised for its innovative significance and impact on the research field of which it speaks. Impact here is a good reflection of quality: it is an indicator of excellence. But there are other papers which are frequently cited because their significance is slightly different: they describe key methodology; they are a thoughtful and wide-ranging review of a field; or they represent contentious views which others seek to refute.

Citation analysis cannot make value judgments about why an article is uncited nor about why it is highly cited. The analysis can only report the citation impact that the publication has achieved. We normally assume, based on many other studies linking bibliometric and peer judgments, that high citation counts correlate on average with the quality of the research.



The figure shows the skewed distribution of more or less frequently cited papers from a sample of UK authored publications in cell biology. The skew in the distribution varies from field to field. It is to compensate for such factors that actual citation counts must be normalised, or rebased, against a world baseline.

We do not seek to account separately for the effect of self-citation. If the citation count is significantly affected by self-citation then the paper is likely to have been infrequently cited. This is therefore only of consequence for low impact activity. Studies show that for large samples at national and organisational level the effect of self-citation has little or no effect on the analytical outcomes and would not alter interpretation of the results.


Time factors

Citations accumulate over time. Older papers therefore have, on average, more citations than more recent work. The graph below shows the pattern of citation accumulation for a set of 33 journals in the

journal category **Materials Science, Biomaterials**. Papers less than eight years old are, on average, still accumulating additional citations. The citation count goes on to reach a plateau for older sources.

The graph shows that the percentage of papers that have never been cited drops over about five years. Beyond five years, between 5% and 10% or more of papers remain uncited.

Account must be taken of these time factors in comparing current research with historical patterns. For these reasons, it is sometimes more appropriate to use a fixed five-year window of papers and citations to compare two periods than to look at the longer term profile of citations and of uncitedness for a recent year and an historical year.



Discipline factors

Citation rates vary between disciplines and fields. For the UK science base as a whole, ten years produces a general plateau beyond which few additional citations would be expected. On the whole, citations accumulate more rapidly and plateau at a higher level in biological sciences than physical sciences, and natural sciences generally cite at a higher rate than social sciences.

Papers are assigned to disciplines (journal categories or research fields) by Clarivate Analytics, bringing cognate research areas together. The journal category classification scheme has been recently revised and updated. Before 2007, journals were assigned to the older, well established Current Contents categories which were informed by extensive work by Thomson and with the research community since the early 1960s. This scheme has been superseded by the 252 Web of Science journal categories which allow for greater disaggregation for the growing volume of research which is published and abstracted.

Papers are allocated according to the journal in which the paper is published. Some journals may be considered to be part of the publication record for more than one research field. As the example below illustrates, the journal *Acta Biomaterialia* is assigned to two journal categories: **Materials Science, Biomaterials** and **Engineering, Biomedical**.

Very few papers are not assigned to any research field and as such will not be included in specific analyses using normalised citation impact data. The journals included in the Clarivate Analytics databases and how they are selected are detailed here <http://scientific.thomsonreuters.com/mjl/>.

Some journals with a very diverse content, including the prestigious journals *Nature* and *Science* were classified as **Multidisciplinary** in databases created prior to 2007. The papers from these


Multidisciplinary journals are now re-assigned to more specific research fields using an algorithm based on the research area(s) of the references cited by the article.

Normalised citation impact

Because citations accumulate over time at a rate that is dependent upon the field of research, all analyses must take both field and year into account. In other words, because the absolute citation count for a specific article is influenced by its field and by the year it was published, we can only make comparisons of indexed data after normalising with reference to these two variables.

We only use citation counts for reviews and articles in calculations of impact, because document type influences the citation count. For example, a review will often be cited more frequently than an article in the same field, but editorials and meeting abstracts are rarely cited and citation rates for conference proceedings are extremely variable. The most common normalisation factors are the average citations per paper for (1) the year and (2) either the field or the journal in which the paper was published. This normalisation is also referred to as 'rebasin' the citation count.

Impact is therefore most commonly analysed in terms of 'normalised impact', or NCI. The following schematic illustrates how the normalised citation impact is calculated at paper level and journal category level.



This article in the journal *Acta Biomaterialia* is assigned to two journal categories: **Materials Science, Biomaterials** and **Engineering, Biomedical**. The world average baselines for, as an example, **Materials science, Biomaterials** are calculated by summing the citations to all the articles and reviews published worldwide in the journal *Acta Biomaterialia* and the other 32 journals assigned to this category for each year, and dividing this by the total number of articles and reviews published in the journal category. This gives the category-specific normalised citation impact (in the above example the category-specific NCI_F for **Materials Science, Biomaterials** is 5.8 and the category-specific NCI_F for **Engineering, Biomedical** is higher at 6.7). Most papers (nearly two-thirds) are assigned to a single journal category whilst a minority are assigned to more than 5.

Citation data provided by Clarivate Analytics are assigned on an annual census date referred to as the Article Time Period. For the majority of publications the Article Time Period is the same as the year of publication, but for a few publications (especially those published at the end of the calendar year in less main-stream journals) the Article Time Period may vary from the actual year of publication.

World average impact data are sourced from the Clarivate Analytics National Science Indicators baseline data for 2016.

Mean normalised citation impact

Research performance has historically been indexed by using average citation impact, usually compared to a world average that accounts for time and discipline. As noted, however, the distribution of citations amongst papers is highly skewed because many papers are never cited while a few papers accumulate very large citation counts. That means that an average may be misleading if assumptions are made about the distribution of the underlying data.

In fact, almost all research activity metrics are skewed: for research income, PhD numbers and publications there are many low activity values and a few exceptionally high values. In reality, therefore, the skewed distribution means that average impact tends to be greater than and often significantly different from either the median or mode in the distribution. This should be borne in mind when reviewing analytical outcomes.

The average (normalised) citation impact can be calculated at an individual paper level where it can be associated with more than one journal category. It can also be calculated for a set of papers at any level from a single country to an individual researcher's output. In the example above, the average citation impact of the *Acta Biomaterialia* paper can be expressed as $((5.8 + 6.7)/2) = 6.3$.

Impact Profiles®


We have developed a bibliometric methodology²¹ that shows the proportion of papers that are uncited and the proportion that lie in each of eight categories of relative citation rates, normalised (rebased) to world average. An Impact Profile® enables an examination and analysis of the strengths and weaknesses of published outputs relative to world average and relative to a reference profile. This provides much more information about the basis and structure of research performance than conventionally reported averages in citation indices.

Papers which are “highly-cited” are often defined in our reports as those with an average citation impact (NCI_F) greater than or equal to 4.0, i.e. those papers which have received greater than or equal to four times the world average number of citations for papers in that subject published in that year. This differs from Clarivate Analytics database of global highly-cited papers, which are the top 1% most frequently cited for their field and year. The top percentile is a powerful indicator of leading performance but is too stringent a threshold for most management analyses.

The proportion of uncited papers in a dataset can be compared to the benchmark for the UK, the USA or any other country. Overall, in a typical ten-year sample, around one-quarter of papers have not been cited within the 10-year period; the majority of these are, of course, those that are most recently published.

²¹ Adams J, Gurney K & Marshall S (2007) Profiling citation impact: A new methodology. *Scientometrics* 72: 325-344.

The Impact Profile® histogram can be presented in a number of ways which are illustrated below.



A: is used to represent the total output of an individual country, institution or researcher with no benchmark data. Visually it highlights the numbers of uncited papers (weaknesses) and highly cited papers (strengths).

B & C: are used to represent the total output of an individual country, institution or researcher (**client**) against an appropriate benchmark dataset (**benchmark**). The data are displayed as either histograms (B) or a combination of histogram and profile (C). Version C prevents the ‘travel’ which occurs in histograms where the eye is drawn to the data most offset to the right, but can be less easy to interpret as categorical data.

D: illustrates the complexity of data which can be displayed using an Impact Profile®. These data show research output in defined journal categories against appropriate benchmarks: **client, research field X; client, research field Y; client, research field Z; benchmark, research field X+Y; benchmark, research field, Z.**

Impact Profiles® enable an examination and analysis of the balance of published outputs relative to world average and relative to a reference profile. This provides much more information about the basis and structure of research performance than conventionally reported averages in citation indices.

An Impact Profile® shows what proportion of papers are uncited and what proportion are in each of eight categories of relative citation rates, normalised to world average (which becomes 1.0 in this graph). Normalised citation rates above 1.0 indicate papers cited more often than world average for the field in which that journal is categorised and in their year of publication.

Attention should be paid to:

- The proportion of uncited papers on the left of the chart
- The proportion of cited papers either side of world average (1.0)

- The location of the most common (modal) group near the centre
- The proportion of papers in the most highly-cited categories to the right, ($\geq 4 \times$ world, $\geq 8 \times$ world).

What are uncited papers?

It may be a surprise that some journal papers are never subsequently cited after publication, even by their authors. This accounts for about half the total global output for a typical, recent 10-year period. We cannot tell why papers are not cited. It is likely that a significant proportion of papers remain uncited because they are reporting negative results which are an essential matter of record in their field but make the content less likely to be referenced in other papers. Inevitably, other papers are uncited because their content is trivial or marginal to the mainstream. However, it should not be assumed that this is the case for all such papers.

There is variation in non-citation between countries and between fields. For example, relatively more engineering papers tend to remain uncited than papers in other sciences, indicative of a disciplinary factor but not a quality factor. While there is also an obvious increase in the likelihood of citation over time, most papers that are going to be cited will be cited within a few years of publication.

What is the threshold for 'highly cited'?

Clarivate Analytics has traditionally used the term 'Highly Cited Paper' to refer to the world's 1% of most frequently cited papers, taking into account year of publication and field. In rough terms, UK papers cited more than eight times as often as relevant world average would fall into the Thomson Highly Cited category. About 1-2% of papers (all papers, cited or uncited) typically pass this hurdle. Such a threshold certainly delimits exceptional papers for international comparisons but, in practice, is an onerous marker for more general management purposes.

After reviewing the outcomes of a number of analyses, we have chosen a more relaxed definition for our descriptive and analytical work. We deem papers that are cited more often than four times the relevant world average to be relatively highly-cited for national comparisons. This covers the two most highly-cited categories in our graphical analyses.

Another bibliometric indicator which can be very useful in small datasets is the Clarivate Analytics quality index. This indicator is calculated from the citation impact relative to the specific journal in which the paper is published.

For the paper on page 65 which has been cited 189 times to the end-December 2014, the expected citation rate for a paper in *Acta Biomaterialia* published in 2005 would be 49.57. Therefore, this paper has been cited more than expected for the journal. For a set of papers, we calculate the quality index as the percentage of papers which are cited more than expected for the relevant journals.

This indicator should be considered alongside that of normalised citation impact as they are complementary. For example, a given set of publications may have a high Clarivate Analytics quality index and relatively low citation impact. This would imply that these papers were well cited in relation to other papers in that journal and that year but when considered in relation to other papers published in more highly-cited journals in the same research field did not perform as well. The interpretation would be that the publications are in relatively low impact journals.

Journal category systems used in our analyses

WEB OF SCIENCE

Acoustics	Classics	Engineering, multidisciplinary
Agricultural economics & policy	Clinical neurology	Engineering, ocean
Agricultural engineering	Communication	Engineering, petroleum
Agriculture, dairy & animal science	Computer science, artificial intelligence	Entomology
Agriculture, multidisciplinary	Computer science, cybernetics	Environmental sciences
Agriculture, soil science	Computer science, hardware & architecture	Environmental studies
Agronomy	Computer science, information systems	Ergonomics
Allergy	Computer science, interdisciplinary applications	Ethics
Anatomy & morphology	Computer science, software engineering	Ethnic studies
Andrology	Computer science, theory & methods	Evolutionary biology
Anesthesiology	Construction & building technology	Family studies
Anthropology	Criminology & penology	Film, radio, television
Applied linguistics	Critical care medicine	Fisheries
Archaeology	Crystallography	Folklore
Architecture	Dance	Food science & technology
Area studies	Demography	Forestry
Art	Dentistry, oral surgery & medicine	Gastroenterology & hepatology
Asian studies	Dermatology	Genetics & heredity
Astronomy & astrophysics	Developmental biology	Geochemistry & geophysics
Automation & control systems	Ecology	Geography
Behavioral sciences	Economics	Geography, physical
Biochemical research methods	Education & educational research	Geology
Biochemistry & molecular biology	Education, scientific disciplines	Geosciences, multidisciplinary
Biodiversity conservation	Education, special	Geriatrics & gerontology
Biology	Electrochemistry	Health care sciences & services
Biology, miscellaneous	Emergency medicine	Health policy & services
Biophysics	Endocrinology & metabolism	Hematology
Biotechnology & applied microbiology	Energy & fuels	History
Business	Engineering, aerospace	History & philosophy of science
Business, finance	Engineering, biomedical	History of social sciences
Cardiac & cardiovascular systems	Engineering, chemical	Horticulture
Cell biology	Engineering, civil	Humanities, multidisciplinary
Chemistry, analytical	Engineering, electrical & electronic	Imaging science & photographic technology
Chemistry, applied	Engineering, environmental	Immunology
Chemistry, inorganic & nuclear	Engineering, geological	Industrial relations & labor
Chemistry, medicinal	Engineering, industrial	Infectious diseases

Chemistry, multidisciplinary	Engineering, manufacturing	Information & library science
Chemistry, organic	Engineering, marine	Instruments & instrumentation
Chemistry, physical	Engineering, mechanical	Integrative & complementary medicine
International relations	Mining & mineral processing	Psychology
Language & linguistics	Multidisciplinary sciences	Psychology, applied
Language & linguistics theory	Music	Psychology, biological
Law	Mycology	Psychology, clinical
Limnology	Nanoscience & nanotechnology	Psychology, developmental
Linguistics	Neuroimaging	Psychology, educational
Literary reviews	Neurosciences	Psychology, experimental
Literary theory & criticism		Psychology, mathematical
Literature	Nuclear science & technology	Psychology, multidisciplinary
Literature, African, Australian, Canadian	Nursing	Psychology, psychoanalysis
Literature, American	Nutrition & dietetics	Psychology, social
Literature, British Isles	Obstetrics & gynecology	Public administration
Literature, German, Dutch, Scandinavian	Oceanography	Public, environmental & occupational health
Literature, romance	Oncology	Radiology, nuclear medicine & medical imaging
Literature, Slavic	Operations research & management science	Rehabilitation
Management	Ophthalmology	Religion
Marine & freshwater biology	Optics	Remote sensing
Materials science, biomaterials	Ornithology	Reproductive biology
Materials science, ceramics	Orthopedics	Respiratory system
Materials science, characterization & testing	Otorhinolaryngology	Rheumatology
Materials science, coatings & films	Paleontology	Robotics
Materials science, composites	Parasitology	Social issues
Materials science, multidisciplinary	Pathology	Social sciences, biomedical
Materials science, paper & wood	Pediatrics	Social sci, interdisciplinary
Materials science, textiles	Peripheral vascular disease	Social sci, mathematical methods
Math & computational biology	Pharmacology & pharmacy	Social work
Mathematics	Philosophy	Sociology
Mathematics, applied	Physics, applied	Soil science
Mathematics, interdisciplinary applications	Physics, atomic, molecular & chemical	Spectroscopy
Mechanics	Physics, condensed matter	Sport sciences
Medical ethics	Physics, fluids & plasmas	Statistics & probability
Medical informatics	Physics, mathematical	Substance abuse
Medical laboratory technology	Physics, multidisciplinary	Surgery
Medicine, general & internal	Physics, nuclear	Telecommunications
Medicine, legal	Physics, particles & fields	Theater
Medicine, research & experimental	Physiology	Thermodynamics
Medieval & renaissance studies	Planning & development	Toxicology

Metallurgy & metallurgical engineering	Plant sciences	Transplantation
Meteorology & atmospheric sci	Poetry	Transportation
Microbiology	Political science	Transportation science & technology
Microscopy	Polymer science	Tropical medicine
Mineralogy	Psychiatry	
Urban studies		
Urology & nephrology		
Veterinary		
Veterinary sciences		
Virology		
Water resources		
Women's studies		
Zoology		

ESSENTIAL SCIENCE INDICATORS

Agricultural Sciences	Geosciences	Pharmacology
Biology & Biochemistry	Immunology	Physics
Chemistry	Law	Plant & Animal Science
Clinical Medicine	Materials Science	Psychology/Psychiatry
Computer Science	Mathematics	Social Sciences, general
Ecology/Environment	Microbiology	Space Science
Economics & Business	Molecular Biology & Genetics	
Education	Multidisciplinary	
Engineering	Neurosciences & Behaviour	

ANNEX 2: MEDICALLY RELATED JOURNAL CATEGORIES

This Annex lists the Web of Science journal categories which capture medically related publications.

Allergy	Nutrition & Dietetics
Anatomy & Morphology	Obstetrics & Gynaecology
Andrology	Ophthalmology
Anaesthesiology	Orthopaedics
Psychology, Biological	Otorhinolaryngology
Audiology & Speech-Language Pathology	Pathology
Behavioural Sciences	Paediatrics
Cell & Tissue Engineering	Pharmacology & Pharmacy
Oncology	Psychiatry
Cardiac & Cardiovascular Systems	Psychology
Critical Care Medicine	Psychology, Psychoanalysis
Emergency Medicine	Psychology, Mathematical
Cytology & Histology	Psychology, Experimental
Dentistry, Oral Surgery & Medicine	Radiology, Nuclear Medicine & Medical Imaging
Dermatology	Rehabilitation
Substance Abuse	Respiratory System
Psychology, Educational	Reproductive Biology
Health Care Sciences & Services	Rheumatology
Endocrinology & Metabolism	Psychology, Social
Ergonomics	Surgery
Gastroenterology & Hepatology	Transplantation
Geriatrics & Gerontology	Tropical Medicine
Gerontology	Urology & Nephrology
Health Policy & Services	Peripheral Vascular Disease
Haematology	Virology
Primary Health Care	
Psychology, Developmental	
Public, Environmental & Occupational Health	
Immunology	
Infectious Diseases	
Psychology, Applied	
Integrative & Complementary Medicine	
Medical Ethics	
Medicine, Legal	
Medical Informatics	
Medical Laboratory Technology	
Medicine, General & Internal	
Medicine, Research & Experimental	
Med, Miscellaneous	
Clinical Neurology	
Neurosciences	
Neuroimaging	
Nursing	

ANNEX 3: COLLABORATION INDEX FOR ALL IMI SUPPORTED RESEARCH PROJECTS

This Annex provides the calculation of the collaboration index for all IMI supported research projects.

Project	X-sector Score	International score	Metric 3	Collaboration Index	Total Papers publications	Citation impact (field normalised)
BTCure	0.61	0.49	1.00	2.10	573	1.86
EU-AIMS	0.66	0.64	1.00	2.30	262	2.32
NEWMEDS	0.63	0.57	1.00	2.20	173	2.25
EMIF	0.79	0.63	1.00	2.42	160	2.72
EUROPAIN	0.51	0.35	1.00	1.86	154	2.39
IMIDIA	0.52	0.48	0.65	1.65	127	1.66
ULTRA-DD	0.58	0.65	0.94	2.17	110	2.10
ORBITO	0.54	0.48	0.56	1.58	107	1.59
CHEM21	0.22	0.27	0.05	0.54	105	1.69
SUMMIT	0.71	0.60	1.00	2.31	99	1.27
PROTECT	0.97	0.64	0.58	2.19	95	1.06
eTOX	0.29	0.37	0.24	0.90	86	1.72
TRANSLOCATION	0.36	0.49	0.40	1.25	84	1.50
MIP-DILI	0.68	0.42	1.00	2.10	82	1.70
Quic-Concept	0.70	0.58	1.00	2.28	80	2.74
U-BIOPRED	0.81	0.63	1.00	2.44	79	1.72
ELF	0.36	0.50	0.10	0.96	75	1.33
Open PHACTS	0.62	0.58	1.00	2.20	71	2.68
STEMBANCC	0.54	0.45	1.00	1.99	71	1.73
PreDiCT-TB	0.56	0.48	0.74	1.78	70	1.31
CANCER-ID	0.74	0.37	1.00	2.11	69	3.27
Pharma-Cog	0.84	0.73	1.00	2.57	69	1.46
DDMoRe	0.57	0.52	0.53	1.62	61	0.69
ABIRISK	0.63	0.37	0.95	1.95	57	1.26
COMPACT	0.15	0.39	0.49	1.03	54	1.89
Onco Track	0.55	0.41	1.00	1.96	53	2.51
DIRECT	0.73	0.65	1.00	2.38	49	2.23
MARCAR	0.43	0.40	0.18	1.01	49	1.18
BioVacSafe	0.46	0.42	1.00	1.88	48	1.49
SPRINTT	0.52	0.56	0.38	1.46	45	2.99
COMBACTE	0.61	0.35	0.67	1.63	41	1.52
Prelect	0.69	0.63	0.82	2.14	36	1.87
RAPP-ID	0.31	0.38	0.15	0.84	36	1.01
K4DD	0.46	0.49	1.00	1.95	35	2.01
AETIONOMY	0.64	0.44	1.00	2.08	33	1.02
GETREAL	0.80	0.80	0.21	1.81	31	3.36
PRECISESADS	0.66	0.68	1.00	2.34	29	1.08
PRO-active	0.96	0.76	0.41	2.13	26	2.00
ND4BB	0.48	0.46	0.46	1.40	24	1.15

Project	X-sector Score	International score	Metric 3	Collaboration Index	Total Papers publications	Citation impact (field normalised)
COMBACTE-MAGNET	0.67	0.70	0.81	2.18	22	1.87
eTRIKS	0.68	0.85	1.00	2.53	22	2.71
ZAPI	0.59	0.65	1.00	2.24	22	2.31

ANNEX 4: BIBLIOGRAPHY OF HOT PAPERS AND HIGHLY-CITED PAPERS

This Annex provides bibliographic data for hot and highly-cited papers. Hot papers are papers that receive citations soon after publication, relative to other papers of the same field and age. For the purpose of this report, highly-cited papers have been defined as those articles and reviews which belong to the world's top decile of papers in that journal category and year of publication, when ranked by number of citations received. A percentage that is above 10 indicates above-average performance.

Papers are listed in ascending alphabetical order (project, first author) and unassigned papers, of which there are three, are listed at the end of each section.

This section lists papers that have been identified as current hot papers or that have been identified as highly-cited in the IMI project publication dataset.

HOT PAPERS ASSOCIATED WITH IMI PROJECTS

- CANCER-ID: SIRAVEGNA, G et al. (2017) Integrating liquid biopsies into the management of cancer, *NAT REV CLIN ONCOL* 14: 531-548
- IMPRiND: FITZPATRICK, AWP et al. (2017) Cryo-EM structures of tau filaments from Alzheimers disease, *NATURE* 547: 185-+
- Quic-Concept: OCONNOR, JPB et al. (2017) Imaging biomarker roadmap for cancer studies, *NAT REV CLIN ONCOL* 14: 169-186
- Unassigned project: VISSCHER, PM et al. (2017) 10 Years of GWAS Discovery: Biology, Function, and Translation, *AM J HUM GENET* 101: 5-22

This section lists papers that perform above average as defined by citation counts in the 10th percentile.

HIGHLY-CITED PAPERS ASSOCIATED WITH IMI PROJECTS

- ABIRISK: HEMMER, B et al. (2015) Role of the innate and adaptive immune responses in the course of multiple sclerosis, *LANCET NEUROL* 14: 406-419
- ABIRISK: KIESEIER, BC et al. (2013) Disease Amelioration With Tocilizumab in a Treatment-Resistant Patient With Neuromyelitis Optica Implication for Cellular Immune Responses, *JAMA NEUROL* 70: 390-393
- ABIRISK: RINGELSTEIN, M et al. (2015) Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder, *JAMA NEUROL* 72: 756-763
- ABIRISK: SHANKAR, G et al. (2014) Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides-Harmonized Terminology and Tactical Recommendations, *AAPS J* 16: 658-673
- ABIRISK: UNGAR, B et al. (2014) The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab, *GUT* 63: 1258-1264
- ABIRISK: WARNKE, C et al. (2015) Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF, *MULT SCLER J* 21: 1036-1044
- ABIRISK: WARNKE, C et al. (2013) Changes to anti-JCV antibody levels in a Swedish national MS cohort, *J NEUROL NEUROSUR PS* 84: 1199-1205
- ABIRISK: WARNKE, C et al. (2014) Cerebrospinal Fluid JC Virus Antibody Index for Diagnosis of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy, *ANN NEUROL* 76: 792-801

- ABIRISK: WENNIGER, LJMD et al. (2013) Immunoglobulin G4+clones identified by next-generation sequencing dominate the B cell receptor repertoire in immunoglobulin G4 associated cholangitis, *HEPATOLOGY* 57: 2390-2398
- ADVANCE: PEBODY, R et al. (2016) Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results, *EUROSURVEILLANCE* 21: 41-51
- ADVANCE: STURKENBOOM, MCJM et al. (2015) The narcolepsy-pandemic influenza story: Can the truth ever be unraveled?, *VACCINE* 33: B6-B13
- AETIONOMY: AUFRAY, C et al. (2016) Making sense of big data in health research: Towards an EU action plan, *GENOME MED* 8:
- AETIONOMY: BEDARF, JR et al. (2017) Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naive Parkinsons disease patients, *GENOME MED* 9:
- AETIONOMY: ERPAPAZOGLU, Z et al. (2017) From dysfunctional endoplasmic reticulum-mitochondria coupling to neurodegeneration, *NEUROCHEM INT* 109: 171-183
- AETIONOMY: GAUTIER, CA et al. (2016) The endoplasmic reticulum-mitochondria interface is perturbed in PARK2 knockout mice and patients with PARK2 mutations, *HUM MOL GENET* 25: 2972-2984
- AETIONOMY: GISPERT, JD et al. (2016) CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD, *NEUROBIOL AGING* 38: 47-55
- AETIONOMY: MOLINUEVO, JL et al. (2014) White matter changes in preclinical Alzheimers disease: a magnetic resonance imaging-diffusion tensor imaging study on cognitively normal older people with positive amyloid beta protein 42 levels, *NEUROBIOL AGING* 35: 2671-2680
- APPROACH: MOBASHERI, A et al. (2017) Osteoarthritis Year in Review 2016: biomarkers (biochemical markers), *OSTEOARTHR CARTILAGE* 25: 199-208
- APPROACH: MOBASHERI, A et al. (2017) The role of metabolism in the pathogenesis of osteoarthritis, *NAT REV RHEUMATOL* 13: 302-311
- APPROACH: RAHMATI, M et al. (2016) Inflammatory mediators in osteoarthritis: A critical review of the state-of-the-art, current prospects, and future challenges, *BONE* 85: 81-90
- APPROACH: RICHARDSON, SM et al. (2016) Mesenchymal stem cells in regenerative medicine: Focus on articular cartilage and intervertebral disc regeneration, *METHODS* 99: 69-80
- BEAT-DKD: RINSCHEN, MM et al. (2017) YAP-mediated mechanotransduction determines the podocytes response to damage, *SCI SIGNAL* 10:
- BioVacSafe: ANDERSEN, P et al. (2014) Novel Vaccination Strategies against Tuberculosis, *CSH PERSPECT MED* 4:
- BioVacSafe: ANDERSEN, P et al. (2014) Tuberculosis vaccines - rethinking the current paradigm, *TRENDS IMMUNOL* 35: 387-395
- BioVacSafe: CLIFF, JM et al. (2015) The human immune response to tuberculosis and its treatment: a view from the blood, *IMMUNOL REV* 264: 88-102
- BioVacSafe: KAUFMANN, SHE et al. (2013) Tuberculosis vaccines: Time to think about the next generation, *SEMIN IMMUNOL* 25: 172-181
- BioVacSafe: KAUFMANN, SHE et al. (2014) Progress in tuberculosis vaccine development and host-directed therapies-a state of the art review, *LANCET RESP MED* 2: 301-320
- BioVacSafe: KAUFMANN, SHE et al. (2013) Inflammation in tuberculosis: interactions, imbalances and interventions, *CURR OPIN IMMUNOL* 25: 441-449
- BioVacSafe: KAUFMANN, SHE et al. (2012) Tuberculosis vaccine development: strength lies in tenacity, *TRENDS IMMUNOL* 33: 373-379
- BioVacSafe: KAUFMANN, SHE et al. (2016) Molecular Determinants in Phagocyte-Bacteria Interactions, *IMMUNITY* 44: 476-491

- BioVacSafe: MAERTZDORF, J et al. (2012) Enabling biomarkers for tuberculosis control, *INT J TUBERC LUNG D* 16: 1140-1148
- BioVacSafe: PERSSON, J et al. (2016) Nasal Immunization Confers High Avidity Neutralizing Antibody Response and Immunity to Primary and Recurrent Genital Herpes in Guinea Pigs, *FRONT IMMUNOL* 7:
- BioVacSafe: RAPPUOLI, R et al. (2014) Vaccines, new opportunities for a new society, *P NATL ACAD SCI USA* 111: 12288-12293
- BioVacSafe: TRICOT, S et al. (2015) Evaluating the Efficiency of Isotope Transmission for Improved Panel Design and a Comparison of the Detection Sensitivities of Mass Cytometer Instruments, *CYTOM PART A* 87A: 357-368
- BioVacSafe: VAN AALST, S et al. (2017) Dynamics of APC recruitment at the site of injection following injection of vaccine adjuvants, *VACCINE* 35: 1622-1629
- BioVacSafe: WEINER, J et al. (2014) Recent advances towards tuberculosis control: vaccines and biomarkers, *J INTERN MED* 275: 467-480
- BTCure: AJEGANOVA, S et al. (2016) Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts, *ANN RHEUM DIS* 75: 1924-1932
- BTCure: AJEGANOVA, S et al. (2017) The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor, *ANN RHEUM DIS* 76: 112-118
- BTCure: AKHMETSHINA, A et al. (2012) Activation of canonical Wnt signalling is required for TGF-beta-mediated fibrosis, *NAT COMMUN* 3:
- BTCure: AMARA, K et al. (2013) Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition, *J EXP MED* 210: 445-455
- BTCure: AMMARI, M et al. (2013) Impact of microRNAs on the understanding and treatment of rheumatoid arthritis, *CURR OPIN RHEUMATOL* 25: 225-233
- BTCure: ARBOREA, G et al. (2017) Intracellular complement - the complosome - in immune cell regulation, *MOL IMMUNOL* 89: 2-9
- BTCure: ARBOREA, G et al. (2016) A novel complement-metabolism-inflammasome axis as a key regulator of immune cell effector function, *EUR J IMMUNOL* 46: 1563-1573
- BTCure: ARNTZ, OJ et al. (2015) Oral administration of bovine milk derived extracellular vesicles attenuates arthritis in two mouse models, *MOL NUTR FOOD RES* 59: 1701-1712
- BTCure: BECKER, C et al. (2013) Complex Roles of Caspases in the Pathogenesis of Inflammatory Bowel Disease, *GASTROENTEROLOGY* 144: 283-293
- BTCure: BOSSINI-CASTILLO, L et al. (2015) A genome-wide association study of rheumatoid arthritis without antibodies against citrullinated peptides, *ANN RHEUM DIS* 74:
- BTCure: BOZEC, A et al. (2014) T Cell Costimulation Molecules CD80/86 Inhibit Osteoclast Differentiation by Inducing the IDO/Tryptophan Pathway, *SCI TRANSL MED* 6:
- BTCure: BRINK, M et al. (2013) Multiplex Analyses of Antibodies Against Citrullinated Peptides in Individuals Prior to Development of Rheumatoid Arthritis, *ARTHRITIS RHEUM-US* 65: 899-910
- BTCure: BUDIN-LJOSNE, I et al. (2017) Dynamic Consent: a potential solution to some of the challenges of modern biomedical research, *BMC MED ETHICS* 18:
- BTCure: BURSKA, AN et al. (2014) Gene expression analysis in RA: towards personalized medicine, *PHARMACOGENOMICS J* 14: 93-106
- BTCure: CAMPBELL, TM et al. (2016) Mesenchymal Stem Cell Alterations in Bone Marrow Lesions in Patients With Hip Osteoarthritis, *ARTHRITIS RHEUMATOL* 68: 1648-1659

- BTCure: CATRINA, AI et al. (2016) Mechanisms involved in triggering rheumatoid arthritis, *IMMUNOL REV* 269: 162-174
- BTCure: CATRINA, AI et al. (2014) Lungs, joints and immunity against citrullinated proteins in rheumatoid arthritis, *NAT REV RHEUMATOL* 10: 645-653
- BTCure: CATRINA, AI et al. (2017) Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis, *NAT REV RHEUMATOL* 13: 79-86
- BTCure: CHATZIDIONISYOU, A et al. (2016) The lung in rheumatoid arthritis, cause or consequence?, *CURR OPIN RHEUMATOL* 28: 76-82
- BTCure: CHOI, IY et al. (2015) MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis, *ANN RHEUM DIS* 74: 499-505
- BTCure: COPE, A et al. (2011) The Th1 life cycle: molecular control of IFN-gamma to IL-10 switching, *TRENDS IMMUNOL* 32: 278-286
- BTCure: CUI, J et al. (2013) Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis, *PLOS GENET* 9:
- BTCure: DALESSIO, S et al. (2014) VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease, *J CLIN INVEST* 124: 3863-3878
- BTCure: DANKS, L et al. (2016) RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation, *ANN RHEUM DIS* 75: 1187-1195
- BTCure: DE AQUINO, SG et al. (2014) Periodontal Pathogens Directly Promote Autoimmune Experimental Arthritis by Inducing a TLR2-and IL-1-Driven Th17 Response, *J IMMUNOL* 192: 4103-4111
- BTCure: DE HAIR, MJH et al. (2014) Features of the Synovium of Individuals at Risk of Developing Rheumatoid Arthritis, *ARTHRITIS RHEUMATOL* 66: 513-522
- BTCure: DE HAIR, MJH et al. (2013) Smoking and overweight determine the likelihood of developing rheumatoid arthritis, *ANN RHEUM DIS* 72: 1654-1658
- BTCure: DEKKERS, JS et al. (2017) Possibilities for preventive treatment in rheumatoid arthritis? Lessons from experimental animal models of arthritis: a systematic literature review and meta-analysis, *ANN RHEUM DIS* 76: 458-467
- BTCure: DOORENSPLEET, ME et al. (2014) Rheumatoid arthritis synovial tissue harbours dominant B-cell and plasma-cell clones associated with autoreactivity, *ANN RHEUM DIS* 73: 756-762
- BTCure: FIGUEIREDO, CP et al. (2017) Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs, *ANN RHEUM DIS* 76: 399-407
- BTCure: FINZEL, S et al. (2011) Repair of bone erosions in rheumatoid arthritis treated with tumour necrosis factor inhibitors is based on bone apposition at the base of the erosion, *ANN RHEUM DIS* 70: 1587-1593
- BTCure: FINZEL, S et al. (2013) Interleukin-6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis: a micro CT study, *ANN RHEUM DIS* 72: 396-400
- BTCure: FISHER, BA et al. (2015) Smoking, *Porphyromonas gingivalis* and the immune response to citrullinated autoantigens before the clinical onset of rheumatoid arthritis in a Southern European nested case-control study, *BMC MUSCULOSKEL DIS* 16:
- BTCure: FRANK-BERTONCELJ, M et al. (2017) Epigenetically-driven anatomical diversity of synovial fibroblasts guides joint-specific fibroblast functions, *NAT COMMUN* 8:
- BTCure: FREELEY, S et al. (2016) The ins and outs of complement-driven immune responses, *IMMUNOL REV* 274: 16-32
- BTCure: FREY, S et al. (2013) The novel cytokine interleukin-36 alpha is expressed in psoriatic and rheumatoid arthritis synovium, *ANN RHEUM DIS* 72: 1569-1574

- BTCure: FRISELL, T et al. (2013) Familial Risks and Heritability of Rheumatoid Arthritis Role of Rheumatoid Factor/Anti-Citrullinated Protein Antibody Status, Number and Type of Affected Relatives, Sex, and Age, *ARTHRITIS RHEUM-US* 65: 2773-2782
- BTCure: FRISELL, T et al. (2016) Familial aggregation of arthritis-related diseases in seropositive and seronegative rheumatoid arthritis: a register-based case-control study in Sweden, *ANN RHEUM DIS* 75: 183-189
- BTCure: GAN, RW et al. (2015) Anti-carbamylated Protein Antibodies Are Present Prior to Rheumatoid Arthritis and Are Associated with Its Future Diagnosis, *J RHEUMATOL* 42: 572-579
- BTCure: GAO, W et al. (2016) Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors, *ANN RHEUM DIS* 75: 311-315
- BTCure: GAO, W et al. (2015) Hypoxia and STAT3 signalling interactions regulate pro-inflammatory pathways in rheumatoid arthritis, *ANN RHEUM DIS* 74: 1275-1283
- BTCure: GERLAG, DM et al. (2012) EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis, *ANN RHEUM DIS* 71: 638-641
- BTCure: GERLAG, DM et al. (2016) Towards prevention of autoantibody-positive rheumatoid arthritis: from lifestyle modification to preventive treatment, *RHEUMATOLOGY* 55: 607-614
- BTCure: GIERA, M et al. (2012) Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LC-MS/MS, *BBA-MOL CELL BIOL L* 1821: 1415-1424
- BTCure: GOULIELMOS, GN et al. (2016) Association of juvenile idiopathic arthritis with PTPN22 rs2476601 is specific to females in a Greek population, *PEDIATR RHEUMATOL* 14:
- BTCure: GUNTHER, C et al. (2013) Apoptosis, necrosis and necroptosis: cell death regulation in the intestinal epithelium, *GUT* 62: 1062-1071
- BTCure: HAN, B et al. (2014) Fine Mapping Seronegative and Seropositive Rheumatoid Arthritis to Shared and Distinct HLA Alleles by Adjusting for the Effects of Heterogeneity, *AM J HUM GENET* 94: 522-532
- BTCure: HARRE, U et al. (2012) Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin, *J CLIN INVEST* 122: 1791-1802
- BTCure: HARRE, U et al. (2015) Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss, *NAT COMMUN* 6:
- BTCure: HASCHKA, J et al. (2016) Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study, *ANN RHEUM DIS* 75: 45-51
- BTCure: HECHT, C et al. (2015) Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA, *ANN RHEUM DIS* 74: 2151-2156
- BTCure: HEILAND, GR et al. (2012) High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis, *ANN RHEUM DIS* 71: 572-574
- BTCure: HELLGREN, K et al. (2017) Rheumatoid Arthritis and Risk of Malignant Lymphoma, *ARTHRITIS RHEUMATOL* 69: 700-708
- BTCure: HENSVOLD, AH et al. (2017) How well do ACPA discriminate and predict RA in the general population: a study based on 12 590 population-representative Swedish twins, *ANN RHEUM DIS* 76: 119-125
- BTCure: HENSVOLD, AH et al. (2015) Environmental and genetic factors in the development of anticitrullinated protein antibodies (ACPAs) and ACPA-positive rheumatoid arthritis: an epidemiological investigation in twins, *ANN RHEUM DIS* 74: 375-380
- BTCure: HOLMDAHL, R et al. (2016) Ncf1 polymorphism reveals oxidative regulation of autoimmune chronic inflammation, *IMMUNOL REV* 269: 228-247

- BTCure: JAMES, EA et al. (2014) Citrulline-Specific Th1 Cells Are Increased in Rheumatoid Arthritis and Their Frequency Is Influenced by Disease Duration and Therapy, *ARTHRITIS RHEUMATOL* 66: 1712-1722
- BTCure: JIANG, X et al. (2016) An Immunochip-based interaction study of contrasting interaction effects with smoking in ACPA-positive versus ACPA-negative rheumatoid arthritis, *RHEUMATOLOGY* 55: 149-155
- BTCure: KATO, M et al. (2014) Dual Role of Autophagy in Stress-Induced Cell Death in Rheumatoid Arthritis Synovial Fibroblasts, *ARTHRITIS RHEUMATOL* 66: 40-48
- BTCure: KELKKA, T et al. (2014) Reactive Oxygen Species Deficiency Induces Autoimmunity with Type 1 Interferon Signature, *ANTIOXID REDOX SIGN* 21: 2231-2245
- BTCure: KERKMAN, PF et al. (2016) Identification and characterisation of citrullinated antigen-specific B cells in peripheral blood of patients with rheumatoid arthritis, *ANN RHEUM DIS* 75: 1170-1176
- BTCure: KHMALADZE, I et al. (2014) Mannan induces ROS-regulated, IL-17A-dependent psoriasis arthritis-like disease in mice, *P NATL ACAD SCI USA* 111: E3669-E3678
- BTCure: KIECHL, S et al. (2013) Blockade of receptor activator of nuclear factor-kappa B (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus, *NAT MED* 19: 358-363
- BTCure: KIECHL, S et al. (2017) Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer, *ONCOTARGET* 8: 3811-3825
- BTCure: KLARENBECK, PL et al. (2012) Inflamed target tissue provides a specific niche for highly expanded T-cell clones in early human autoimmune disease, *ANN RHEUM DIS* 71: 1088-1093
- BTCure: KLEIN, K et al. (2016) The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts, *ANN RHEUM DIS* 75: 422-429
- BTCure: KLEIN, K et al. (2013) Epigenetic modifications in rheumatoid arthritis, a review, *CURR OPIN PHARMACOL* 13: 420-425
- BTCure: KLEIN, K et al. (2015) Epigenetics in rheumatoid arthritis, *CURR OPIN RHEUMATOL* 27: 76-82
- BTCure: KLEYER, A et al. (2014) Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies, *ANN RHEUM DIS* 73: 854-860
- BTCure: KLOCKE, K et al. (2016) Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood, *P NATL ACAD SCI USA* 113: E2383-E2392
- BTCure: KOENDERS, MI et al. (2015) Novel therapeutic targets in rheumatoid arthritis, *TRENDS PHARMACOL SCI* 36: 189-195
- BTCure: KOLEV, M et al. (2015) Complement Regulates Nutrient Influx and Metabolic Reprogramming during Th1 Cell Responses, *IMMUNITY* 42: 1033-1047
- BTCure: KOLEV, M et al. (2017) Keeping it All Going - Complement Meets Metabolism, *FRONT IMMUNOL* 8:
- BTCure: KOLIARAKI, V et al. (2015) IKK beta in intestinal mesenchymal cells promotes initiation of colitis-associated cancer, *J EXP MED* 212: 2235-2251
- BTCure: KOPPEJAN, H et al. (2016) Role of Anti-Carbamylated Protein Antibodies Compared to Anti-Citrullinated Protein Antibodies in Indigenous North Americans With Rheumatoid Arthritis, Their First-Degree Relatives, and Healthy Controls, *ARTHRITIS RHEUMATOL* 68: 2090-2098
- BTCure: KRISHNAMURTHY, A et al. (2016) Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss, *ANN RHEUM DIS* 75: 721-729

- BTCure: KUMARI, S et al. (2013) Tumor Necrosis Factor Receptor Signaling in Keratinocytes Triggers Interleukin-24-Dependent Psoriasis-like Skin Inflammation in Mice, *IMMUNITY* 39: 899-911
- BTCure: LE FRIEC, G et al. (2012) The CD46-Jagged1 interaction is critical for human T(H)1 immunity, *NAT IMMUNOL* 13: 1213-+
- BTCure: LENZ, TL et al. (2015) Widespread non-additive and interaction effects within HLA loci modulate the risk of autoimmune diseases, *NAT GENET* 47: 1085-+
- BTCure: LEPPKES, M et al. (2014) Pleiotropic functions of TNF-alpha in the regulation of the intestinal epithelial response to inflammation, *INT IMMUNOL* 26: 509-515
- BTCure: LIN, NY et al. (2013) Autophagy regulates TNF alpha-mediated joint destruction in experimental arthritis, *ANN RHEUM DIS* 72: 761-768
- BTCure: LISZEWSKI, MK et al. (2013) Intracellular Complement Activation Sustains T Cell Homeostasis and Mediates Effector Differentiation, *IMMUNITY* 39: 1143-1157
- BTCure: LOPEZ-MEJIAS, R et al. (2016) Cardiovascular risk assessment in patients with rheumatoid arthritis: The relevance of clinical, genetic and serological markers, *AUTOIMMUN REV* 15: 1013-1030
- BTCure: LOPEZ-POSADAS, R et al. (2016) Rho-A prenylation and signaling link epithelial homeostasis to intestinal inflammation, *J CLIN INVEST* 126: 611-626
- BTCure: LUNDBERG, K et al. (2013) Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein/peptide antibody fine specificity profile, *ANN RHEUM DIS* 72: 652-658
- BTCure: LUO, YB et al. (2015) Microbiota from Obese Mice Regulate Hematopoietic Stem Cell Differentiation by Altering the Bone Niche, *CELL METAB* 22: 886-894
- BTCure: MALMSTROM, V et al. (2017) The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting, *NAT REV IMMUNOL* 17: 60-75
- BTCure: MARESZ, KJ et al. (2013) Porphyromonas gingivalis Facilitates the Development and Progression of Destructive Arthritis through Its Unique Bacterial Peptidylarginine Deiminase (PAD), *PLOS PATHOG* 9:
- BTCure: MARQUEZ, A et al. (2017) A combined large-scale meta-analysis identifies COG6 as a novel shared risk locus for rheumatoid arthritis and systemic lupus erythematosus, *ANN RHEUM DIS* 76: 286-294
- BTCure: MARTIN, P et al. (2015) Capture Hi-C reveals novel candidate genes and complex long-range interactions with related autoimmune risk loci, *NAT COMMUN* 6:
- BTCure: MASCALZONI, D et al. (2015) International Charter of principles for sharing bio-specimens and data, *EUR J HUM GENET* 23: 721-728
- BTCure: MENON, B et al. (2014) Interleukin-17+CD8+T Cells Are Enriched in the Joints of Patients With Psoriatic Arthritis and Correlate With Disease Activity and Joint Damage Progression, *ARTHRITIS RHEUMATOL* 66: 1272-1281
- BTCure: MESSEMAKER, TC et al. (2015) Immunogenetics of rheumatoid arthritis: Understanding functional implications, *J AUTOIMMUN* 64: 74-81
- BTCure: MUNOZ, LE et al. (2016) Nanoparticles size-dependently initiate self-limiting NETosis-driven inflammation, *P NATL ACAD SCI USA* 113: E5856-E5865
- BTCure: NIKITOPOULOU, I et al. (2012) Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis, *J EXP MED* 209: 923-931
- BTCure: OKADA, Y et al. (2014) Genetics of rheumatoid arthritis contributes to biology and drug discovery, *NATURE* 506: 376-+
- BTCure: ORELLANA, C et al. (2015) Postmenopausal hormone therapy and the risk of rheumatoid arthritis: results from the Swedish EIRA population-based case-control study, *EUR J EPIDEMIOL* 30: 449-457

- BTCure: OSPELT, C et al. (2017) Carbamylation of vimentin is inducible by smoking and represents an independent autoantigen in rheumatoid arthritis, ANN RHEUM DIS 76: 1176-1183
- BTCure: PALUMBO-ZERR, K et al. (2015) Orphan nuclear receptor NR4A1 regulates transforming growth factor-beta signaling and fibrosis, NAT MED 21: 62-70
- BTCure: PANDIS, I et al. (2012) Identification of microRNA-221/222 and microRNA-323-3p association with rheumatoid arthritis via predictions using the human tumour necrosis factor transgenic mouse model, ANN RHEUM DIS 71: 1716-1723
- BTCure: PFEIFLE, R et al. (2017) Regulation of autoantibody activity by the IL-23-T(H)17 axis determines the onset of autoimmune disease, NAT IMMUNOL 18: 104-113
- BTCure: PIETERS, BCH et al. (2015) Commercial Cow Milk Contains Physically Stable Extracellular Vesicles Expressing Immunoregulatory TGF-beta, PLOS ONE 10:
- BTCure: QUIRKE, AM et al. (2014) Heightened immune response to autocitrullinated Porphyromonas gingivalis peptidylarginine deiminase: a potential mechanism for breaching immunologic tolerance in rheumatoid arthritis, ANN RHEUM DIS 73: 263-269
- BTCure: RAASCHOU, P et al. (2015) TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study, ANN RHEUM DIS 74: 2137-2143
- BTCure: RECH, J et al. (2016) Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment, ANN RHEUM DIS 75: 1637-1644
- BTCure: REYNISDOTTIR, G et al. (2016) Signs of immune activation and local inflammation are present in the bronchial tissue of patients with untreated early rheumatoid arthritis, ANN RHEUM DIS 75: 1722-1727
- BTCure: REYNISDOTTIR, G et al. (2014) Structural Changes and Antibody Enrichment in the Lungs Are Early Features of Anti-Citrullinated Protein Antibody-Positive Rheumatoid Arthritis, ARTHRITIS RHEUMATOL 66: 31-39
- BTCure: RODRIGUEZ-CARRIO, J et al. (2017) Altered Innate Lymphoid Cell Subsets in Human Lymph Node Biopsy Specimens Obtained During the At-Risk and Earliest Phases of Rheumatoid Arthritis, ARTHRITIS RHEUMATOL 69: 70-76
- BTCure: ROMBOUTS, Y et al. (2016) Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis, ANN RHEUM DIS 75: 578-585
- BTCure: ROMBOUTS, Y et al. (2015) Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis, ANN RHEUM DIS 74: 234-241
- BTCure: SCHER, JU et al. (2016) The lung microbiota in early rheumatoid arthritis and autoimmunity, MICROBIOME 4:
- BTCure: SCHETT, G et al. (2012) Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment, NAT REV RHEUMATOL 8: 656-664
- BTCure: SCHETT, G et al. (2013) Diabetes Is an Independent Predictor for Severe Osteoarthritis Results from a longitudinal cohort study, DIABETES CARE 36: 403-409
- BTCure: SCHULZ, AR et al. (2017) Silver nanoparticles for the detection of cell surface antigens in mass cytometry, CYTOM PART A 91A: 25-33
- BTCure: SHI, J et al. (2014) Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies, AUTOIMMUN REV 13: 225-230
- BTCure: SHI, J et al. (2011) Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage, P NATL ACAD SCI USA 108: 17372-17377

- BTCure: SHI, J et al. (2013) Brief Report: AntiCarbamylated Protein Antibodies Are Present in Arthralgia Patients and Predict the Development of Rheumatoid Arthritis, *ARTHRITIS RHEUM-US* 65: 911-915
- BTCure: SHI, J et al. (2014) Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis, *ANN RHEUM DIS* 73: 780-783
- BTCure: SIMON, D et al. (2017) Age- and Sex-Dependent Changes of Intra-articular Cortical and Trabecular Bone Structure and the Effects of Rheumatoid Arthritis, *J BONE MINER RES* 32: 722-730
- BTCure: SUURMOND, J et al. (2014) Activation of human basophils by combined toll-like receptor-and FcεRI-triggering can promote Th2 skewing of naive T helper cells, *EUR J IMMUNOL* 44: 386-396
- BTCure: SUURMOND, J et al. (2016) Mast cells in rheumatic disease, *EUR J PHARMACOL* 778: 116-124
- BTCure: SUWANNALAI, P et al. (2012) Avidity maturation of anti-citrullinated protein antibodies in rheumatoid arthritis, *ARTHRITIS RHEUM-US* 64: 1323-1328
- BTCure: TACCONI, C et al. (2015) Vascular Endothelial Growth Factor C Disrupts the Endothelial Lymphatic Barrier to Promote Colorectal Cancer Invasion, *GASTROENTEROLOGY* 148: 1438-+
- BTCure: TADDEO, A et al. (2015) Long-lived plasma cells are early and constantly generated in New Zealand Black/New Zealand White F1 mice and their therapeutic depletion requires a combined targeting of autoreactive plasma cells and their precursors, *ARTHRITIS RES THER* 17:
- BTCure: TRENKMANN, M et al. (2013) Tumor Necrosis Factor alpha-Induced MicroRNA-18a Activates Rheumatoid Arthritis Synovial Fibroblasts Through a Feedback Loop in NF-kappa B Signaling, *ARTHRITIS RHEUM-US* 65: 916-927
- BTCure: TROUW, LA et al. (2012) Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis, *AUTOIMMUN REV* 12: 318-322
- BTCure: TROUW, LA et al. (2017) Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis, *NAT REV RHEUMATOL* 13: 331-339
- BTCure: TUNCEL, J et al. (2017) MHC class II alleles associated with Th1 rather than Th17 type immunity drive the onset of early arthritis in a rat model of rheumatoid arthritis, *EUR J IMMUNOL* 47: 563-574
- BTCure: UDALOVA, IA et al. (2016) Macrophage heterogeneity in the context of rheumatoid arthritis, *NAT REV RHEUMATOL* 12: 472-485
- BTCure: UDERHARDT, S et al. (2012) 12/15-Lipoxygenase Orchestrates the Clearance of Apoptotic Cells and Maintains Immunologic Tolerance, *IMMUNITY* 36: 834-846
- BTCure: ULUCKAN, O et al. (2016) Chronic skin inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling in osteoblasts, *SCI TRANSL MED* 8:
- BTCure: VAN BAARSEN, LGM et al. (2014) Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?, *ARTHRITIS RES THER* 16:
- BTCure: VAN DE BOVENKAMP, FS et al. (2016) The Emerging Importance of IgG Fab Glycosylation in Immunity, *J IMMUNOL* 196: 1435-1441
- BTCure: VAN HEEMST, J et al. (2015) Crossreactivity to vinculin and microbes provides a molecular basis for HLA-based protection against rheumatoid arthritis, *NAT COMMUN* 6:
- BTCure: VAN NIES, JAB et al. (2014) What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review, *ANN RHEUM DIS* 73: 861-870
- BTCure: VAN STEENBERGEN, HW et al. (2015) Characterising arthralgia in the preclinical phase of rheumatoid arthritis using MRI, *ANN RHEUM DIS* 74: 1225-1232

- BTCure: VAN ZANTEN, A et al. (2017) Presence of anticitrullinated protein antibodies in a large population-based cohort from the Netherlands, *ANN RHEUM DIS* 76: 1184-1190
- BTCure: VIATTE, S et al. (2015) Association of HLA-DRB1 Haplotypes With Rheumatoid Arthritis Severity, Mortality, and Treatment Response, *JAMA-J AM MED ASSOC* 313: 1645-1656
- BTCure: VIBERG, J et al. (2016) FREEDOM OF CHOICE ABOUT INCIDENTAL FINDINGS CAN FRUSTRATE PARTICIPANTS TRUE PREFERENCES, *BIOETHICS* 30: 203-209
- BTCure: VICENTE, R et al. (2016) Deregulation and therapeutic potential of microRNAs in arthritic diseases, *NAT REV RHEUMATOL* 12: 211-220
- BTCure: VLACHOU, K et al. (2016) Elimination of Granulocytic Myeloid-Derived Suppressor Cells in Lupus-Prone Mice Linked to Reactive Oxygen Species-Dependent Extracellular Trap Formation, *ARTHRITIS RHEUMATOL* 68: 449-461
- BTCure: WALTER, GJ et al. (2013) Interaction with activated monocytes enhances cytokine expression and suppressive activity of human CD4+CD45ro+CD25+CD127low regulatory T cells, *ARTHRITIS RHEUM-US* 65: 627-638
- BTCure: WENNIGER, LJMD et al. (2013) Immunoglobulin G4+clones identified by next-generation sequencing dominate the B cell receptor repertoire in immunoglobulin G4 associated cholangitis, *HEPATOLOGY* 57: 2390-2398
- BTCure: WESLEY, A et al. (2013) Association between body mass index and anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis: Results from a population-based case-control study, *ARTHRIT CARE RES* 65: 107-112
- BTCure: WIGERBLAD, G et al. (2016) Autoantibodies to citrullinated proteins induce joint pain independent of inflammation via a chemokine-dependent mechanism, *ANN RHEUM DIS* 75: 730-738
- BTCure: WUNDERLICH, C et al. (2017) Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients-A longitudinal analysis, *SEMIN ARTHRITIS RHEU* 46: 709-714
- BTCure: YARWOOD, A et al. (2015) A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk, *ANN RHEUM DIS* 74: 170-176
- BTCure: YAU, ACY et al. (2016) Rheumatoid arthritis: identifying and characterising polymorphisms using rat models, *DIS MODEL MECH* 9: 1111-1123
- BTCure: YTTERBERG, AJ et al. (2015) Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation, *ANN RHEUM DIS* 74: 1772-1777
- CANCER-ID: ALIX-PANABIERES, C et al. (2017) Epithelial-mesenchymal plasticity in circulating tumor cells, *J MOL MED* 95: 133-142
- CANCER-ID: ALIX-PANABIERES, C et al. (2016) Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy, *CANCER DISCOV* 6: 479-491
- CANCER-ID: ANDREE, KC et al. (2016) Challenges in circulating tumor cell detection by the CellSearch system, *MOL ONCOL* 10: 395-407
- CANCER-ID: ARENA, S et al. (2016) MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations, *SCI TRANSL MED* 8:
- CANCER-ID: AUFRAY, C et al. (2016) Making sense of big data in health research: Towards an EU action plan, *GENOME MED* 8:
- CANCER-ID: BARAULT, L et al. (2015) Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer, *ANN ONCOL* 26: 1994-1999
- CANCER-ID: BARDELLI, A et al. (2017) Liquid Biopsies, What We Do Not Know (Yet), *CANCER CELL* 31: 172-179

- CANCER-ID: BIDARD, FC et al. (2016) Circulating tumor cells in breast cancer, *MOL ONCOL* 10: 418-430
- CANCER-ID: CABEL, L et al. (2017) Circulating tumor cells: clinical validity and utility, *INT J CLIN ONCOL* 22: 421-430
- CANCER-ID: CHUDZIAK, J et al. (2016) Clinical evaluation of a novel microfluidic device for epitope-independent enrichment of circulating tumour cells in patients with small cell lung cancer, *ANALYST* 141: 669-678
- CANCER-ID: FUJII, T et al. (2017) Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers, *CLIN CANCER RES* 23: 3657-3666
- CANCER-ID: GORGES, TM et al. (2016) Accession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells, *CLIN CHEM* 62: 1504-1515
- CANCER-ID: GORGES, TM et al. (2016) Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel In Vivo Device for Capturing Circulating Tumor Cells, *CLIN CANCER RES* 22: 2197-2206
- CANCER-ID: HANSEN, A et al. (2016) Characterization of different CTC subpopulations in non-small cell lung cancer, *SCI REP-UK* 6:
- CANCER-ID: HEITZER, E et al. (2016) Non-invasive detection of genome-wide somatic copy number alterations by liquid biopsies, *MOL ONCOL* 10: 494-502
- CANCER-ID: HVICHIA, GE et al. (2016) A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells, *INT J CANCER* 138: 2894-2904
- CANCER-ID: MISALE, S et al. (2015) Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers, *NAT COMMUN* 6:
- CANCER-ID: PAILLER, E et al. (2017) Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non-Small Cell Lung Cancer Patients, *CANCER RES* 77: 2222-2230
- CANCER-ID: PANTEL, K et al. (2016) The biology of circulating tumor cells, *ONCOGENE* 35: 1216-1224
- CANCER-ID: PERAKIS, S et al. (2017) Emerging concepts in liquid biopsies, *BMC MED* 15:
- CANCER-ID: PICCO, G et al. (2017) Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusions, *EMBO MOL MED* 9: 293-303
- CANCER-ID: RIVA, F et al. (2016) Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer, *MOL ONCOL* 10: 481-493
- CANCER-ID: RUSSO, M et al. (2016) Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer, *CANCER DISCOV* 6: 147-153
- CANCER-ID: RUSSO, M et al. (2016) Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer, *CANCER DISCOV* 6: 36-44
- CANCER-ID: SIRAVEGNA, G et al. (2017) Integrating liquid biopsies into the management of cancer, *NAT REV CLIN ONCOL* 14: 531-548
- CANCER-ID: SIRAVEGNA, G et al. (2017) Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor, *ANN ONCOL* 28: 1302-1308
- CANCER-ID: SIRAVEGNA, G et al. (2016) Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients, *MOL ONCOL* 10: 475-480
- CANCER-ID: STOECKLEIN, NH et al. (2016) Challenges for CTC-based liquid biopsies: low CTC frequency and diagnostic leukapheresis as a potential solution, *EXPERT REV MOL DIAGN* 16: 147-164
- CANCER-ID: ULZ, P et al. (2016) Inferring expressed genes by whole-genome sequencing of plasma DNA, *NAT GENET* 48: 1273-1278

- CANCER-ID: WANG, HX et al. (2017) Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motion, *ONCOTARGET* 8: 1884-1912
- CHEM21: ALEKU, GA et al. (2017) A reductive aminase from *Aspergillus oryzae*, *NAT CHEM* 9: 961-969
- CHEM21: ALEKU, GA et al. (2016) Stereoselectivity and Structural Characterization of an Irvine Reductase (IRED) from *Amycolatopsis orientalis*, *ACS CATAL* 6: 3880-3889
- CHEM21: ASHCROFT, CP et al. (2015) Survey of Solvent Usage in Papers Published in Organic Process Research & Development 1997-2012, *ORG PROCESS RES DEV* 19: 740-747
- CHEM21: BOTH, P et al. (2016) Whole-Cell Biocatalysts for Stereoselective C-H Amination Reactions, *ANGEW CHEM INT EDIT* 55: 1511-1513
- CHEM21: CIOC, RC et al. (2014) Multicomponent reactions: advanced tools for sustainable organic synthesis, *GREEN CHEM* 16: 2958-2975
- CHEM21: HUSSAIN, S et al. (2015) An (R)-Imine Reductase Biocatalyst for the Asymmetric Reduction of Cyclic Imines, *CHEMCATCHEM* 7: 579-583
- CHEM21: LENZ, M et al. (2017) Asymmetric Ketone Reduction by Imine Reductases, *CHEMBIOCHEM* 18: 253-256
- CHEM21: MCELROY, CR et al. (2015) Towards a holistic approach to metrics for the 21st century pharmaceutical industry, *GREEN CHEM* 17: 3111-3121
- CHEM21: PRAT, D et al. (2016) CHEM21 selection guide of classical- and less classical-solvents, *GREEN CHEM* 18: 288-296
- CHEM21: PRAT, D et al. (2014) A survey of solvent selection guides, *GREEN CHEM* 16: 4546-4551
- CHEM21: REAY, AJ et al. (2015) Catalytic C-H bond functionalisation chemistry: the case for quasi-heterogeneous catalysis, *CHEM COMMUN* 51: 16289-16307
- CHEM21: SCHELLER, PN et al. (2014) Enzyme Toolbox: Novel Enantiocomplementary Imine Reductases, *CHEMBIOCHEM* 15: 2201-2204
- CHEM21: TURRINI, NG et al. (2017) Biocatalytic access to nonracemic gamma-oxo esters via stereoselective reduction using ene-reductases, *GREEN CHEM* 19: 511-518
- CHEM21: VAN DER HEIJDEN, G et al. (2016) 2-Bromo-6-isocyanopyridine as a Universal Convertible Isocyanide for Multicomponent Chemistry, *ORG LETT* 18: 984-987
- CHEM21: VOGL, T et al. (2016) A Toolbox of Diverse Promoters Related to Methanol Utilization: Functionally Verified Parts for Heterologous Pathway Expression in *Pichia pastoris*, *ACS SYNTH BIOL* 5: 172-186
- CHEM21: WENINGER, A et al. (2016) Combinatorial optimization of CRISPR/Cas9 expression enables precision genome engineering in the methylotrophic yeast *Pichia pastoris*, *J BIOTECHNOL* 235: 139-149
- CHEM21: WINDLE, CL et al. (2014) Engineering aldolases as biocatalysts, *CURR OPIN CHEM BIOL* 19: 25-33
- COMBACTE: ANDREY, DO et al. (2017) Antimicrobial activity of ceftaroline against methicillin-resistant *Staphylococcus aureus* (MRSA) isolates collected in 2013-2014 at the Geneva University Hospitals, *EUR J CLIN MICROBIOL* 36: 343-350
- COMBACTE: BARBIER, F et al. (2016) Colonization and infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae in ICU patients: what impact on outcomes and carbapenem exposure?, *J ANTIMICROB CHEMOTH* 71: 1088-1097
- COMBACTE: DE KRAKER, MEA et al. (2017) Good epidemiological practice: a narrative review of appropriate scientific methods to evaluate the impact of antimicrobial stewardship interventions, *CLIN MICROBIOL INFEC* 23: 819-825
- COMBACTE: DOCOBO-PEREZ, F et al. (2015) Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance, *ANTIMICROB AGENTS CH* 59: 5602-5610

- COMBACTE: ISRAEL, L et al. (2017) Human Adaptive Immunity Rescues an Inborn Error of Innate Immunity, *CELL* 168: 789-+
- COMBACTE: PALING, FP et al. (2017) Staphylococcus aureus colonization at ICU admission as a risk factor for developing S. aureus ICU pneumonia, *CLIN MICROBIOL INFECTION* 23:
- COMBACTE: SCHECHNER, V et al. (2013) Epidemiological Interpretation of Studies Examining the Effect of Antibiotic Usage on Resistance, *CLIN MICROBIOL REV* 26: 289-307
- COMBACTE: SZTAJER, H et al. (2014) Cross-feeding and interkingdom communication in dual-species biofilms of *Streptococcus mutans* and *Candida albicans*, *ISME J* 8: 2256-2271
- COMBACTE: TACKE, D et al. (2014) Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology, *ANN HEMATOL* 93: 1449-1456
- COMBACTE-CARE: GRABEIN, B et al. (2017) Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature, *CLIN MICROBIOL INFECTION* 23: 363-372
- COMBACTE-CARE: PALING, FP et al. (2017) Staphylococcus aureus colonization at ICU admission as a risk factor for developing S. aureus ICU pneumonia, *CLIN MICROBIOL INFECTION* 23:
- COMBACTE-CARE: TARTARI, E et al. (2017) The global hand-sanitizing relay: promoting hand hygiene through innovation, *J HOSP INFECTION* 95: 189-193
- COMBACTE-MAGNET: GRABEIN, B et al. (2017) Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature, *CLIN MICROBIOL INFECTION* 23: 363-372
- COMBACTE-MAGNET: JUAN, C et al. (2017) Host and Pathogen Biomarkers for Severe *Pseudomonas aeruginosa* Infections, *J INFECT DIS* 215: S44-S51
- COMBACTE-MAGNET: PALING, FP et al. (2017) Staphylococcus aureus colonization at ICU admission as a risk factor for developing S. aureus ICU pneumonia, *CLIN MICROBIOL INFECTION* 23:
- COMBACTE-MAGNET: TARTARI, E et al. (2017) The global hand-sanitizing relay: promoting hand hygiene through innovation, *J HOSP INFECTION* 95: 189-193
- COMBACTE-NET: GRABEIN, B et al. (2017) Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature, *CLIN MICROBIOL INFECTION* 23: 363-372
- COMPACT: CARVALHO, CDS et al. (2014) Carrier interactions with the biological barriers of the lung: Advanced in vitro models and challenges for pulmonary drug delivery, *ADV DRUG DELIVER REV* 75: 129-140
- COMPACT: COLOMBO, SF et al. (2015) Mechanistic profiling of the siRNA delivery dynamics of lipid-polymer hybrid nanoparticles, *J CONTROL RELEASE* 201: 22-31
- COMPACT: GARCIA-DIAZ, M et al. (2015) Improved insulin loading in poly(lactic-co-glycolic) acid (PLGA) nanoparticles upon self-assembly with lipids, *INT J PHARMACEUT* 482: 84-91
- COMPACT: HELDRING, N et al. (2015) Therapeutic Potential of Multipotent Mesenchymal Stromal Cells and Their Extracellular Vesicles, *HUM GENE THER* 26: 506-517
- COMPACT: KRISTENSEN, M et al. (2016) Applications and Challenges for Use of Cell-Penetrating Peptides as Delivery Vectors for Peptide and Protein Cargos, *INT J MOL SCI* 17:
- COMPACT: LACHELT, U et al. (2015) Nucleic Acid Therapeutics Using Polyplexes: A Journey of 50 Years (and Beyond), *CHEM REV* 115: 11043-11078
- COMPACT: LORENZER, C et al. (2015) Going beyond the liver: Progress and challenges of targeted delivery of siRNA therapeutics, *J CONTROL RELEASE* 203: 1-15
- COMPACT: NORDIN, JZ et al. (2015) Ultrafiltration with size-exclusion liquid chromatography for high yield isolation of extracellular vesicles preserving intact biophysical and functional properties, *NANOMED-NANOTECHNOL* 11: 879-883

- COMPACT: OLOUGHLIN, AJ et al. (2017) Functional Delivery of Lipid-Conjugated siRNA by Extracellular Vesicles, *MOL THER* 25: 1580-1587
- COMPACT: STEPHANSEN, K et al. (2016) Interactions between Surfactants in Solution and Electrospun Protein Fibers: Effects on Release Behavior and Fiber Properties, *MOL PHARMACEUT* 13: 748-755
- COMPACT: VERDURMEN, WPR et al. (2015) Efficient cell-specific uptake of binding proteins into the cytoplasm through engineered modular transport systems, *J CONTROL RELEASE* 200: 13-22
- COMPACT: WILLMS, E et al. (2016) Cells release subpopulations of exosomes with distinct molecular and biological properties, *SCI REP-UK* 6:
- COMPACT: ZHANG, W et al. (2016) Targeted siRNA Delivery Using a Lipo-Oligoaminoamide Nanocore with an Influenza Peptide and Transferrin Shell, *ADV HEALTHC MATER* 5: 1493-1504
- DDMoRe: BUCHEL, F et al. (2013) Path2Models: large-scale generation of computational models from biochemical pathway maps, *BMC SYST BIOL* 7:
- DDMoRe: CHELLIAH, V et al. (2015) BioModels: ten-year anniversary, *NUCLEIC ACIDS RES* 43: D542-D548
- DDMoRe: DOSNE, AG et al. (2016) Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling, *J PHARMACOKINET PHAR* 43: 583-596
- DDMoRe: NIELSEN, EI et al. (2013) Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs, *PHARMACOL REV* 65: 1053-1090
- DIRECT: AHMAD, S et al. (2013) Gene x Physical Activity Interactions in Obesity: Combined Analysis of 111,421 Individuals of European Ancestry, *PLOS GENET* 9:
- DIRECT: BREIER, M et al. (2014) Targeted Metabolomics Identifies Reliable and Stable Metabolites in Human Serum and Plasma Samples, *PLOS ONE* 9:
- DIRECT: DUJIC, T et al. (2017) Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A MetGen Meta-Analysis, *CLIN PHARMACOL THER* 101: 763-772
- DIRECT: FRANKS, PW et al. (2016) Exposing the exposures responsible for type 2 diabetes and obesity, *SCIENCE* 354: 69-73
- DIRECT: HOCHER, B et al. (2017) Metabolomics for clinical use and research in chronic kidney disease, *NAT REV NEPHROL* 13: 269-284
- DIRECT: MCCARTHY, MI et al. (2017) Painting a new picture of personalised medicine for diabetes, *DIABETOLOGIA* 60: 793-799
- DIRECT: NICA, AC et al. (2013) Cell-type, allelic, and genetic signatures in the human pancreatic beta cell transcriptome, *GENOME RES* 23: 1554-1562
- DIRECT: PASQUALI, L et al. (2014) Pancreatic islet enhancer clusters enriched in type 2 diabetes risk-associated variants, *NAT GENET* 46: 136-+
- DIRECT: PEDERSEN, HK et al. (2016) Human gut microbes impact host serum metabolome and insulin sensitivity, *NATURE* 535: 376-+
- DRIVE-AB: DEAK, D et al. (2016) Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of US Food and Drug Administration-Approved Antibiotics, 2010-2015, *ANN INTERN MED* 165: 363-+
- DRIVE-AB: DE KRAKER, MEA et al. (2017) Good epidemiological practice: a narrative review of appropriate scientific methods to evaluate the impact of antimicrobial stewardship interventions, *CLIN MICROBIOL INFEC* 23: 819-825
- DRIVE-AB: FRIEDMAN, ND et al. (2016) The negative impact of antibiotic resistance, *CLIN MICROBIOL INFEC* 22: 416-422
- DRIVE-AB: HARBARTH, S et al. (2015) Antibiotic research and development: business as usual?, *J ANTIMICROB CHEMOTH* 70: 1604-1607

- DRIVE-AB: TEILLANT, A et al. (2015) Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a literature review and modelling study, *LANCET INFECT DIS* 15: 1429-1437
- EBiSC: STAPPERT, L et al. (2015) The role of microRNAs in human neural stem cells, neuronal differentiation and subtype specification, *CELL TISSUE RES* 359: 47-64
- Ebola+: HUTTNER, A et al. (2017) A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa, *SCI TRANSL MED* 9:
- EBOVAC1: CAMACHO, A et al. (2017) Real-time dynamic modelling for the design of a cluster-randomized phase 3 Ebola vaccine trial in Sierra Leone, *VACCINE* 35: 544-551
- EBOVAC1: FUNK, S et al. (2016) Comparative Analysis of Dengue and Zika Outbreaks Reveals Differences by Setting and Virus, *PLOS NEGLECT TROP D* 10:
- EBOVAC1: MILLIGAN, ID et al. (2016) Safety and Immunogenicity of Novel Adenovirus Type 26-and Modified Vaccinia Ankara-Vectored Ebola Vaccines A Randomized Clinical Trial, *JAMA-J AM MED ASSOC* 315: 1610-1623
- EBOVAC1: SISSOKO, D et al. (2017) Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study, *LANCET GLOB HEALTH* 5: E80-E88
- EHR4CR: COOREVITS, P et al. (2013) Electronic health records: new opportunities for clinical research, *J INTERN MED* 274: 547-560
- EHR4CR: DE MOOR, G et al. (2015) Using electronic health records for clinical research: The case of the EHR4CR project, *J BIOMED INFORM* 53: 162-173
- ELF: ABDELRAHEEM, EMM et al. (2016) Artificial Macrocycles by Ugi Reaction and Passerini Ring Closure, *J ORG CHEM* 81: 8789-8795
- ELF: BESNARD, J et al. (2015) The Joint European Compound Library: boosting precompetitive research, *DRUG DISCOV TODAY* 20: 181-186
- ELF: CHANDGUDE, AL et al. (2017) N-Hydroxyimide Ugi Reaction toward alpha-Hydrazino Amides, *ORG LETT* 19: 1228-1231
- ELF: ELEFTHERIADIS, N et al. (2015) Rational Development of a Potent 15-Lipoxygenase-1 Inhibitor with in Vitro and ex Vivo Anti-inflammatory Properties, *J MED CHEM* 58: 7850-7862
- ELF: GARCIA-CASTRO, M et al. (2016) Scaffold Diversity Synthesis and Its Application in Probe and Drug Discovery, *ANGEW CHEM INT EDIT* 55: 7586-7605
- ELF: KARAWAJCZYK, A et al. (2015) Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective, *DRUG DISCOV TODAY* 20: 1310-1316
- ELF: LIAO, GP et al. (2015) Versatile Multicomponent Reaction Macrocyclic Synthesis Using alpha-Isocyano-omega-carboxylic Acids, *ORG LETT* 17: 4980-4983
- ELF: MULLER, G et al. (2017) Charting Biologically Relevant Spirocyclic Compound Space, *CHEM-EUR J* 23: 703-710
- ELF: MURRAY, AT et al. (2017) Synthesis of Epibatidine Analogues by Pyrrole Diels-Alder Reactions: Rapid Access to Azabicyclo[2.2.1]heptane and 3,8-Diazabicyclo[3.2.1]octane Scaffolds for Library Synthesis, *EUR J ORG CHEM* : 138-148
- ELF: NEOCHORITIS, CG et al. (2015) Efficient Isocyanide-less Isocyanide-Based Multicomponent Reactions, *ORG LETT* 17: 2002-2005
- ELF: PAILLARD, G et al. (2016) The ELF Honest Data Broker: informatics enabling public-private collaboration in a precompetitive arena, *DRUG DISCOV TODAY* 21: 97-102
- ELF: PATIL, P et al. (2017) De Novo Assembly of Highly Substituted Morpholines and Piperazines, *ORG LETT* 19: 642-645
- ELF: PICAZO, E et al. (2015) Small molecule inhibitors of ebola virus infection, *DRUG DISCOV TODAY* 20: 277-286
- ELF: SURMIAK, E et al. (2017) Rational design and synthesis of 1,5-disubstituted tetrazoles as potent inhibitors of the MDM2-p53 interaction, *EUR J MED CHEM* 126: 384-407

- ELF: ZARGANES-TZITZIKAS, T et al. (2015) Multicomponent Reactions, Union of MCRs and Beyond, CHEM REC 15: 981-996
- EMIF: AUFRAY, C et al. (2016) Making sense of big data in health research: Towards an EU action plan, GENOME MED 8:
- EMIF: BROOKES, AJ et al. (2015) Human genotype-phenotype databases: aims, challenges and opportunities, NAT REV GENET 16: 702-715
- EMIF: CUYVERS, E et al. (2016) Genetic variations underlying Alzheimers disease: evidence from genome-wide association studies and beyond, LANCET NEUROL 15: 857-868
- EMIF: DAHLMAN, I et al. (2016) Numerous Genes in Loci Associated With Body Fat Distribution Are Linked to Adipose Function, DIABETES 65: 433-437
- EMIF: DAHLMAN, I et al. (2015) The fat cell epigenetic signature in post-obese women is characterized by global hypomethylation and differential DNA methylation of adipogenesis genes, INT J OBESITY 39: 910-919
- EMIF: DE VOS, A et al. (2015) C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimers disease, ALZHEIMERS DEMENT 11: 1461-1469
- EMIF: FRISONI, GB et al. (2017) Strategic roadmap for an early diagnosis of Alzheimers disease based on biomarkers, LANCET NEUROL 16: 661-676
- EMIF: GUTIERREZ-SACRISTAN, A et al. (2015) PsyGeNET: a knowledge platform on psychiatric disorders and their genes, BIOINFORMATICS 31: 3075-3077
- EMIF: HELLWIG, K et al. (2015) Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimers disease, ALZHEIMERS RES THER 7:
- EMIF: HYE, A et al. (2014) Plasma proteins predict conversion to dementia from prodromal disease, ALZHEIMERS DEMENT 10: 799-807
- EMIF: HYOTYLAINEN, T et al. (2016) Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease, NAT COMMUN 7:
- EMIF: JACK, CR et al. (2016) Suspected non-Alzheimer disease pathophysiology - concept and controversy, NAT REV NEUROL 12: 117-124
- EMIF: JANSEN, WJ et al. (2015) Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia A Meta-analysis, JAMA-J AM MED ASSOC 313: 1924-1938
- EMIF: KUHLMANN, J et al. (2017) CSF A beta(1-42) - an excellent but complicated Alzheimers biomarker - a route to standardisation, CLIN CHIM ACTA 467: 27-33
- EMIF: LE BASTARD, N et al. (2015) Importance and Impact of Preanalytical Variables on Alzheimer Disease Biomarker Concentrations in Cerebrospinal Fluid, CLIN CHEM 61: 734-743
- EMIF: LEE, S et al. (2016) Integrated Network Analysis Reveals an Association between Plasma Mannose Levels and Insulin Resistance, CELL METAB 24: 172-184
- EMIF: LEWCZUK, P et al. (2017) Non-Phosphorylated Tau as a Potential Biomarker of Alzheimers Disease: Analytical and Diagnostic Characterization, J ALZHEIMERS DIS 55: 159-170
- EMIF: LEWCZUK, P et al. (2017) Cerebrospinal Fluid A beta(42/40) Corresponds Better than A beta(42) to Amyloid PET in Alzheimers Disease, J ALZHEIMERS DIS 55: 813-822
- EMIF: LOTTA, LA et al. (2017) Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance, NAT GENET 49: 17-26
- EMIF: LOTTA, LA et al. (2016) Genetic Predisposition to an Impaired Metabolism of the Branched-Chain Amino Acids and Risk of Type 2 Diabetes: A Mendelian Randomisation Analysis, PLOS MED 13:
- EMIF: LUNNON, K et al. (2017) Mitochondrial genes are altered in blood early in Alzheimers disease, NEUROBIOL AGING 53: 36-47
- EMIF: LUUKKONEN, PK et al. (2016) Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease, J HEPATOL 64: 1167-1175

- EMIF: MARDINOGLU, A et al. (2017) Personal model-assisted identification of NAD(+) and glutathione metabolism as intervention target in NAFLD, *MOL SYST BIOL* 13:
- EMIF: OSSENKOPPELE, R et al. (2015) Prevalence of Amyloid PET Positivity in Dementia Syndromes A Meta-analysis, *JAMA-J AM MED ASSOC* 313: 1939-1949
- EMIF: OSTERGAARD, SD et al. (2015) Associations between Potentially Modifiable Risk Factors and Alzheimer Disease: A Mendelian Randomization Study, *PLOS MED* 12:
- EMIF: PAYNE, F et al. (2014) Hypomorphism in human NSMCE2 linked to primordial dwarfism and insulin resistance, *J CLIN INVEST* 124: 4028-4038
- EMIF: PINI, L et al. (2016) Brain atrophy in Alzheimers Disease and aging, *AGEING RES REV* 30: 25-48
- EMIF: PROITSI, P et al. (2017) Association of blood lipids with Alzheimers disease: A comprehensive lipidomics analysis, *ALZHEIMERS DEMENT* 13: 140-151
- EMIF: QUERALT-ROSINACH, N et al. (2016) DisGeNET-RDF: harnessing the innovative power of the Semantic Web to explore the genetic basis of diseases, *BIOINFORMATICS* 32: 2236-2238
- EMIF: ROWE, ER et al. (2016) Conserved Amphipathic Helices Mediate Lipid Droplet Targeting of Perilipins 1-3, *J BIOL CHEM* 291: 6664-6678
- EMIF: SATTAR, N et al. (2014) Type 2 diabetes as a disease of ectopic fat?, *BMC MED* 12:
- EMIF: SATTAR, N et al. (2015) Type 2 diabetes in migrant south Asians: mechanisms, mitigation, and management, *LANCET DIABETES ENDO* 3: 1004-1016
- EMIF: SKILLBACK, T et al. (2015) Cerebrospinal fluid tau and amyloid-beta(1-42) in patients with dementia, *BRAIN* 138: 2716-2731
- EMIF: SLEEGERS, K et al. (2015) A 22-single nucleotide polymorphism Alzheimers disease risk score correlates with family history, onset age, and cerebrospinal fluid A beta(42), *ALZHEIMERS DEMENT* 11: 1452-1460
- EMIF: SNOWDEN, SG et al. (2017) Association between fatty acid metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: A nontargeted metabolomic study, *PLOS MED* 14:
- EMIF: SOOD, S et al. (2015) A novel multi-tissue RNA diagnostic of healthy ageing relates to cognitive health status, *GENOME BIOL* 16:
- EMIF: STRUYFS, H et al. (2015) Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-beta Isoforms for Early and Differential Dementia Diagnosis, *J ALZHEIMERS DIS* 45: 813-822
- EMIF: SUAREZ-CALVET, M et al. (2016) sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimers disease and associate with neuronal injury markers, *EMBO MOL MED* 8: 466-476
- EMIF: SWERDLOW, DI et al. (2015) HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials, *LANCET* 385: 351-361
- EMIF: TANG, EYH et al. (2015) Current Developments in Dementia Risk Prediction Modelling: An Updated Systematic Review, *PLOS ONE* 10:
- EMIF: TEN KATE, M et al. (2017) Clinical validity of medial temporal atrophy as a biomarker for Alzheimers disease in the context of a structured 5-phase development framework, *NEUROBIOL AGING* 52: 167-182
- EMIF: TOLEDO, JB et al. (2015) Alzheimers disease cerebrospinal fluid biomarker in cognitively normal subjects, *BRAIN* 138: 2701-2715
- EMIF: VAN BUSSELL, EF et al. (2017) Dementia incidence trend over 1992-2014 in the Netherlands: Analysis of primary care data, *PLOS MED* 14:
- EMIF: VAN CAUWENBERGHE, C et al. (2016) The genetic landscape of Alzheimer disease: clinical implications and perspectives, *GENET MED* 18: 421-430
- EMIF: VAN DER MUSSELE, S et al. (2014) Depression in Mild Cognitive Impairment is associated with Progression to Alzheimers Disease: A Longitudinal Study, *J ALZHEIMERS DIS* 42: 1239-1250

- EMIF: VOS, SJB et al. (2013) Preclinical Alzheimers disease and its outcome: a longitudinal cohort study, *LANCET NEUROL* 12: 957-965
- EMIF: VOS, SJB et al. (2016) NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers, *NEUROBIOL AGING* 44: 1-8
- EMIF: VOS, SJB et al. (2017) Modifiable Risk Factors for Prevention of Dementia in Midlife, Late Life and the Oldest-Old: Validation of the LIBRA Index, *J ALZHEIMERS DIS* 58: 537-547
- EMIF: VOS, SJB et al. (2015) Prevalence and prognosis of Alzheimers disease at the mild cognitive impairment stage, *BRAIN* 138: 1327-1338
- EMIF: YKI-JARVINEN, H et al. (2015) Nutritional Modulation of Non-Alcoholic Fatty Liver Disease and Insulin Resistance, *NUTRIENTS* 7: 9127-9138
- EMIF: YKI-JARVINEN, H et al. (2016) Diagnosis of non-alcoholic fatty liver disease (NAFLD), *DIABETOLOGIA* 59: 1104-1111
- EMIF: ZHOU, Y et al. (2015) Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2, *J HEPATOL* 62: 657-663
- ENABLE: GRAU-CAMPISTANY, A et al. (2016) Tryptophan-containing lipopeptide antibiotics derived from polymyxin B with activity against Gram positive and Gram negative bacteria, *BBA-BIOMEMBRANES* 1858: 333-343
- ENABLE: HUGHES, D et al. (2015) Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms, *NAT REV GENET* 16: 459-471
- ENABLE: RABANAL, F et al. (2015) A bioinspired peptide scaffold with high antibiotic activity and low in vivo toxicity, *SCI REP-UK* 5:
- eTOX: ARIGHI, CN et al. (2011) Overview of the BioCreative III Workshop, *BMC BIOINFORMATICS* 12:
- eTOX: BAUER-MEHREN, A et al. (2010) DisGeNET: a Cytoscape plugin to visualize, integrate, search and analyze gene-disease networks, *BIOINFORMATICS* 26: 2924-2926
- eTOX: BENTO, AP et al. (2014) The ChEMBL bioactivity database: an update, *NUCLEIC ACIDS RES* 42: D1083-D1090
- eTOX: BRAVO, A et al. (2015) Extraction of relations between genes and diseases from text and large-scale data analysis: implications for translational research, *BMC BIOINFORMATICS* 16:
- eTOX: CANZAR, S et al. (2013) Charge Group Partitioning in Biomolecular Simulation, *J COMPUT BIOL* 20: 188-198
- eTOX: CARBONELL, P et al. (2017) Hepatotoxicity Prediction by Systems Biology Modeling of Disturbed Metabolic Pathways Using Gene Expression Data, *ALTEX-ALTERN ANIM EX* 34: 219-234
- eTOX: CARRIO, P et al. (2014) Applicability Domain Analysis (ADAN): A Robust Method for Assessing the Reliability of Drug Property Predictions, *J CHEM INF MODEL* 54: 1500-1511
- eTOX: CHICHE, J et al. (2012) In vivo pH in metabolic-defective Ras-transformed fibroblast tumors: Key role of the monocarboxylate transporter, MCT4, for inducing an alkaline intracellular pH, *INT J CANCER* 130: 1511-1520
- eTOX: ELLISON, CM et al. (2016) Adverse Outcome Pathway (AOP) Informed Modeling of Aquatic Toxicology: QSARs, Read-Across, and Interspecies Verification of Modes of Action, *ENVIRON SCI TECHNOL* 50: 3995-4007
- eTOX: ENOCH, SJ et al. (2011) A review of the electrophilic reaction chemistry involved in covalent protein binding relevant to toxicity, *CRIT REV TOXICOL* 41: 783-802
- eTOX: FURLONG, LI et al. (2013) Human diseases through the lens of network biology, *TRENDS GENET* 29: 150-159
- eTOX: GARCIA-SERNA, R et al. (2015) Large-Scale Predictive Drug Safety: From Structural Alerts to Biological Mechanisms, *CHEM RES TOXICOL* 28: 1875-1887
- eTOX: KLEPSCH, F et al. (2014) Ligand and Structure-Based Classification Models for Prediction of P-Glycoprotein Inhibitors, *J CHEM INF MODEL* 54: 218-229

- eTOX: KLEPSCH, F et al. (2011) Exhaustive Sampling of Docking Poses Reveals Binding Hypotheses for Propafenone Type Inhibitors of P-Glycoprotein, PLOS COMPUT BIOL 7:
- eTOX: KRALLINGER, M et al. (2015) CHEMDNER: The drugs and chemical names extraction challenge, J CHEMINFORMATICS 7:
- eTOX: KRALLINGER, M et al. (2015) The CHEMDNER corpus of chemicals and drugs and its annotation principles, J CHEMINFORMATICS 7:
- eTOX: MONTANARI, F et al. (2016) Flagging Drugs That Inhibit the Bile Salt Export Pump, MOL PHARMACEUT 13: 163-171
- eTOX: OBIOL-PARDO, C et al. (2011) A Multiscale Simulation System for the Prediction of Drug-Induced Cardiotoxicity, J CHEM INF MODEL 51: 483-492
- eTOX: OOMEN, AG et al. (2014) Concern-driven integrated approaches to nanomaterial testing and assessment - report of the NanoSafety Cluster Working Group 10, NANOTOXICOLOGY 8: 334-348
- eTOX: QUERALT-ROSINACH, N et al. (2016) DisGeNET-RDF: harnessing the innovative power of the Semantic Web to explore the genetic basis of diseases, BIOINFORMATICS 32: 2236-2238
- eTOX: VAZQUEZ, M et al. (2011) Text Mining for Drugs and Chemical Compounds: Methods, Tools and Applications, MOL INFORM 30: 506-519
- eTRIKS: AGUSTI, A et al. (2015) Personalized Respiratory Medicine: Exploring the Horizon, Addressing the Issues Summary of a BRN-AJRCCM Workshop Held in Barcelona on June 12, 2014, AM J RESP CRIT CARE 191: 391-401
- eTRIKS: AUFRAY, C et al. (2016) Making sense of big data in health research: Towards an EU action plan, GENOME MED 8:
- eTRIKS: BALAUR, I et al. (2017) EpiGeNet: A Graph Database of Interdependencies Between Genetic and Epigenetic Events in Colorectal Cancer, J COMPUT BIOL 24: 969-980
- eTRIKS: BALAUR, I et al. (2017) Recon2Neo4j: applying graph database technologies for managing comprehensive genome-scale networks, BIOINFORMATICS 33: 1096-1098
- eTRIKS: DEBRAY, TPA et al. (2015) Get real in individual participant data (IPD) meta-analysis: a review of the methodology, RES SYNTH METHODS 6: 293-309
- eTRIKS: EFTHIMIOU, O et al. (2016) GetReal in network meta-analysis: a review of the methodology, RES SYNTH METHODS 7: 236-263
- eTRIKS: FLEMING, L et al. (2015) The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts, EUR RESPIR J 46: 1322-1333
- eTRIKS: LEFAUDEUX, D et al. (2017) U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics, J ALLERGY CLIN IMMUN 139: 1797-1807
- eTRIKS: LYSENKO, A et al. (2016) Representing and querying disease networks using graph databases, BIODATA MIN 9:
- eTRIKS: NORDON, C et al. (2016) The Efficacy-Effectiveness Gap : Historical Background and Current Conceptualization, VALUE HEALTH 19: 75-81
- eTRIKS: ROCCA-SERRA, P et al. (2016) Data standards can boost metabolomics research, and if there is a will, there is a way, METABOLOMICS 12:
- eTRIKS: SHAW, DE et al. (2015) Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort, EUR RESPIR J 46: 1308-1321
- Eu2P: DREISCHULTE, T et al. (2015) Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury, KIDNEY INT 88: 396-403
- EU-AIMS: AKDENIZ, C et al. (2014) The neurobiology of social environmental risk for schizophrenia: an evolving research field, SOC PSYCH PSYCH EPID 49: 507-517
- EU-AIMS: ARORA, M et al. (2017) Fetal and postnatal metal dysregulation in autism, NAT COMMUN 8:

- EU-AIMS: AUYEUNG, B et al. (2015) Oxytocin increases eye contact during a real-time, naturalistic social interaction in males with and without autism, *TRANSL PSYCHIAT* 5:
- EU-AIMS: BABAIEV, O et al. (2016) Neuroligin 2 deletion alters inhibitory synapse function and anxiety-associated neuronal activation in the amygdala, *NEUROPHARMACOLOGY* 100: 56-65
- EU-AIMS: BARON-COHEN, S et al. (2014) Attenuation of Typical Sex Differences in 800 Adults with Autism vs. 3,900 Controls, *PLOS ONE* 9:
- EU-AIMS: BASIL, P et al. (2014) Prenatal maternal immune activation causes epigenetic differences in adolescent mouse brain, *TRANSL PSYCHIAT* 4:
- EU-AIMS: BAUDOIN, SJ et al. (2012) Shared Synaptic Pathophysiology in Syndromic and Nonsyndromic Rodent Models of Autism, *SCIENCE* 338: 128-132
- EU-AIMS: BOLTE, S et al. (2016) How can clinicians detect and treat autism early? Methodological trends of technology use in research, *ACTA PAEDIATR* 105: 137-144
- EU-AIMS: BOURGERON, T et al. (2015) From the genetic architecture to synaptic plasticity in autism spectrum disorder, *NAT REV NEUROSCI* 16: 551-563
- EU-AIMS: BRAUN, U et al. (2016) Dynamic brain network reconfiguration as a potential schizophrenia genetic risk mechanism modulated by NMDA receptor function, *P NATL ACAD SCI USA* 113: 12568-12573
- EU-AIMS: BUDRECK, EC et al. (2013) Neuroligin-1 controls synaptic abundance of NMDA-type glutamate receptors through extracellular coupling, *P NATL ACAD SCI USA* 110: 725-730
- EU-AIMS: CASTELLANOS-RYAN, N et al. (2014) Neural and Cognitive Correlates of the Common and Specific Variance Across Externalizing Problems in Young Adolescence, *AM J PSYCHIAT* 171: 1310-1319
- EU-AIMS: CASTELLANOS-RYAN, N et al. (2016) The Structure of Psychopathology in Adolescence and Its Common Personality and Cognitive Correlates, *J ABNORM PSYCHOL* 125: 1039-1052
- EU-AIMS: CATANI, M et al. (2016) Frontal networks in adults with autism spectrum disorder, *BRAIN* 139: 616-630
- EU-AIMS: CONSTANTINO, JN et al. (2016) Diagnosis of autism spectrum disorder: reconciling the syndrome, its diverse origins, and variation in expression, *LANCET NEUROL* 15: 279-291
- EU-AIMS: DAGE, JL et al. (2014) Pharmacological characterisation of ligand- and voltage-gated ion channels expressed in human iPSC-derived forebrain neurons, *PSYCHOPHARMACOLOGY* 231: 1105-1124
- EU-AIMS: DEANS, PJM et al. (2017) Psychosis Risk Candidate ZNF804A Localizes to Synapses and Regulates Neurite Formation and Dendritic Spine Structure, *BIOL PSYCHIAT* 82: 49-61
- EU-AIMS: DELORME, R et al. (2013) Progress toward treatments for synaptic defects in autism, *NAT MED* 19: 685-694
- EU-AIMS: DERE, E et al. (2014) Heterozygous Ambra1 deficiency in mice: a genetic trait with autism-like behavior restricted to the female gender, *FRONT BEHAV NEUROSCI* 8:
- EU-AIMS: DISTLER, U et al. (2014) In-depth protein profiling of the postsynaptic density from mouse hippocampus using data-independent acquisition proteomics, *PROTEOMICS* 14: 2607-2613
- EU-AIMS: ECKER, C et al. (2013) Translational approaches to the biology of Autism: false dawn or a new era?, *MOL PSYCHIATR* 18: 435-442
- EU-AIMS: ECKER, C et al. (2015) Neuroimaging in autism spectrum disorder: brain structure and function across the lifespan, *LANCET NEUROL* 14: 1121-1134
- EU-AIMS: ECKER, C et al. (2014) Neuroimaging in autism-from basic science to translational research, *NAT REV NEUROL* 10: 82-91

- EU-AIMS: ECKER, C et al. (2017) Association Between the Probability of Autism Spectrum Disorder and Normative Sex-Related Phenotypic Diversity in Brain Structure, *JAMA PSYCHIAT* 74: 329-338
- EU-AIMS: EL-KORDI, A et al. (2013) Development of an autism severity score for mice using *Nlgn4* null mutants as a construct-valid model of heritable monogenic autism, *BEHAV BRAIN RES* 251: 41-49
- EU-AIMS: ELSABBAGH, M et al. (2016) Autism and the Social Brain: The First-Year Puzzle, *BIOL PSYCHIAT* 80: 94-99
- EU-AIMS: EVANS, DW et al. (2017) Development of Two Dimensional Measures of Restricted and Repetitive Behavior in Parents and Children, *J AM ACAD CHILD PSY* 56: 51-58
- EU-AIMS: EY, E et al. (2013) The Autism ProSAP1/Shank2 mouse model displays quantitative and structural abnormalities in ultrasonic vocalisations, *BEHAV BRAIN RES* 256: 677-689
- EU-AIMS: FLORIS, DL et al. (2016) Atypically Rightward Cerebral Asymmetry in Male Adults With Autism Stratifies Individuals With and Without Language Delay, *HUM BRAIN MAPP* 37: 230-253
- EU-AIMS: FRANKE, B et al. (2016) Genetic influences on schizophrenia and subcortical brain volumes: large-scale proof of concept, *NAT NEUROSCI* 19: 420-+
- EU-AIMS: FRENCH, L et al. (2015) Early Cannabis Use, Polygenic Risk Score for Schizophrenia, and Brain Maturation in Adolescence, *JAMA PSYCHIAT* 72: 1002-1011
- EU-AIMS: GABRIELE, S et al. (2014) Blood serotonin levels in autism spectrum disorder: A systematic review and meta-analysis, *EUR NEUROPSYCHOPHARM* 24: 919-929
- EU-AIMS: GLIGA, T et al. (2015) Enhanced Visual Search in Infancy Predicts Emerging Autism Symptoms, *CURR BIOL* 25: 1727-1730
- EU-AIMS: HEINRICH, A et al. (2016) Prediction of alcohol drinking in adolescents: Personality-traits, behavior, brain responses, and genetic variations in the context of reward sensitivity, *BIOL PSYCHOL* 118: 79-87
- EU-AIMS: JEDLICKA, P et al. (2015) Neuroligin-1 regulates excitatory synaptic transmission, LTP and EPSP-spike coupling in the dentate gyrus in vivo, *BRAIN STRUCT FUNCT* 220: 47-58
- EU-AIMS: JOHNSON, MH et al. (2015) Annual Research Review: Infant development, autism, and ADHD - early pathways to emerging disorders, *J CHILD PSYCHOL PSYC* 56: 228-247
- EU-AIMS: JOHNSON, MH et al. (2015) Brain adaptation and alternative developmental trajectories, *DEV PSYCHOPATHOL* 27: 425-442
- EU-AIMS: JONES, EJH et al. (2014) Developmental pathways to autism: A review of prospective studies of infants at risk, *NEUROSCI BIOBEHAV R* 39: 1-33
- EU-AIMS: KAS, MJ et al. (2014) Assessing behavioural and cognitive domains of autism spectrum disorders in rodents: current status and future perspectives, *PSYCHOPHARMACOLOGY* 231: 1125-1146
- EU-AIMS: KLEIJER, KTE et al. (2014) Neurobiology of autism gene products: towards pathogenesis and drug targets, *PSYCHOPHARMACOLOGY* 231: 1037-1062
- EU-AIMS: KONG, A et al. (2012) Rate of de novo mutations and the importance of fathers age to disease risk, *NATURE* 488: 471-475
- EU-AIMS: KRUEGER-BURG, D et al. (2017) Organizers of inhibitory synapses come of age, *CURR OPIN NEUROBIOL* 45: 66-77
- EU-AIMS: KUMAR, G et al. (2015) Strain-dependent effects on acquisition and reversal of visual and spatial tasks in a rat touchscreen battery of cognition, *PHYSIOL BEHAV* 144: 26-36
- EU-AIMS: LAI, MC et al. (2015) Sex/Gender Differences and Autism: Setting the Scene for Future Research, *J AM ACAD CHILD PSY* 54: 11-24
- EU-AIMS: LAI, MC et al. (2013) Biological sex affects the neurobiology of autism, *BRAIN* 136: 2799-2815
- EU-AIMS: LAI, MC et al. (2014) Autism, *LANCET* 383: 896-910

- EU-AIMS: LAI, MC et al. (2015) Identifying the lost generation of adults with autism spectrum conditions, *LANCET PSYCHIAT* 2: 1013-1027
- EU-AIMS: LILJA, J et al. (2017) SHANK proteins limit integrin activation by directly interacting with Rap1 and R-Ras, *NAT CELL BIOL* 19: 292-+
- EU-AIMS: LOTH, E et al. (2014) Oxytocin Receptor Genotype Modulates Ventral Striatal Activity to Social Cues and Response to Stressful Life Events, *BIOL PSYCHIAT* 76: 367-376
- EU-AIMS: MACKEY, S et al. (2017) Brain Regions Related to Impulsivity Mediate the Effects of Early Adversity on Antisocial Behavior, *BIOL PSYCHIAT* 82: 275-282
- EU-AIMS: MAN, KKC et al. (2015) Exposure to selective serotonin reuptake inhibitors during pregnancy and risk of autism spectrum disorder in children: A systematic review and meta-analysis of observational studies, *NEUROSCI BIOBEHAV R* 49: 82-89
- EU-AIMS: MERCATI, O et al. (2017) CNTN6 mutations are risk factors for abnormal auditory sensory perception in autism spectrum disorders, *MOL PSYCHIATR* 22: 625-633
- EU-AIMS: MEYER-LINDENBERG, A et al. (2012) Neural mechanisms of social risk for psychiatric disorders, *NAT NEUROSCI* 15: 663-668
- EU-AIMS: MURRAY, ML et al. (2014) Pharmacological treatments prescribed to people with autism spectrum disorder (ASD) in primary health care, *PSYCHOPHARMACOLOGY* 231: 1011-1021
- EU-AIMS: NAAIJEN, J et al. (2017) Glutamatergic and GABAergic gene sets in attention-deficit/hyperactivity disorder: association to overlapping traits in ADHD and autism, *TRANSL PSYCHIAT* 7:
- EU-AIMS: NEES, F et al. (2017) Brain substrates of reward processing and the mu-opioid receptor: a pathway into pain?, *PAIN* 158: 212-219
- EU-AIMS: OGURO-ANDO, A et al. (2017) A current view on contactin-4, -5, and -6: Implications in neurodevelopmental disorders, *MOL CELL NEUROSCI* 81: 72-83
- EU-AIMS: OREKHOVA, EV et al. (2014) EEG hyper-connectivity in high-risk infants is associated with later autism, *J NEURODEV DISORD* 6:
- EU-AIMS: PERSICO, AM et al. (2013) Autism genetics, *BEHAV BRAIN RES* 251: 95-112
- EU-AIMS: PERSICO, AM et al. (2015) Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives, *EUR NEUROPSYCHOPHARM* 25: 1513-1531
- EU-AIMS: PETER, S et al. (2016) Dysfunctional cerebellar Purkinje cells contribute to autism-like behaviour in Shank2-deficient mice, *NAT COMMUN* 7:
- EU-AIMS: RICHIARDI, J et al. (2015) Correlated gene expression supports synchronous activity in brain networks, *SCIENCE* 348: 1241-1244
- EU-AIMS: RUGGERI, B et al. (2014) Biomarkers in autism spectrum disorder: the old and the new, *PSYCHOPHARMACOLOGY* 231: 1201-1216
- EU-AIMS: SACCO, R et al. (2015) Head circumference and brain size in autism spectrum disorder: A systematic review and meta-analysis, *PSYCHIAT RES-NEUROIM* 234: 239-251
- EU-AIMS: SALOMONE, E et al. (2016) Use of early intervention for young children with autism spectrum disorder across Europe, *AUTISM* 20: 233-249
- EU-AIMS: SANEFUJI, M et al. (2017) Double-dissociation between the mechanism leading to impulsivity and inattention in Attention Deficit Hyperactivity Disorder: A resting-state functional connectivity study, *CORTEK* 86: 290-302
- EU-AIMS: SCHMEISSER, MJ et al. (2015) Translational neurobiology in Shank mutant mice - Model systems for neuropsychiatric disorders, *ANN ANAT* 200: 115-117
- EU-AIMS: SCHREINER, D et al. (2017) Synapse biology in the `circuit-age- paths toward molecular connectomics, *CURR OPIN NEUROBIOL* 42: 102-110
- EU-AIMS: SCHREINER, D et al. (2014) Targeted Combinatorial Alternative Splicing Generates Brain Region-Specific Repertoires of Neurexins, *NEURON* 84: 386-398
- EU-AIMS: SHEPHARD, E et al. (2017) Mid-childhood outcomes of infant siblings at familial high-risk of autism spectrum disorder, *AUTISM RES* 10: 546-557

- EU-AIMS: SIDDIQUI, TJ et al. (2013) An LRRTM4-HSPG Complex Mediates Excitatory Synapse Development on Dentate Gyrus Granule Cells, NEURON 79: 680-695
- EU-AIMS: SPOOREN, W et al. (2012) Synapse dysfunction in autism: a molecular medicine approach to drug discovery in neurodevelopmental disorders, TRENDS PHARMACOL SCI 33: 669-684
- EU-AIMS: STEIN, JL et al. (2012) Identification of common variants associated with human hippocampal and intracranial volumes, NAT GENET 44: 552-+
- EU-AIMS: STRINGARIS, A et al. (2015) The Brains Response to Reward Anticipation and Depression in Adolescence: Dimensionality, Specificity, and Longitudinal Predictions in a Community-Based Sample, AM J PSYCHIAT 172: 1215-1223
- EU-AIMS: TORRICO, B et al. (2017) Lack of replication of previous autism spectrum disorder GWAS hits in European populations, AUTISM RES 10: 202-211
- EU-AIMS: TOST, H et al. (2015) Environmental influence in the brain, human welfare and mental health, NAT NEUROSCI 18: 1421-1431
- EU-AIMS: TRAUNMULLER, L et al. (2016) Control of neuronal synapse specification by a highly dedicated alternative splicing program, SCIENCE 352: 982-986
- EU-AIMS: VAN ELST, K et al. (2014) Food for thought: Dietary changes in essential fatty acid ratios and the increase in autism spectrum disorders, NEUROSCI BIOBEHAV R 45: 369-378
- EU-AIMS: VISSER, JC et al. (2016) Autism spectrum disorder and attention-deficit/hyperactivity disorder in early childhood: A review of unique and shared characteristics and developmental antecedents, NEUROSCI BIOBEHAV R 65: 229-263
- EU-AIMS: WASS, SV et al. (2015) Shorter spontaneous fixation durations in infants with later emerging autism, SCI REP-UK 5:
- EU-AIMS: WEBB, SJ et al. (2014) The motivation for very early intervention for infants at high risk for autism spectrum disorders, INT J SPEECH-LANG PA 16: 36-42
- EU-AIMS: WHELAN, R et al. (2012) Adolescent impulsivity phenotypes characterized by distinct brain networks, NAT NEUROSCI 15: 920-U153
- EU-AIMS: WHELAN, R et al. (2014) Neuropsychosocial profiles of current and future adolescent alcohol misusers, NATURE 512: 185-+
- EU-AIMS: WILSON, CE et al. (2014) The Neuropsychology of Male Adults With High-Functioning Autism or Asperger Syndrome, AUTISM RES 7: 568-581
- EU-AIMS: ZUKO, A et al. (2013) Contactins in the neurobiology of autism, EUR J PHARMACOL 719: 63-74
- EUROPAIN: AASVANG, EK et al. (2010) Predictive Risk Factors for Persistent Postherniotomy Pain, ANESTHESIOLOGY 112: 957-969
- EUROPAIN: ANDERSEN, KG et al. (2011) Persistent Pain After Breast Cancer Treatment: A Critical Review of Risk Factors and Strategies for Prevention, J PAIN 12: 725-746
- EUROPAIN: ANDERSEN, KG et al. (2015) Predictive factors for the development of persistent pain after breast cancer surgery, PAIN 156: 2413-2422
- EUROPAIN: ANDREWS, N et al. (2012) Spontaneous burrowing behaviour in the rat is reduced by peripheral nerve injury or inflammation associated pain, EUR J PAIN 16: 485-495
- EUROPAIN: BAASTRUP, C et al. (2010) Spinal-, brainstem- and cerebrally mediated responses at- and below-level of a spinal cord contusion in rats: Evaluation of pain-like behavior, PAIN 151: 670-679
- EUROPAIN: BARON, R et al. (2012) Subgrouping of patients with neuropathic pain according to pain-related sensory abnormalities: a first step to a stratified treatment approach, LANCET NEUROL 11: 999-1005
- EUROPAIN: CALVO, M et al. (2012) The role of the immune system in the generation of neuropathic pain, LANCET NEUROL 11: 629-642

- EUROPAIN: CASPANI, O et al. (2014) Tramadol reduces anxiety-related and depression-associated behaviors presumably induced by pain in the chronic constriction injury model of neuropathic pain in rats, PHARMACOL BIOCHEM BE 124: 290-296
- EUROPAIN: COLLOCA, L et al. (2017) Neuropathic pain, NAT REV DIS PRIMERS 3:
- EUROPAIN: DEMANT, DT et al. (2015) Pain relief with lidocaine 5% patch in localized peripheral neuropathic pain in relation to pain phenotype: a randomised, double-blind, and placebo-controlled, phenotype panel study, PAIN 156: 2234-2244
- EUROPAIN: DEMANT, DT et al. (2014) The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: A randomised, double-blind, placebo-controlled phenotype-stratified study, PAIN 155: 2263-2273
- EUROPAIN: DENK, F et al. (2013) HDAC inhibitors attenuate the development of hypersensitivity in models of neuropathic pain, PAIN 154: 1668-1679
- EUROPAIN: DERRY, S et al. (2013) Topical capsaicin (high concentration) for chronic neuropathic pain in adults, COCHRANE DB SYST REV :
- EUROPAIN: DWORKIN, RH et al. (2013) Interventional management of neuropathic pain: NeuPSIG recommendations, PAIN 154: 2249-2261
- EUROPAIN: EIJKELKAMP, N et al. (2013) A role for Piezo2 in EPAC1-dependent mechanical allodynia, NAT COMMUN 4:
- EUROPAIN: ELLIS, A et al. (2013) Neuroinflammation and the generation of neuropathic pain, BRIT J ANAESTH 111: 26-37
- EUROPAIN: FINNERUP, NB et al. (2016) Neuropathic pain: an updated grading system for research and clinical practice, PAIN 157: 1599-1606
- EUROPAIN: FINNERUP, NB et al. (2010) The evidence for pharmacological treatment of neuropathic pain, PAIN 150: 573-581
- EUROPAIN: FINNERUP, NB et al. (2012) Spinal Cord Injury Pain: Mechanisms and Management, CURR PAIN HEADACHE R 16: 207-216
- EUROPAIN: GIERTHMHULEN, J et al. (2014) Mechanism-based treatment in complex regional pain syndromes, NAT REV NEUROL 10: 518-528
- EUROPAIN: GILRON, I et al. (2013) Combination pharmacotherapy for management of chronic pain: from bench to bedside, LANCET NEUROL 12: 1084-1095
- EUROPAIN: HAROUTIUNIAN, S et al. (2013) The neuropathic component in persistent postsurgical pain: A systematic literature review, PAIN 154: 95-102
- EUROPAIN: HAROUTOUNIAN, S et al. (2014) Primary afferent input critical for maintaining spontaneous pain in peripheral neuropathy, PAIN 155: 1272-1279
- EUROPAIN: HAUSER, W et al. (2012) The Role of Antidepressants in the Management of Fibromyalgia Syndrome A Systematic Review and Meta-Analysis, CNS DRUGS 26: 297-307
- EUROPAIN: HUANG, WL et al. (2013) A clinically relevant rodent model of the HIV antiretroviral drug stavudine induced painful peripheral neuropathy, PAIN 154: 560-575
- EUROPAIN: JENSEN, TS et al. (2014) Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms, LANCET NEUROL 13: 924-935
- EUROPAIN: JOHNSON, RW et al. (2014) Postherpetic Neuralgia, NEW ENGL J MED 371: 1526-1533
- EUROPAIN: KOSEK, E et al. (2016) Do we need a third mechanistic descriptor for chronic pain states?, PAIN 157: 1382-1386
- EUROPAIN: LENZ, M et al. (2011) Bilateral somatosensory cortex disinhibition in complex regional pain syndrome type I, NEUROLOGY 77: 1096-1101
- EUROPAIN: MARINUS, J et al. (2011) Clinical features and pathophysiology of complex regional pain syndrome, LANCET NEUROL 10: 637-648
- EUROPAIN: MCDONNELL, A et al. (2016) Inherited erythromelalgia due to mutations in SCN9A: natural history, clinical phenotype and somatosensory profile, BRAIN 139: 1052-1065

- EUROPAIN: MEJDAHL, MK et al. (2013) Persistent pain and sensory disturbances after treatment for breast cancer: six year nationwide follow-up study, *BMJ-BRIT MED J* 346:
- EUROPAIN: MINETT, MS et al. (2014) Pain without Nociceptors? Nav1.7-Independent Pain Mechanisms, *CELL REP* 6: 301-312
- EUROPAIN: PERKINS, JR et al. (2014) A comparison of RNA-seq and exon arrays for whole genome transcription profiling of the L5 spinal nerve transection model of neuropathic pain in the rat, *MOL PAIN* 10:
- EUROPAIN: PETERSEN, GL et al. (2014) The magnitude of placebo effects in pain: A meta-analysis, *PAIN* 155: 1426-1434
- EUROPAIN: PHILLIPS, TJC et al. (2010) Pharmacological Treatment of Painful HIV-Associated Sensory Neuropathy: A Systematic Review and Meta-Analysis of Randomised Controlled Trials, *PLOS ONE* 5:
- EUROPAIN: QUICK, K et al. (2012) TRPC3 and TRPC6 are essential for normal mechanotransduction in subsets of sensory neurons and cochlear hair cells, *OPEN BIOL* 2:
- EUROPAIN: SEGERDAHL, AR et al. (2015) The dorsal posterior insula subserves a fundamental role in human pain, *NAT NEUROSCI* 18: 499+
- EUROPAIN: SERRA, J et al. (2014) Hyperexcitable C nociceptors in fibromyalgia, *ANN NEUROL* 75: 196-208
- EUROPAIN: SERRA, J et al. (2012) Microneurographic identification of spontaneous activity in C-nociceptors in neuropathic pain states in humans and rats, *PAIN* 153: 42-55
- EUROPAIN: SIKANDAR, S et al. (2012) Visceral pain: the ins and outs, the ups and downs, *CURR OPIN SUPPORT PA* 6: 17-26
- EUROPAIN: SISIGNANO, M et al. (2014) Mechanism-based treatment for chemotherapy-induced peripheral neuropathic pain, *NAT REV NEUROL* 10: 694-707
- EUROPAIN: TREEDE, RD et al. (2015) A classification of chronic pain for ICD-11, *PAIN* 156: 1003-1007
- EUROPAIN: VASE, L et al. (2015) Predictors of the placebo analgesia response in randomized controlled trials of chronic pain: a meta-analysis of the individual data from nine industrially sponsored trials, *PAIN* 156: 1795-1802
- EUROPAIN: VENTZEL, L et al. (2016) Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel, *PAIN* 157: 560-568
- EUROPAIN: VOLLERT, J et al. (2016) Quantitative sensory testing using DFNS protocol in Europe: an evaluation of heterogeneity across multiple centers in patients with peripheral neuropathic pain and healthy subjects, *PAIN* 157: 750-758
- EUROPAIN: WIJAYASINGHE, N et al. (2016) Ultrasound Guided Intercostobrachial Nerve Blockade in Patients with Persistent Pain after Breast Cancer Surgery: A Pilot Study, *PAIN PHYSICIAN* 19: E309-E317
- EUROPAIN: WIJAYASINGHE, N et al. (2017) Analgesic and Sensory Effects of the Pecs Local Anesthetic Block in Patients with Persistent Pain after Breast Cancer Surgery: A Pilot Study, *PAIN PRACT* 17: 185-191
- EUROPAIN: WILDGAARD, K et al. (2011) Consequences of persistent pain after lung cancer surgery: a nationwide questionnaire study, *ACTA ANAESTH SCAND* 55: 60-68
- FLUCOP: MANENTI, A et al. (2017) Comparative analysis of influenza A(H3N2) virus hemagglutinin specific IgG subclass and IgA responses in children and adults after influenza vaccination, *VACCINE* 35: 191-198
- FLUCOP: PEBODY, R et al. (2016) Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results, *EUROSURVEILLANCE* 21: 41-51
- GETREAL: EFTHIMIOU, O et al. (2016) GetReal in network meta-analysis: a review of the methodology, *RES SYNTH METHODS* 7: 236-263

- GETREAL: EFTHIMIOU, O et al. (2017) Combining randomized and nonrandomized evidence in network meta-analysis, *STAT MED* 36: 1210-1226
- GETREAL: KALKMAN, S et al. (2017) Series: Pragmatic trials and real world evidence: Paper 4. Informed consent, *J CLIN EPIDEMIOL* 89: 181-187
- GETREAL: MAKADY, A et al. (2017) Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies, *VALUE HEALTH* 20: 520-532
- GETREAL: MAKADY, A et al. (2017) What Is Real-World Data? A Review of Definitions Based on Literature and Stakeholder Interviews, *VALUE HEALTH* 20: 858-865
- GETREAL: NORDON, C et al. (2016) The Efficacy-Effectiveness Gap : Historical Background and Current Conceptualization, *VALUE HEALTH* 19: 75-81
- GETREAL: RENGERINK, KO et al. (2017) Series: Pragmatic trials and real world evidence: Paper 3. Patient selection challenges and consequences, *J CLIN EPIDEMIOL* 89: 173-180
- GETREAL: WORSLEY, SD et al. (2017) Series: Pragmatic trials and real world evidence: Paper 2. Setting, sites, and investigator selection, *J CLIN EPIDEMIOL* 88: 14-20
- GETREAL: ZUIDGEEST, MGP et al. (2017) Series: Pragmatic trials and real world evidence: Paper 1. Introduction, *J CLIN EPIDEMIOL* 88: 7-13
- iABC: ALIBERTI, S et al. (2016) Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration, *EUR RESPIR J* 48: 632-647
- IMIDIA: BERARD, X et al. (2013) Role of hemodynamic forces in the ex vivo arterialization of human saphenous veins, *J VASC SURG* 57: 1371-1382
- IMIDIA: BOSCO, D et al. (2011) CONNEXINS: KEY MEDIATORS OF ENDOCRINE FUNCTION, *PHYSIOL REV* 91: 1393-1445
- IMIDIA: BROICHHAGEN, J et al. (2014) Optical control of insulin release using a photoswitchable sulfonyleurea, *NAT COMMUN* 5:
- IMIDIA: CARRAT, GR et al. (2017) Decreased STARD10 Expression Is Associated with Defective Insulin Secretion in Humans and Mice, *AM J HUM GENET* 100: 238-256
- IMIDIA: CHABOSSEAU, P et al. (2016) Zinc and diabetes, *ARCH BIOCHEM BIOPHYS* 611: 79-85
- IMIDIA: CHABOSSEAU, P et al. (2014) Mitochondrial and ER-Targeted eCALWY Probes Reveal High Levels of Free Zn²⁺, *ACS CHEM BIOL* 9: 2111-2120
- IMIDIA: CHAKRAVARTHY, H et al. (2017) Converting Adult Pancreatic Islet alpha Cells into beta Cells by Targeting Both Dnmt1 and Arx, *CELL METAB* 25: 622-634
- IMIDIA: COHRS, CM et al. (2017) Vessel Network Architecture of Adult Human Islets Promotes Distinct Cell-Cell Interactions In Situ and Is Altered After Transplantation, *ENDOCRINOLOGY* 158: 1373-1385
- IMIDIA: DAMOND, N et al. (2016) Blockade of glucagon signaling prevents or reverses diabetes onset only if residual beta-cells persist, *ELIFE* 5:
- IMIDIA: GERBER, PA et al. (2017) The Role of Oxidative Stress and Hypoxia in Pancreatic Beta-Cell Dysfunction in Diabetes Mellitus, *ANTIOXID REDOX SIGN* 26: 501-+
- IMIDIA: GONZALEZ, CD et al. (2011) The emerging role of autophagy in the pathophysiology of diabetes mellitus, *AUTOPHAGY* 7: 2-11
- IMIDIA: HODSON, DJ et al. (2014) ADCY5 Couples Glucose to Insulin Secretion in Human Islets, *DIABETES* 63: 3009-3021
- IMIDIA: HODSON, DJ et al. (2013) Lipotoxicity disrupts incretin-regulated human beta cell connectivity, *J CLIN INVEST* 123: 4182-4194
- IMIDIA: HUCH, M et al. (2013) Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis, *EMBO J* 32: 2708-2721
- IMIDIA: JOHNSTON, NR et al. (2016) Beta Cell Hubs Dictate Pancreatic Islet Responses to Glucose, *CELL METAB* 24: 389-401
- IMIDIA: KONE, M et al. (2014) LKB1 and AMPK differentially regulate pancreatic beta-cell identity, *FASEB J* 28: 4972-4985

- IMIDIA: LENZEN, S et al. (2014) A Fresh View of Glycolysis and Glucokinase Regulation: History and Current Status, *J BIOL CHEM* 289: 12189-12194
- IMIDIA: MARTINEZ-SANCHEZ, A et al. (2017) MiRNAs in beta-Cell Development, Identity, and Disease, *FRONT GENET* 7:
- IMIDIA: MITCHELL, RK et al. (2016) Molecular Genetic Regulation of Slc30a8/ZnT8 Reveals a Positive Association With Glucose Tolerance, *MOL ENDOCRINOL* 30: 77-91
- IMIDIA: MITCHELL, RK et al. (2015) Selective disruption of Tcf7l2 in the pancreatic beta cell impairs secretory function and lowers beta cell mass, *HUM MOL GENET* 24: 1390-1399
- IMIDIA: RAVASSARD, P et al. (2011) A genetically engineered human pancreatic beta cell line exhibiting glucose-inducible insulin secretion, *J CLIN INVEST* 121: 3589-3597
- IMIDIA: ROGGLI, E et al. (2010) Involvement of MicroRNAs in the Cytotoxic Effects Exerted by Proinflammatory Cytokines on Pancreatic beta-Cells, *DIABETES* 59: 978-986
- IMIDIA: ROGGLI, E et al. (2012) Changes in MicroRNA Expression Contribute to Pancreatic beta-Cell Dysfunction in Prediabetic NOD Mice, *DIABETES* 61: 1742-1751
- IMIDIA: RUTTER, GA et al. (2015) SLC30A8 mutations in type 2 diabetes, *DIABETOLOGIA* 58: 31-36
- IMIDIA: RUTTER, GA et al. (2015) Pancreatic beta-cell identity, glucose sensing and the control of insulin secretion, *BIOCHEM J* 466: 203-218
- IMIDIA: SANTIAGO, MF et al. (2011) Targeting Pannexin1 Improves Seizure Outcome, *PLOS ONE* 6:
- IMIDIA: SCHARFMANN, R et al. (2014) Development of a conditionally immortalized human pancreatic beta cell line, *J CLIN INVEST* 124: 2087-2098
- IMIDIA: WOODFIN, A et al. (2011) The junctional adhesion molecule JAM-C regulates polarized transendothelial migration of neutrophils in vivo, *NAT IMMUNOL* 12: 761-U145
- IMPRiND: FITZPATRICK, AWP et al. (2017) Cryo-EM structures of tau filaments from Alzheimers disease, *NATURE* 547: 185-+
- INNODIA: GRIECO, FA et al. (2017) MicroRNAs miR-23a-3p, miR-23b-3p, and miR-149-5p Regulate the Expression of Proapoptotic BH3-Only Proteins DP5 and PUMA in Human Pancreatic beta-Cells, *DIABETES* 66: 100-112
- INNODIA: MARROQUI, L et al. (2017) Interferon-alpha mediates human beta cell HLA class I overexpression, endoplasmic reticulum stress and apoptosis, three hallmarks of early human type 1 diabetes, *DIABETOLOGIA* 60: 656-667
- iPiE: BAUMER, A et al. (2017) Baseline toxicity and ion-trapping models to describe the pH-dependence of bacterial toxicity of pharmaceuticals, *ENVIRON SCI-PROC IMP* 19: 901-916
- iPiE: ESCHER, BI et al. (2017) General baseline toxicity QSAR for nonpolar, polar and ionisable chemicals and their mixtures in the bioluminescence inhibition assay with *Aliivibrio fischeri*, *ENVIRON SCI-PROC IMP* 19: 414-428
- iPiE: QUERALT-ROSINACH, N et al. (2016) DisGeNET-RDF: harnessing the innovative power of the Semantic Web to explore the genetic basis of diseases, *BIOINFORMATICS* 32: 2236-2238
- K4DD: ARISTOTELOUS, T et al. (2013) Discovery of beta 2 Adrenergic Receptor Ligands Using Biosensor Fragment Screening of Tagged Wild-Type Receptor, *ACS MED CHEM LETT* 4: 1005-1010
- K4DD: BOCQUET, N et al. (2015) Real-time monitoring of binding events on a thermostabilized human A(2A) receptor embedded in a lipid bilayer by surface plasmon resonance, *BBA-BIOMEMBRANES* 1848: 1224-1233
- K4DD: DE WITTE, WEA et al. (2016) In vivo Target Residence Time and Kinetic Selectivity: The Association Rate Constant as Determinant, *TRENDS PHARMACOL SCI* 37: 831-842
- K4DD: DE WITTE, WEA et al. (2016) Mechanistic models enable the rational use of in vitro drug-target binding kinetics for better drug effects in patients, *EXPERT OPIN DRUG DIS* 11: 45-63

- K4DD: GUO, D et al. (2017) Kinetic Aspects of the Interaction between Ligand and G Protein-Coupled Receptor: The Case of the Adenosine Receptors, CHEM REV 117: 38-66
- K4DD: HOFFMANN, C et al. (2015) Ligand Residence Time at G-protein-Coupled Receptors-Why We Should Take Our Time To Study It, MOL PHARMACOL 88: 552-560
- K4DD: HOTHERSALL, JD et al. (2016) Can residence time offer a useful strategy to target agonist drugs for sustained GPCR responses?, DRUG DISCOV TODAY 21: 90-96
- K4DD: NEDERPELT, I et al. (2016) Characterization of 12 GnRH peptide agonists - a kinetic perspective, BRIT J PHARMACOL 173: 128-141
- K4DD: SEGALA, E et al. (2016) Controlling the Dissociation of Ligands from the Adenosine A(2A) Receptor through Modulation of Salt Bridge Strength, J MED CHEM 59: 6470-6479
- K4DD: STANK, A et al. (2016) Protein Binding Pocket Dynamics, ACCOUNTS CHEM RES 49: 809-815
- MARCAR: BRAEUNING, A et al. (2014) Phenobarbital-Mediated Tumor Promotion in Transgenic Mice with Humanized CAR and PXR, TOXICOL SCI 140: 259-270
- MARCAR: LEMPIAINEN, H et al. (2013) Identification of Dlk1-Dio3 Imprinted Gene Cluster Noncoding RNAs as Novel Candidate Biomarkers for Liver Tumor Promotion, TOXICOL SCI 131: 375-386
- MARCAR: LUISIER, R et al. (2014) Phenobarbital Induces Cell Cycle Transcriptional Responses in Mouse Liver Humanized for Constitutive Androstane and Pregnane X Receptors, TOXICOL SCI 139: 501-511
- MARCAR: NESTOR, CE et al. (2015) Rapid reprogramming of epigenetic and transcriptional profiles in mammalian culture systems, GENOME BIOL 16:
- MARCAR: REDDINGTON, JP et al. (2013) Redistribution of H3K27me3 upon DNA hypomethylation results in de-repression of Polycomb target genes, GENOME BIOL 14:
- MARCAR: REDDINGTON, JP et al. (2013) Non-canonical functions of the DNA methylome in gene regulation, BIOCHEM J 451: 13-23
- MARCAR: SPROUL, D et al. (2013) Genomic insights into cancer-associated aberrant CpG island hypermethylation, BRIEF FUNCT GENOMICS 12: 174-190
- MARCAR: THOMSON, JP et al. (2012) Non-genotoxic carcinogen exposure induces defined changes in the 5-hydroxymethylome, GENOME BIOL 13:
- MIP-DILI: ASPLUND, A et al. (2016) One Standardized Differentiation Procedure Robustly Generates Homogenous Hepatocyte Cultures Displaying Metabolic Diversity from a Large Panel of Human Pluripotent Stem Cells, STEM CELL REV REP 12: 90-104
- MIP-DILI: BACHOUR-EL AZZI, P et al. (2015) Comparative Localization and Functional Activity of the Main Hepatobiliary Transporters in HepaRG Cells and Primary Human Hepatocytes, TOXICOL SCI 145: 157-168
- MIP-DILI: BELL, CC et al. (2016) Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease, SCI REP-UK 6:
- MIP-DILI: DEN BRAVER-SEWRADJ, SP et al. (2016) Inter-donor variability of phase I/phase II metabolism of three reference drugs in cryopreserved primary human hepatocytes in suspension and monolayer, TOXICOL IN VITRO 33: 71-79
- MIP-DILI: GOLDRING, C et al. (2017) Stem Cell-Derived Models to Improve Mechanistic Understanding and Prediction of Human Drug-Induced Liver Injury, HEPATOLOGY 65: 710-721
- MIP-DILI: HERPERS, B et al. (2016) Activation of the Nrf2 response by intrinsic hepatotoxic drugs correlates with suppression of NF-kappa B activation and sensitizes toward TNF alpha-induced cytotoxicity, ARCH TOXICOL 90: 1163-1179
- MIP-DILI: IVANOV, M et al. (2014) Epigenetic mechanisms of importance for drug treatment, TRENDS PHARMACOL SCI 35: 384-396
- MIP-DILI: IVANOV, M et al. (2013) Ontogeny, distribution and potential roles of 5-hydroxymethylcytosine in human liver function, GENOME BIOL 14:

- MIP-DILI: IVANOV, M et al. (2012) Epigenomics and Interindividual Differences in Drug Response, *CLIN PHARMACOL THER* 92: 727-736
- MIP-DILI: KAMALIAN, L et al. (2015) The utility of HepG2 cells to identify direct mitochondrial dysfunction in the absence of cell death, *TOXICOL IN VITRO* 29: 732-740
- MIP-DILI: KIM, SH et al. (2015) Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury, *HEPATOLOGY* 62: 887-899
- MIP-DILI: LAUSCHKE, VM et al. (2017) The role of microRNAs in liver injury at the crossroad between hepatic cell death and regeneration, *BIOCHEM BIOPH RES CO* 482: 399-407
- MIP-DILI: LAUSCHKE, VM et al. (2016) Novel 3D Culture Systems for Studies of Human Liver Function and Assessments of the Hepatotoxicity of Drugs and Drug Candidates, *CHEM RES TOXICOL* 29: 1936-1955
- MIP-DILI: OGESE, MO et al. (2017) New Approaches to Investigate Drug-Induced Hypersensitivity, *CHEM RES TOXICOL* 30: 239-259
- MIP-DILI: OORTS, M et al. (2016) Drug-induced cholestasis risk assessment in sandwich-cultured human hepatocytes, *TOXICOL IN VITRO* 34: 179-186
- MIP-DILI: SHARANEK, A et al. (2015) Cellular Accumulation and Toxic Effects of Bile Acids in Cyclosporine A-Treated HepaRG Hepatocytes, *TOXICOL SCI* 147: 573-587
- MIP-DILI: SHARANEK, A et al. (2016) Rho-kinase/myosin light chain kinase pathway plays a key role in the impairment of bile canaliculi dynamics induced by cholestatic drugs, *SCI REP-UK* 6:
- MIP-DILI: SISON-YOUNG, RL et al. (2017) A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity, *ARCH TOXICOL* 91: 1385-1400
- MIP-DILI: SUTHERLAND, JJ et al. (2016) Assessing Concordance of Drug-Induced Transcriptional Response in Rodent Liver and Cultured Hepatocytes, *PLOS COMPUT BIOL* 12:
- MIP-DILI: WINK, S et al. (2017) High-content imaging-based BAC-GFP toxicity pathway reporters to assess chemical adversity liabilities, *ARCH TOXICOL* 91: 1367-1383
- MIP-DILI: WINK, S et al. (2014) Quantitative High Content Imaging of Cellular Adaptive Stress Response Pathways in Toxicity for Chemical Safety Assessment, *CHEM RES TOXICOL* 27: 338-355
- ND4BB: ABU KWAIK, Y et al. (2013) Microbial quest for food in vivo: Nutritional virulence as an emerging paradigm, *CELL MICROBIOL* 15: 882-890
- ND4BB: AUFRAY, C et al. (2016) Making sense of big data in health research: Towards an EU action plan, *GENOME MED* 8:
- ND4BB: KOSTYANEV, T et al. (2016) The Innovative Medicines Initiatives New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance, *J ANTIMICROB CHEMOTH* 71: 290-295
- ND4BB: RABANAL, F et al. (2015) A bioinspired peptide scaffold with high antibiotic activity and low in vivo toxicity, *SCI REP-UK* 5:
- NEWMEDS: AKDENIZ, C et al. (2014) The neurobiology of social environmental risk for schizophrenia: an evolving research field, *SOC PSYCH PSYCH EPID* 49: 507-517
- NEWMEDS: ANACKER, C et al. (2013) Role for the kinase SGK1 in stress, depression, and glucocorticoid effects on hippocampal neurogenesis, *P NATL ACAD SCI USA* 110: 8708-8713
- NEWMEDS: ARTIGAS, F et al. (2013) Serotonin receptors involved in antidepressant effects, *PHARMACOL THERAPEUT* 137: 119-131
- NEWMEDS: ARTIGAS, F et al. (2015) Developments in the field of antidepressants, where do we go now?, *EUR NEUROPSYCHOPHARM* 25: 657-670
- NEWMEDS: BORTOLOZZI, A et al. (2012) Selective siRNA-mediated suppression of 5-HT_{1A} autoreceptors evokes strong anti-depressant-like effects, *MOL PSYCHIATR* 17: 612-623

- NEWMEDS: BRAUN, U et al. (2015) Dynamic reconfiguration of frontal brain networks during executive cognition in humans, *P NATL ACAD SCI USA* 112: 11678-11683
- NEWMEDS: BRAUN, U et al. (2012) Test-retest reliability of resting-state connectivity network characteristics using fMRI and graph theoretical measures, *NEUROIMAGE* 59: 1404-1412
- NEWMEDS: BUSSEY, TJ et al. (2012) New translational assays for preclinical modelling of cognition in schizophrenia: The touchscreen testing method for mice and rats, *NEUROPHARMACOLOGY* 62: 1191-1203
- NEWMEDS: CAO, H et al. (2014) Test-retest reliability of fMRI-based graph theoretical properties during working memory, emotion processing, and resting state, *NEUROIMAGE* 84: 888-900
- NEWMEDS: DIREK, N et al. (2017) An Analysis of Two Genome-wide Association Meta-analyses Identifies a New Locus for Broad Depression Phenotype, *BIOL PSYCHIAT* 82: 322-329
- NEWMEDS: DOYLE, OM et al. (2013) Quantifying the Attenuation of the Ketamine Pharmacological Magnetic Resonance Imaging Response in Humans: A Validation Using Antipsychotic and Glutamatergic Agents, *J PHARMACOL EXP THER* 345: 151-160
- NEWMEDS: FEJGIN, K et al. (2014) A Mouse Model that Recapitulates Cardinal Features of the 15q13.3 Microdeletion Syndrome Including Schizophrenia- and Epilepsy-Related Alterations, *BIOL PSYCHIAT* 76: 128-137
- NEWMEDS: GASTAMBIDE, F et al. (2012) Selective Remediation of Reversal Learning Deficits in the Neurodevelopmental MAM Model of Schizophrenia by a Novel mGlu5 Positive Allosteric Modulator, *NEUROPSYCHOPHARMACOL* 37: 1057-1066
- NEWMEDS: GILMOUR, G et al. (2012) NMDA receptors, cognition and schizophrenia - Testing the validity of the NMDA receptor hypofunction hypothesis, *NEUROPHARMACOLOGY* 62: 1401-1412
- NEWMEDS: GODSIL, BP et al. (2013) The hippocampal-prefrontal pathway: The weak link in psychiatric disorders?, *EUR NEUROPSYCHOPHARM* 23: 1165-1181
- NEWMEDS: GRIMM, O et al. (2015) Acute ketamine challenge increases resting state prefrontal-hippocampal connectivity in both humans and rats, *PSYCHOPHARMACOLOGY* 232: 4231-4241
- NEWMEDS: HORNER, AE et al. (2013) The touchscreen operant platform for testing learning and memory in rats and mice, *NAT PROTOC* 8: 1961-1984
- NEWMEDS: INGASON, A et al. (2011) Maternally Derived Microduplications at 15q11-q13: Implication of Imprinted Genes in Psychotic Illness, *AM J PSYCHIAT* 168: 408-417
- NEWMEDS: INIESTA, R et al. (2016) Machine learning, statistical learning and the future of biological research in psychiatry, *PSYCHOL MED* 46: 2455-2465
- NEWMEDS: INIESTA, R et al. (2016) Combining clinical variables to optimize prediction of antidepressant treatment outcomes, *J PSYCHIATR RES* 78: 94-102
- NEWMEDS: JACQUEMONT, S et al. (2011) Mirror extreme BMI phenotypes associated with gene dosage at the chromosome 16p11.2 locus, *NATURE* 478: 97-U111
- NEWMEDS: KAPUR, S et al. (2012) Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it?, *MOL PSYCHIATR* 17: 1174-1179
- NEWMEDS: KATHERINE, E et al. (2012) Genetic Predictors of Response to Serotonergic and Noradrenergic Antidepressants in Major Depressive Disorder: A Genome-Wide Analysis of Individual-Level Data and a Meta-Analysis, *PLOS MED* 9:
- NEWMEDS: KEELER, JF et al. (2011) Translating cognition from animals to humans, *BIOCHEM PHARMACOL* 81: 1356-1366
- NEWMEDS: KIROV, G et al. (2012) De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia, *MOL PSYCHIATR* 17: 142-153

- NEWMEDS: LLADO-PELFORT, L et al. (2012) 5-HT1A Receptor Agonists Enhance Pyramidal Cell Firing in Prefrontal Cortex Through a Preferential Action on GABA Interneurons, *CEREB CORTEX* 22: 1487-1497
- NEWMEDS: LO, MT et al. (2017) Genome-wide analyses for personality traits identify six genomic loci and show correlations with psychiatric disorders, *NAT GENET* 49: 152-156
- NEWMEDS: LUSTIG, C et al. (2013) CNTRICS final animal model task selection: Control of attention, *NEUROSCI BIOBEHAV R* 37: 2099-2110
- NEWMEDS: LYON, L et al. (2012) Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models, *PSYCHOPHARMACOLOGY* 220: 647-672
- NEWMEDS: MAR, AC et al. (2013) The touchscreen operant platform for assessing executive function in rats and mice, *NAT PROTOC* 8: 1985-2005
- NEWMEDS: MARQUAND, AF et al. (2012) Dissociable effects of methylphenidate, atomoxetine and placebo on regional cerebral blood flow in healthy volunteers at rest: A multi-class pattern recognition approach, *NEUROIMAGE* 60: 1015-1024
- NEWMEDS: MCALLISTER, KAL et al. (2013) Dissociation between memory retention across a delay and pattern separation following medial prefrontal cortex lesions in the touchscreen TUNL task, *NEUROBIOL LEARN MEM* 101: 120-126
- NEWMEDS: MEYER-LINDENBERG, A et al. (2012) Neural mechanisms of social risk for psychiatric disorders, *NAT NEUROSCI* 15: 663-668
- NEWMEDS: MEYER-LINDENBERG, A et al. (2010) From maps to mechanisms through neuroimaging of schizophrenia, *NATURE* 468: 194-202
- NEWMEDS: MEYER-LINDENBERG, A et al. (2011) Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine, *NAT REV NEUROSCI* 12: 524-538
- NEWMEDS: NORD, M et al. (2013) Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain, *INT J NEUROPSYCHOPH* 16: 1577-1586
- NEWMEDS: OOMEN, CA et al. (2013) The touchscreen operant platform for testing working memory and pattern separation in rats and mice, *NAT PROTOC* 8: 2006-2021
- NEWMEDS: PALOYELIS, Y et al. (2016) A Spatiotemporal Profile of In Vivo Cerebral Blood Flow Changes Following Intranasal Oxytocin in Humans, *BIOL PSYCHIAT* 79: 693-705
- NEWMEDS: PLICHTA, MM et al. (2014) Amygdala habituation: A reliable fMRI phenotype, *NEUROIMAGE* 103: 383-390
- NEWMEDS: PLICHTA, MM et al. (2012) Test-retest reliability of evoked BOLD signals from a cognitive-emotive fMRI test battery, *NEUROIMAGE* 60: 1746-1758
- NEWMEDS: POWER, RA et al. (2015) Polygenic risk scores for schizophrenia and bipolar disorder predict creativity, *NAT NEUROSCI* 18: 953-+
- NEWMEDS: SMITH, JW et al. (2011) A comparison of the effects of ketamine and phencyclidine with other antagonists of the NMDA receptor in rodent assays of attention and working memory, *PSYCHOPHARMACOLOGY* 217: 255-269
- NEWMEDS: STEFANSSON, H et al. (2014) CNVs conferring risk of autism or schizophrenia affect cognition in controls, *NATURE* 505: 361-+
- NEWMEDS: SULLIVAN, PF et al. (2013) A mega-analysis of genome-wide association studies for major depressive disorder, *MOL PSYCHIATR* 18: 497-511
- NEWMEDS: TANSEY, KE et al. (2013) Contribution of Common Genetic Variants to Antidepressant Response, *BIOL PSYCHIAT* 73: 679-682
- NEWMEDS: UHER, R et al. (2012) Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms, *PSYCHOL MED* 42: 967-980

- NEWMEDS: UHER, R et al. (2012) SELF-REPORT AND CLINICIAN-RATED MEASURES OF DEPRESSION SEVERITY: CAN ONE REPLACE THE OTHER?, *DEPRESS ANXIETY* 29: 1043-1049
- NEWMEDS: UHER, R et al. (2014) Gene-environment interactions in common mental disorders: an update and strategy for a genome-wide search, *SOC PSYCH PSYCH EPID* 49: 3-14
- NEWMEDS: ZINK, CF et al. (2012) Human neuroimaging of oxytocin and vasopressin in social cognition, *HORM BEHAV* 61: 400-409
- Onco Track: ALGAR, WR et al. (2012) Quantum Dots as Simultaneous Acceptors and Donors in Time-Gated Forster Resonance Energy Transfer Relays: Characterization and Biosensing, *J AM CHEM SOC* 134: 1876-1891
- Onco Track: BETTERMANN, K et al. (2012) SUMOylation in carcinogenesis, *CANCER LETT* 316: 113-125
- Onco Track: BUTCHER, LM et al. (2015) Probe Lasso: A novel method to rope in differentially methylated regions with 450K DNA methylation data, *METHODS* 72: 21-28
- Onco Track: FEBER, A et al. (2014) Using high-density DNA methylation arrays to profile copy number alterations, *GENOME BIOL* 15:
- Onco Track: GEISSLER, D et al. (2014) Lanthanides and Quantum Dots as Forster Resonance Energy Transfer Agents for Diagnostics and Cellular Imaging, *INORG CHEM* 53: 1824-1838
- Onco Track: HILDEBRANDT, N et al. (2011) Biofunctional Quantum Dots: Controlled Conjugation for Multiplexed Biosensors, *ACS NANO* 5: 5286-5290
- Onco Track: HOTZER, B et al. (2012) Fluorescence in Nanobiotechnology: Sophisticated Fluorophores for Novel Applications, *SMALL* 8: 2297-2326
- Onco Track: JIN, ZW et al. (2015) A Rapid, Amplification-Free, and Sensitive Diagnostic Assay for Single-Step Multiplexed Fluorescence Detection of MicroRNA, *ANGEW CHEM INT EDIT* 54: 10024-10029
- Onco Track: JIN, ZW et al. (2012) Semiconductor quantum dots for in vitro diagnostics and cellular imaging, *TRENDS BIOTECHNOL* 30: 394-403
- Onco Track: KARGL, J et al. (2016) GPR55 promotes migration and adhesion of colon cancer cells indicating a role in metastasis, *BRIT J PHARMACOL* 173: 142-154
- Onco Track: KE, RQ et al. (2013) In situ sequencing for RNA analysis in preserved tissue and cells, *NAT METHODS* 10: 857-+
- Onco Track: LECHNER, M et al. (2013) Identification and functional validation of HPV-mediated hypermethylation in head and neck squamous cell carcinoma, *GENOME MED* 5:
- Onco Track: MORRIS, TJ et al. (2014) ChAMP: 450k Chip Analysis Methylation Pipeline, *BIOINFORMATICS* 30: 428-430
- Onco Track: QIU, X et al. (2015) Rapid and Multiplexed MicroRNA Diagnostic Assay Using Quantum Dot-Based Forster Resonance Energy Transfer, *ACS NANO* 9: 8449-8457
- Onco Track: SCHUTTE, M et al. (2017) Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors, *NAT COMMUN* 8:
- Onco Track: TAIWO, O et al. (2012) Methylome analysis using MeDIP-seq with low DNA concentrations, *NAT PROTOC* 7: 617-636
- Onco Track: TANIGUCHI, K et al. (2017) YAP-IL-6ST autoregulatory loop activated on APC loss controls colonic tumorigenesis, *P NATL ACAD SCI USA* 114: 1643-1648
- Onco Track: WEGNER, KD et al. (2013) Quantum-Dot-Based Forster Resonance Energy Transfer Immunoassay for Sensitive Clinical Diagnostics of Low-Volume Serum Samples, *ACS NANO* 7: 7411-7419
- Onco Track: WEGNER, KD et al. (2014) Nanobodies and Nanocrystals: Highly Sensitive Quantum Dot-Based Homogeneous FRET Immunoassay for Serum-Based EGFR Detection, *SMALL* 10: 734-740

- Onco Track: WEGNER, KD et al. (2015) Quantum dots: bright and versatile in vitro and in vivo fluorescence imaging biosensors, CHEM SOC REV 44: 4792-4834
- Open PHACTS: BENTO, AP et al. (2014) The ChEMBL bioactivity database: an update, NUCLEIC ACIDS RES 42: D1083-D1090
- Open PHACTS: DUMONTIER, M et al. (2014) The Semanticscience Integrated Ontology (SIO) for biomedical research and knowledge discovery, J BIOMED SEMANT 5:
- Open PHACTS: FURLONG, LI et al. (2013) Human diseases through the lens of network biology, TRENDS GENET 29: 150-159
- Open PHACTS: GAULTON, A et al. (2017) The ChEMBL database in 2017, NUCLEIC ACIDS RES 45: D945-D954
- Open PHACTS: GRAY, AJG et al. (2014) Applying linked data approaches to pharmacology: Architectural decisions and implementation, SEMANT WEB 5: 101-113
- Open PHACTS: JUPP, S et al. (2014) The EBI RDF platform: linked open data for the life sciences, BIOINFORMATICS 30: 1338-1339
- Open PHACTS: KUTMON, M et al. (2016) WikiPathways: capturing the full diversity of pathway knowledge, NUCLEIC ACIDS RES 44: D488-D494
- Open PHACTS: LIZIO, M et al. (2015) Gateways to the FANTOM5 promoter level mammalian expression atlas, GENOME BIOL 16:
- Open PHACTS: MONTANARI, F et al. (2016) Selectivity profiling of BCRP versus P-gp inhibition: from automated collection of polypharmacology data to multi-label learning, J CHEMINFORMATICS 8:
- Open PHACTS: PINERO, J et al. (2017) DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants, NUCLEIC ACIDS RES 45: D833-D839
- Open PHACTS: PINERO, J et al. (2015) DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes, DATABASE-OXFORD :
- Open PHACTS: QUERALT-ROSINACH, N et al. (2016) DisGeNET-RDF: harnessing the innovative power of the Semantic Web to explore the genetic basis of diseases, BIOINFORMATICS 32: 2236-2238
- Open PHACTS: WILD, DJ et al. (2012) Systems chemical biology and the Semantic Web: what they mean for the future of drug discovery research, DRUG DISCOV TODAY 17: 469-474
- Open PHACTS: WILLIAMS, AJ et al. (2012) Open PHACTS: semantic interoperability for drug discovery, DRUG DISCOV TODAY 17: 1188-1198
- Open PHACTS: WILLIAMS, AJ et al. (2012) Towards a gold standard: regarding quality in public domain chemistry databases and approaches to improving the situation, DRUG DISCOV TODAY 17: 685-701
- ORBITO: AUGUSTIJNS, P et al. (2014) A review of drug solubility in human intestinal fluids: Implications for the prediction of oral absorption, EUR J PHARM SCI 57: 322-332
- ORBITO: BERGSTROM, CAS et al. (2014) Early pharmaceutical profiling to predict oral drug absorption: Current status and unmet needs, EUR J PHARM SCI 57: 173-199
- ORBITO: DAHLGREN, D et al. (2016) Regional Intestinal Permeability of Three Model Drugs in Human, MOL PHARMACEUT 13: 3013-3021
- ORBITO: HARWOOD, MD et al. (2016) In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-Glycoprotein and Breast Cancer Resistance Protein: Part I: A Cross-Laboratory Comparison of Transporter-Protein Abundances and Relative Expression Factors in Human Intestine and Caco-2 Cell, DRUG METAB DISPOS 44: 297-307
- ORBITO: HARWOOD, MD et al. (2015) Application of an LC-MS/MS method for the simultaneous quantification of human intestinal transporter proteins absolute abundance using a QconCAT technique, J PHARMACEUT BIOMED 110: 27-33

- ORBITO: HENS, B et al. (2015) Gastrointestinal behavior of nano- and microsized fenofibrate: In vivo evaluation in man and in vitro simulation by assessment of the permeation potential, EUR J PHARM SCI 77: 40-47
- ORBITO: HENS, B et al. (2017) Exploring gastrointestinal variables affecting drug and formulation behavior: Methodologies, challenges and opportunities, INT J PHARMACEUT 519: 79-97
- ORBITO: KHADRA, I et al. (2015) Statistical investigation of simulated intestinal fluid composition on the equilibrium solubility of biopharmaceutics classification system class II drugs, EUR J PHARM SCI 67: 65-75
- ORBITO: KOSTEWICZ, ES et al. (2014) PBPK models for the prediction of in vivo performance of oral dosage forms, EUR J PHARM SCI 57: 300-321
- ORBITO: KOSTEWICZ, ES et al. (2014) In vitro models for the prediction of in vivo performance of oral dosage forms, EUR J PHARM SCI 57: 342-366
- ORBITO: KOURENTAS, A et al. (2016) An in vitro biorelevant gastrointestinal transfer (BioGIT) system for forecasting concentrations in the fasted upper small intestine: Design, implementation, and evaluation, EUR J PHARM SCI 82: 106-114
- ORBITO: KOZIOLEK, M et al. (2015) Investigation of pH and Temperature Profiles in the GI Tract of Fasted Human Subjects Using the Intellicap((R)) System, J PHARM SCI-US 104: 2855-2863
- ORBITO: KOZIOLEK, M et al. (2016) Navigating the human gastrointestinal tract for oral drug delivery: Uncharted waters and new frontiers, ADV DRUG DELIVER REV 101: 75-88
- ORBITO: MARGOLSKEE, A et al. (2017) IMI - oral biopharmaceutics tools project - evaluation of bottom-up PBPK prediction success part 1: Characterisation of the OrBiTo database of compounds, EUR J PHARM SCI 96: 598-609
- ORBITO: MARGOLSKEE, A et al. (2017) IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results, EUR J PHARM SCI 96: 610-625
- ORBITO: MARKOPOULOS, C et al. (2015) In-vitro simulation of luminal conditions for evaluation of performance of oral drug products: Choosing the appropriate test media, EUR J PHARM BIOPHARM 93: 173-182
- ORBITO: RUFF, A et al. (2017) Prediction of Ketoconazole absorption using an updated in vitro transfer model coupled to physiologically based pharmacokinetic modelling, EUR J PHARM SCI 100: 42-55
- ORBITO: SJOGREN, E et al. (2014) In vivo methods for drug absorption - Comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects, EUR J PHARM SCI 57: 99-151
- ORBITO: VAN DEN ABEELE, J et al. (2017) The dynamic gastric environment and its impact on drug and formulation behaviour, EUR J PHARM SCI 96: 207-231
- ORBITO: VAN DEN ABEELE, J et al. (2017) Exploring the link between gastric motility and intragastric drug distribution in man, EUR J PHARM BIOPHARM 112: 75-84
- ORBITO: ZHOU, Z et al. (2017) Statistical investigation of simulated fed intestinal media composition on the equilibrium solubility of oral drugs, EUR J PHARM SCI 99: 95-104
- Pharma-Cog: BABILONI, C et al. (2013) Resting state cortical electroencephalographic rhythms are related to gray matter volume in subjects with mild cognitive impairment and Alzheimers disease, HUM BRAIN MAPP 34: 1427-1446
- Pharma-Cog: CARRILLO, MC et al. (2012) Worldwide Alzheimers Disease Neuroimaging Initiative, ALZHEIMERS DEMENT 8: 337-342
- Pharma-Cog: DRAGO, V et al. (2011) Disease Tracking Markers for Alzheimers Disease at the Prodromal (MCI) Stage, J ALZHEIMERS DIS 26: 159-199

- Pharma-Cog: FRISONI, GB et al. (2010) The clinical use of structural MRI in Alzheimer disease, *NAT REV NEUROL* 6: 67-77
- Pharma-Cog: JOVICICH, J et al. (2014) Multisite longitudinal reliability of tract-based spatial statistics in diffusion tensor imaging of healthy elderly subjects, *NEUROIMAGE* 101: 390-403
- Pharma-Cog: JOVICICH, J et al. (2016) Longitudinal reproducibility of default-mode network connectivity in healthy elderly participants: A multicentric resting-state fMRI study, *NEUROIMAGE* 124: 442-454
- Pharma-Cog: JOVICICH, J et al. (2013) Brain morphometry reproducibility in multi-center 3 T MRI studies: A comparison of cross-sectional and longitudinal segmentations, *NEUROIMAGE* 83: 472-484
- Pharma-Cog: LANGUILLE, S et al. (2012) The grey mouse lemur: A non-human primate model for ageing studies, *AGEING RES REV* 11: 150-162
- Pharma-Cog: LIM, CK et al. (2017) Involvement of the kynurenine pathway in the pathogenesis of Parkinsons disease, *PROG NEUROBIOL* 155: 76-95
- Pharma-Cog: PINI, L et al. (2016) Brain atrophy in Alzheimers Disease and aging, *AGEING RES REV* 30: 25-48
- PRECISESADS: ALVAREZ-ERRICO, D et al. (2015) Epigenetic control of myeloid cell differentiation, identity and function, *NAT REV IMMUNOL* 15: 7-17
- PRECISESADS: BOSSINI-CASTILLO, L et al. (2015) Immunogenetics of systemic sclerosis: Defining heritability, functional variants and shared-autoimmunity pathways, *J AUTOIMMUN* 64: 53-65
- PRECISESADS: KONSTA, OD et al. (2016) Defective DNA methylation in salivary gland epithelial acini from patients with Sjogrens syndrome is associated with SSB gene expression, anti-SSB/LA detection, and lymphocyte infiltration, *J AUTOIMMUN* 68: 30-38
- PRECISESADS: RAHMAN, M et al. (2016) IgM antibodies against malondialdehyde and phosphorylcholine are together strong protection markers for atherosclerosis in systemic lupus erythematosus: Regulation and underlying mechanisms, *CLIN IMMUNOL* 166: 27-37
- PRECISESADS: TERUEL, M et al. (2016) The genetic basis of systemic lupus erythematosus: What are the risk factors and what have we learned, *J AUTOIMMUN* 74: 161-175
- Predect: DE JONG, M et al. (2014) Imaging preclinical tumour models: improving translational power, *NAT REV CANCER* 14: 481-493
- Predect: ESTRADA, MF et al. (2016) Modelling the tumour microenvironment in long-term microencapsulated 3D co-cultures recapitulates phenotypic features of disease progression, *BIOMATERIALS* 78: 50-61
- Predect: GUALDA, EJ et al. (2015) SPIM-fluid: open source light-sheet based platform for high-throughput imaging, *BIOMED OPT EXPRESS* 6: 4447-4456
- Predect: HICKMAN, JA et al. (2014) Three-dimensional models of cancer for pharmacology and cancer cell biology: Capturing tumor complexity in vitro/ex vivo, *BIOTECHNOL J* 9: 1115-1128
- Predect: MALANI, D et al. (2017) Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML, *LEUKEMIA* 31: 1187-1195
- Predect: METSALU, T et al. (2015) ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap, *NUCLEIC ACIDS RES* 43: W566-W570
- Predect: NIEMINEN, AI et al. (2013) Myc-induced AMPK-phospho p53 pathway activates Bak to sensitize mitochondrial apoptosis, *P NATL ACAD SCI USA* 110: E1839-E1848
- Predect: SANTO, VE et al. (2017) Drug screening in 3D in vitro tumor models: overcoming current pitfalls of efficacy read-outs, *BIOTECHNOL J* 12:
- Predect: SFLOMOS, G et al. (2016) A Preclinical Model for ER alpha-Positive Breast Cancer Points to the Epithelial Microenvironment as Determinant of Luminal Phenotype and Hormone Response, *CANCER CELL* 29: 407-422

- Predect: STOCK, K et al. (2016) Capturing tumor complexity in vitro: Comparative analysis of 2D and 3D tumor models for drug discovery, *SCI REP-UK* 6:
- Predect: TANOS, T et al. (2013) Progesterone/RANKL Is a Major Regulatory Axis in the Human Breast, *SCI TRANSL MED* 5:
- PreDiCT-TB: ATES, LS et al. (2015) Essential Role of the ESX-5 Secretion System in Outer Membrane Permeability of Pathogenic Mycobacteria, *PLOS GENET* 11:
- PreDiCT-TB: BORITSCH, EC et al. (2016) Key experimental evidence of chromosomal DNA transfer among selected tuberculosis-causing mycobacteria, *P NATL ACAD SCI USA* 113: 9876-9881
- PreDiCT-TB: BORITSCH, EC et al. (2016) pks5-recombination-mediated surface remodelling in Mycobacterium tuberculosis emergence, *NAT MICROBIOL* 1:
- PreDiCT-TB: KAUFMANN, SHE et al. (2016) Molecular Determinants in Phagocyte-Bacteria Interactions, *IMMUNITY* 44: 476-491
- PreDiCT-TB: LIPWORTH, S et al. (2016) Defining dormancy in mycobacterial disease, *TUBERCULOSIS* 99: 131-142
- PreDiCT-TB: MANINA, G et al. (2015) Stress and Host Immunity Amplify Mycobacterium tuberculosis Phenotypic Heterogeneity and Induce Nongrowing Metabolically Active Forms, *CELL HOST MICROBE* 17: 32-46
- PreDiCT-TB: SISNIEGA, A et al. (2013) Monte Carlo study of the effects of system geometry and antiscatter grids on cone-beam CT scatter distributions, *MED PHYS* 40:
- PreDiCT-TB: SVENSSON, EM et al. (2013) Model-Based Estimates of the Effects of Efavirenz on Bedaquiline Pharmacokinetics and Suggested Dose Adjustments for Patients Coinfected with HIV and Tuberculosis, *ANTIMICROB AGENTS CH* 57: 2780-2787
- PreDiCT-TB: SVENSSON, EM et al. (2015) Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug, *J ANTIMICROB CHEMOTH* 70: 1106-1114
- PreDiCT-TB: ZUMLA, AI et al. (2014) New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects, *LANCET INFECT DIS* 14: 327-340
- PRO-active: DEMEYER, H et al. (2016) The Minimal Important Difference in Physical Activity in Patients with COPD, *PLOS ONE* 11:
- PRO-active: DEMEYER, H et al. (2017) Physical activity is increased by a 12-week semiautomated telecoaching programme in patients with COPD: a multicentre randomised controlled trial, *THORAX* 72: 415-423
- PRO-active: DEMEYER, H et al. (2014) Standardizing the Analysis of Physical Activity in Patients With COPD Following a Pulmonary Rehabilitation Program, *CHEST* 146: 318-327
- PRO-active: GIMENO-SANTOS, E et al. (2015) The PROactive instruments to measure physical activity in patients with chronic obstructive pulmonary disease, *EUR RESPIR J* 46: 988-1000
- PRO-active: GIMENO-SANTOS, E et al. (2014) Determinants and outcomes of physical activity in patients with COPD: a systematic review, *THORAX* 69: 731-739
- PRO-active: RABINOVICH, RA et al. (2013) Validity of physical activity monitors during daily life in patients with COPD, *EUR RESPIR J* 42: 1205-1215
- PRO-active: TROOSTERS, T et al. (2016) Enhancing exercise tolerance and physical activity in COPD with combined pharmacological and non-pharmacological interventions: PHYSACTO randomised, placebo-controlled study design, *BMJ OPEN* 6:
- PRO-active: VAN REMOORTEL, H et al. (2012) Validity of activity monitors in health and chronic disease: a systematic review, *INT J BEHAV NUTR PHY* 9:
- PRO-active: VAN REMOORTEL, H et al. (2012) Validity of Six Activity Monitors in Chronic Obstructive Pulmonary Disease: A Comparison with Indirect Calorimetry, *PLOS ONE* 7:
- PROTECT: ABBING-KARAHAGOPIAN, V et al. (2014) Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications, *EUR J CLIN PHARMACOL* 70: 849-857

- PROTECT: ALI, MS et al. (2015) Reporting of covariate selection and balance assessment in propensity score analysis is suboptimal: a systematic review, *J CLIN EPIDEMIOL* 68: 122-131
- PROTECT: BELITSER, SV et al. (2011) Measuring balance and model selection in propensity score methods, *PHARMACOEPIDEM DR S* 20: 1115-1129
- PROTECT: CANDORE, G et al. (2015) Comparison of Statistical Signal Detection Methods Within and Across Spontaneous Reporting Databases, *DRUG SAFETY* 38: 577-587
- PROTECT: LALMOHAMED, A et al. (2012) Causes of death in patients with multiple sclerosis and matched referent subjects: a population-based cohort study, *EUR J NEUROL* 19: 1007-1014
- PROTECT: LALMOHAMED, A et al. (2012) Risk of fracture after bariatric surgery in the United Kingdom: population based, retrospective cohort study, *BMJ-BRIT MED J* 345:
- PROTECT: MT-ISA, S et al. (2014) Balancing benefit and risk of medicines: a systematic review and classification of available methodologies, *PHARMACOEPIDEM DR S* 23: 667-678
- PROTECT: RYAN, PB et al. (2013) A Comparison of the Empirical Performance of Methods for a Risk Identification System, *DRUG SAFETY* 36: S143-S158
- PROTECT: RYAN, PB et al. (2013) Defining a Reference Set to Support Methodological Research in Drug Safety, *DRUG SAFETY* 36: S33-S47
- PROTECT: VAN STAA, TP et al. (2012) Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data, *DIABETOLOGIA* 55: 654-665
- PROTECT: WISNIEWSKI, AFZ et al. (2016) Good Signal Detection Practices: Evidence from IMI PROTECT, *DRUG SAFETY* 39: 469-490
- Quic-Concept: AERTS, HJWL et al. (2014) Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach, *NAT COMMUN* 5:
- Quic-Concept: ASSELIN, MC et al. (2012) Quantifying heterogeneity in human tumours using MRI and PET, *EUR J CANCER* 48: 447-455
- Quic-Concept: BOLLINENI, VR et al. (2016) A systematic review on [F-18]FLT-PET uptake as a measure of treatment response in cancer patients, *EUR J CANCER* 55: 81-97
- Quic-Concept: CHALLAPALLI, A et al. (2013) F-18-ICMT-11, a Caspase-3-Specific PET Tracer for Apoptosis: Biodistribution and Radiation Dosimetry, *J NUCL MED* 54: 1551-1556
- Quic-Concept: COROLLER, TP et al. (2015) CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma, *RADIOTHER ONCOL* 114: 345-350
- Quic-Concept: DUBOIS, LJ et al. (2015) New ways to image and target tumour hypoxia and its molecular responses, *RADIOTHER ONCOL* 116: 352-357
- Quic-Concept: EVEN, AJG et al. (2017) Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach, *ONCOTARGET* 8: 3870-3880
- Quic-Concept: GUYADER, JM et al. (2015) Influence of image registration on apparent diffusion coefficient images computed from free-breathing diffusion MR images of the abdomen, *J MAGN RESON IMAGING* 42: 315-330
- Quic-Concept: HUIZINGA, W et al. (2016) PCA-based groupwise image registration for quantitative MRI, *MED IMAGE ANAL* 29: 65-78
- Quic-Concept: LAMBIN, P et al. (2017) Decision support systems for personalized and participative radiation oncology, *ADV DRUG DELIVER REV* 109: 131-153
- Quic-Concept: LAMBIN, P et al. (2012) Radiomics: Extracting more information from medical images using advanced feature analysis, *EUR J CANCER* 48: 441-446
- Quic-Concept: LAMBIN, P et al. (2013) Predicting outcomes in radiation oncology-multifactorial decision support systems, *NAT REV CLIN ONCOL* 10: 27-40
- Quic-Concept: LAMBIN, P et al. (2015) Modern clinical research: How rapid learning health care and cohort multiple randomised clinical trials complement traditional evidence based medicine, *ACTA ONCOL* 54: 1289-1300

- Quic-Concept: LAMBIN, P et al. (2013) Rapid Learning health care in oncology - An approach towards decision support systems enabling customised radiotherapy, *RADIOTHER ONCOL* 109: 159-164
- Quic-Concept: LEIJENAAR, RTH et al. (2013) Stability of FDG-PET Radiomics features: An integrated analysis of test-retest and inter-observer variability, *ACTA ONCOL* 52: 1391-1397
- Quic-Concept: LEIJENAAR, RTH et al. (2015) External validation of a prognostic CT-based radiomic signature in oropharyngeal squamous cell carcinoma, *ACTA ONCOL* 54: 1423-1429
- Quic-Concept: LEIJENAAR, RTH et al. (2015) The effect of SUV discretization in quantitative FDG-PET Radiomics: the need for standardized methodology in tumor texture analysis, *SCI REP-UK* 5:
- Quic-Concept: OCONNOR, JPB et al. (2017) Imaging biomarker roadmap for cancer studies, *NAT REV CLIN ONCOL* 14: 169-186
- Quic-Concept: PANTH, KM et al. (2015) Is there a causal relationship between genetic changes and radiomics-based image features? An in vivo preclinical experiment with doxycycline inducible GADD34 tumor cells, *RADIOTHER ONCOL* 116: 462-466
- Quic-Concept: PARMAR, C et al. (2014) Robust Radiomics Feature Quantification Using Semiautomatic Volumetric Segmentation, *PLOS ONE* 9:
- Quic-Concept: PEETERS, SGJA et al. (2015) TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [F-18]HX4 Hypoxia PET Imaging, *CLIN CANCER RES* 21: 2984-2992
- Quic-Concept: PEETERS, SGJA et al. (2015) Current preclinical and clinical applications of hypoxia PET imaging using 2-nitroimidazoles, *Q J NUCL MED MOL IM* 59: 39-57
- Quic-Concept: ROELOFS, E et al. (2014) International data-sharing for radiotherapy research: An open-source based infrastructure for multicentric clinical data mining, *RADIOTHER ONCOL* 110: 370-374
- Quic-Concept: SCHELHAAS, S et al. (2017) Preclinical Applications of 3'-Deoxy-3'-[F-18]Fluoro-thymidine in Oncology - A Systematic Review, *THERANOSTICS* 7: 40-50
- Quic-Concept: VAN DER HEIDE, UA et al. (2012) Functional MRI for radiotherapy dose painting, *MAGN RESON IMAGING* 30: 1216-1223
- Quic-Concept: VELAZQUEZ, ER et al. (2013) Volumetric CT-based segmentation of NSCLC using 3D-Slicer, *SCI REP-UK* 3:
- Quic-Concept: ZEGERS, CML et al. (2016) Evaluation of tumour hypoxia during radiotherapy using [F-18]HX4 PET imaging and blood biomarkers in patients with head and neck cancer, *EUR J NUCL MED MOL I* 43: 2139-2146
- RAPP-ID: AFSHARI, A et al. (2012) Bench-to-bedside review: Rapid molecular diagnostics for bloodstream infection - a new frontier?, *CRIT CARE* 16:
- RAPP-ID: KNEZ, K et al. (2014) Emerging technologies for hybridization based single nucleotide polymorphism detection, *ANALYST* 139: 353-370
- RAPP-ID: SCHECHNER, V et al. (2013) Epidemiological Interpretation of Studies Examining the Effect of Antibiotic Usage on Resistance, *CLIN MICROBIOL REV* 26: 289-307
- RHAPSODY: FRANKS, PW et al. (2016) Exposing the exposures responsible for type 2 diabetes and obesity, *SCIENCE* 354: 69-73
- RHAPSODY: MCCARTHY, MI et al. (2017) Painting a new picture of personalised medicine for diabetes, *DIABETOLOGIA* 60: 793-799
- RTCure: RAUBER, S et al. (2017) Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells, *NAT MED* 23: 938-+
- SafeSciMET: HESLOP, JA et al. (2015) Concise Review: Workshop Review: Understanding and Assessing the Risks of Stem Cell-Based Therapies, *STEM CELL TRANSL MED* 4: 389-400
- SAFE-T: MIKUS, M et al. (2017) Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury, *LIVER INT* 37: 132-140

- SAFE-T: ROBLES-DIAZ, M et al. (2014) Use of Hys Law and a New Composite Algorithm to Predict Acute Liver Failure in Patients With Drug-Induced Liver Injury, *GASTROENTEROLOGY* 147: 109-U204
- SAFE-T: SUADES, R et al. (2014) Circulating CD45(+)/CD3(+) lymphocyte-derived microparticles map lipid-rich atherosclerotic plaques in familial hypercholesterolaemia patients, *THROMB HAEMOSTASIS* 111: 111-121
- SPRINTT: AUFFRAY, C et al. (2016) Making sense of big data in health research: Towards an EU action plan, *GENOME MED* 8:
- SPRINTT: CALVANI, R et al. (2017) Systemic inflammation, body composition, and physical performance in old community-dwellers, *J CACHEXIA SARCOPENI* 8: 69-77
- SPRINTT: CALVANI, R et al. (2017) Biomarkers for physical frailty and sarcopenia, *AGING CLIN EXP RES* 29: 29-34
- SPRINTT: CALVANI, R et al. (2015) Biomarkers for physical frailty and sarcopenia: state of the science and future developments, *J CACHEXIA SARCOPENI* 6: 278-286
- SPRINTT: CESARI, M et al. (2017) The need of operational paradigms for frailty in older persons: the SPRINTT project, *AGING CLIN EXP RES* 29: 3-10
- SPRINTT: CESARI, M et al. (2017) Rationale for a preliminary operational definition of physical frailty and sarcopenia in the SPRINTT trial, *AGING CLIN EXP RES* 29: 81-88
- SPRINTT: CRUZ-JENTOFT, AJ et al. (2017) Nutrition, frailty, and sarcopenia, *AGING CLIN EXP RES* 29: 43-48
- SPRINTT: LANDI, F et al. (2016) Impact of physical function impairment and multimorbidity on mortality among community-living older persons with sarcopaenia: results from the iSIRENTE prospective cohort study, *BMJ OPEN* 6:
- SPRINTT: LANDI, F et al. (2017) The Sarcopenia and Physical fRailty IN older people: multi-component Treatment strategies (SPRINTT) randomized controlled trial: design and methods, *AGING CLIN EXP RES* 29: 89-100
- SPRINTT: LANDI, F et al. (2017) Age-Related Variations of Muscle Mass, Strength, and Physical Performance in Community-Dwellers: Results From the Milan EXPO Survey, *J AM MED DIR ASSOC* 18:
- SPRINTT: LANDI, F et al. (2015) Sarcopenia as the Biological Substrate of Physical Frailty, *CLIN LIVER DIS* 19: 367-+
- SPRINTT: LANDI, F et al. (2016) Anorexia of Aging: Risk Factors, Consequences, and Potential Treatments, *NUTRIENTS* 8:
- SPRINTT: MARZETTI, E et al. (2017) Physical activity and exercise as countermeasures to physical frailty and sarcopenia, *AGING CLIN EXP RES* 29: 35-42
- SPRINTT: MARZETTI, E et al. (2017) Sarcopenia: an overview, *AGING CLIN EXP RES* 29: 11-17
- SPRINTT: MARZETTI, E et al. (2017) Altered mitochondrial quality control signaling in muscle of old gastric cancer patients with cachexia, *EXP GERONTOL* 87: 92-99
- SPRINTT: PICCA, A et al. (2017) Fueling Inflamm-Aging through Mitochondrial Dysfunction: Mechanisms and Molecular Targets, *INT J MOL SCI* 18:
- SPRINTT: SIRVEN, N et al. (2017) The cost of frailty in France, *EUR J HEALTH ECON* 18: 243-253
- SPRINTT: SIRVEN, N et al. (2017) The Dynamics of Hospital Use among Older People Evidence for Europe Using SHARE Data, *HEALTH SERV RES* 52: 1168-1184
- SPRINTT: VON HAEHLING, S et al. (2015) The wasting continuum in heart failure: from sarcopenia to cachexia, *P NUTR SOC* 74: 367-377
- SPRINTT: VON HAEHLING, S et al. (2017) Muscle wasting and cachexia in heart failure: mechanisms and therapies, *NAT REV CARDIOL* 14: 323-341
- STEMBANCC: BADGER, JL et al. (2014) Parkinsons disease in a dish - Using stem cells as a molecular tool, *NEUROPHARMACOLOGY* 76: 88-96

- STEMBANCC: CAO, LS et al. (2016) Pharmacological reversal of a pain phenotype in iPSC-derived sensory neurons and patients with inherited erythromelalgia, *SCI TRANSL MED* 8:
- STEMBANCC: FERNANDES, HJR et al. (2016) ER Stress and Autophagic Perturbations Lead to Elevated Extracellular alpha-Synuclein in GBA-N370S LEParkinsons iPSC-Derived Dopamine Neurons, *STEM CELL REP* 6: 342-356
- STEMBANCC: HANDEL, AE et al. (2016) Assessing similarity to primary tissue and cortical layer identity in induced pluripotent stem cell-derived cortical neurons through single-cell transcriptomics, *HUM MOL GENET* 25: 989-1000
- STEMBANCC: HEYWOOD, WE et al. (2015) Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay, *MOL NEURODEGENER* 10:
- STEMBANCC: HOCHER, B et al. (2017) Metabolomics for clinical use and research in chronic kidney disease, *NAT REV NEPHROL* 13: 269-284
- STEMBANCC: KAYE, J et al. (2015) Dynamic consent: a patient interface for twenty-first century research networks, *EUR J HUM GENET* 23: 141-146
- STEMBANCC: KEMPF, H et al. (2016) Large-scale production of human pluripotent stem cell derived cardiomyocytes, *ADV DRUG DELIVER REV* 96: 18-30
- STEMBANCC: KEMPF, H et al. (2015) Cardiac differentiation of human pluripotent stem cells in scalable suspension culture, *NAT PROTOC* 10: 1345-1361
- STEMBANCC: KEMPF, H et al. (2014) Controlling Expansion and Cardiomyogenic Differentiation of Human Pluripotent Stem Cells in Scalable Suspension Culture, *STEM CELL REP* 3: 1132-1146
- STEMBANCC: KROPP, C et al. (2016) Impact of Feeding Strategies on the Scalable Expansion of Human Pluripotent Stem Cells in Single-Use Stirred Tank Bioreactors, *STEM CELL TRANSL MED* 5: 1289-1301
- STEMBANCC: PAILLUSSON, S et al. (2017) alpha-Synuclein binds to the ER-mitochondria tethering protein VAPB to disrupt Ca²⁺ homeostasis and mitochondrial ATP production, *ACTA NEUROPATHOL* 134: 129-149
- STEMBANCC: PATSCH, C et al. (2015) Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells, *NAT CELL BIOL* 17: 994-U294
- STEMBANCC: VIREECK, J et al. (2016) Long noncoding RNA Chast promotes cardiac remodeling, *SCI TRANSL MED* 8:
- SUMMIT: BOEKHOLDT, SM et al. (2012) Association of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins A Meta-analysis, *JAMA-J AM MED ASSOC* 307: 1302-1309
- SUMMIT: BONI, E et al. (2012) A Reconfigurable and Programmable FPGA-Based System for Nonstandard Ultrasound Methods, *IEEE T ULTRASON FERR* 59: 1378-1385
- SUMMIT: DE MARINIS, Y et al. (2016) Epigenetic regulation of the thioredoxin-interacting protein (TXNIP) gene by hyperglycemia in kidney, *KIDNEY INT* 89: 342-353
- SUMMIT: FALL, T et al. (2013) The Role of Adiposity in Cardiometabolic Traits: A Mendelian Randomization Analysis, *PLOS MED* 10:
- SUMMIT: GONCALVES, I et al. (2015) Elevated Plasma Levels of MMP-12 Are Associated With Atherosclerotic Burden and Symptomatic Cardiovascular Disease in Subjects With Type 2 Diabetes, *ARTERIOSCL THROM VAS* 35: 1723-1731
- SUMMIT: JUSTICE, AE et al. (2017) Genome-wide meta-analysis of 241,258 adults accounting for smoking behaviour identifies novel loci for obesity traits, *NAT COMMUN* 8:
- SUMMIT: LOOKER, HC et al. (2015) Biomarkers of rapid chronic kidney disease progression in type 2 diabetes, *KIDNEY INT* 88: 888-896
- SUMMIT: MOSLEY, JD et al. (2016) A genome-wide association study identifies variants in KCNIP4 associated with ACE inhibitor-induced cough, *PHARMACOGENOMICS J* 16: 231-237

- SUMMIT: PATRONO, C et al. (2013) Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither?, EUR HEART J 34: 3403-U17
- SUMMIT: PATRONO, C et al. (2015) The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin, J AM COLL CARDIOL 66: 74-85
- SUMMIT: POSTMUS, I et al. (2014) Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins, NAT COMMUN 5:
- SUMMIT: RICCI, S et al. (2013) ACCURACY AND REPRODUCIBILITY OF A NOVEL DYNAMIC VOLUME FLOW MEASUREMENT METHOD, ULTRASOUND MED BIOL 39: 1903-1914
- SUMMIT: ROCCA, B et al. (2012) The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes, J THROMB HAEMOST 10: 1220-1230
- SUMMIT: SANDHOLM, N et al. (2012) New Susceptibility Loci Associated with Kidney Disease in Type 1 Diabetes, PLOS GENET 8:
- SUMMIT: SANDHOLM, N et al. (2017) The Genetic Landscape of Renal Complications in Type 1 Diabetes, J AM SOC NEPHROL 28: 557-574
- TRANSLOCATION: ANES, J et al. (2015) The ins and outs of RND efflux pumps in Escherichia coli, FRONT MICROBIOL 6:
- TRANSLOCATION: AUFRAY, C et al. (2016) Making sense of big data in health research: Towards an EU action plan, GENOME MED 8:
- TRANSLOCATION: BAJAJ, H et al. (2017) Bacterial Outer Membrane Porins as Electrostatic Nanosieves: Exploring Transport Rules of Small Polar Molecules, ACS NANO 11: 5465-5473
- TRANSLOCATION: BAJAJ, H et al. (2016) Molecular Basis of Filtering Carbapenems by Porins from beta-Lactam-resistant Clinical Strains of Escherichia coli, J BIOL CHEM 291: 2837-2847
- TRANSLOCATION: BHAMIDIMARRI, SP et al. (2016) Role of Electroosmosis in the Permeation of Neutral Molecules: CymA and Cyclodextrin as an Example, BIOPHYS J 110: 600-611
- TRANSLOCATION: DAURY, L et al. (2016) Tripartite assembly of RND multidrug efflux pumps, NAT COMMUN 7:
- TRANSLOCATION: DAVIN-REGLI, A et al. (2015) Enterobacter aerogenes and Enterobacter cloacae, versatile bacterial pathogens confronting antibiotic treatment, FRONT MICROBIOL 6:
- TRANSLOCATION: DREIER, J et al. (2015) Interaction of antibacterial compounds with RND efflux pumps in Pseudomonas aeruginosa, FRONT MICROBIOL 6:
- TRANSLOCATION: EICHER, T et al. (2014) Coupling of remote alternating-access transport mechanisms for protons and substrates in the multidrug efflux pump AcrB, ELIFE 3:
- TRANSLOCATION: GASSER, V et al. (2015) Cellular organization of siderophore biosynthesis in Pseudomonas aeruginosa: Evidence for siderosomes, J INORG BIOCHEM 148: 27-34
- TRANSLOCATION: GHAI, I et al. (2017) General Method to Determine the Flux of Charged Molecules through Nanopores Applied to beta-Lactamase Inhibitors and OmpF, J PHYS CHEM LETT 8: 1295-1301
- TRANSLOCATION: GLENWRIGHT, AJ et al. (2017) Structural basis for nutrient acquisition by dominant members of the human gut microbiota, NATURE 541: 407-+
- TRANSLOCATION: GUTSMANN, T et al. (2015) Protein reconstitution into freestanding planar lipid membranes for electrophysiological characterization, NAT PROTOC 10: 188-198
- TRANSLOCATION: KINANA, AD et al. (2016) Aminoacyl beta-naphthylamides as substrates and modulators of AcrB multidrug efflux pump, P NATL ACAD SCI USA 113: 1405-1410
- TRANSLOCATION: MASI, M et al. (2017) Mechanisms of envelope permeability and antibiotic influx and efflux in Gram-negative bacteria, NAT MICROBIOL 2:
- TRANSLOCATION: MISLIN, GLA et al. (2014) Siderophore-dependent iron uptake systems as gates for antibiotic Trojan horse strategies against Pseudomonas aeruginosa, METALLOMICS 6: 408-420

- TRANSLOCATION: POTHULA, KR et al. (2016) Simulations of outer membrane channels and their permeability, *BBA-BIOMEMBRANES* 1858: 1760-1771
- TRANSLOCATION: RUGGERONE, P et al. (2013) RND Efflux Pumps: Structural Information Translated into Function and Inhibition Mechanisms, *CURR TOP MED CHEM* 13: 3079-3100
- TRANSLOCATION: SJUTS, H et al. (2016) Molecular basis for inhibition of AcrB multidrug efflux pump by novel and powerful pyranopyridine derivatives, *P NATL ACAD SCI USA* 113: 3509-3514
- TRANSLOCATION: ZHOU, Y et al. (2015) Thinking Outside the Bug : A Unique Assay To Measure Intracellular Drug Penetration in Gram-Negative Bacteria, *ANAL CHEM* 87: 3579-3584
- U-BIOPRED: ANTO, JM et al. (2012) Understanding the complexity of IgE-related phenotypes from childhood to young adulthood: A Mechanisms of the Development of Allergy (MeDALL) Seminar, *J ALLERGY CLIN IMMUN* 129: 943-U421
- U-BIOPRED: AUFFRAY, C et al. (2016) Making sense of big data in health research: Towards an EU action plan, *GENOME MED* 8:
- U-BIOPRED: AUFFRAY, C et al. (2010) An Integrative Systems Biology Approach to Understanding Pulmonary Diseases, *CHEST* 137: 1410-1416
- U-BIOPRED: BEL, EH et al. (2011) Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI), *THORAX* 66: 910-917
- U-BIOPRED: BIGLER, J et al. (2017) A Severe Asthma Disease Signature from Gene Expression Profiling of Peripheral Blood from U-BIOPRED Cohorts, *AM J RESP CRIT CARE* 195: 1311-1320
- U-BIOPRED: BOUSQUET, J et al. (2011) Systems medicine and integrated care to combat chronic noncommunicable diseases, *GENOME MED* 3:
- U-BIOPRED: CARRARO, S et al. (2013) Asthma severity in childhood and metabolomic profiling of breath condensate, *ALLERGY* 68: 110-117
- U-BIOPRED: CHUNG, KF et al. (2014) Defining Phenotypes in Asthma: A Step Towards Personalized Medicine, *DRUGS* 74: 719-728
- U-BIOPRED: DURHAM, AL et al. (2016) Targeted anti-inflammatory therapeutics in asthma and chronic obstructive lung disease, *TRANSL RES* 167: 192-203
- U-BIOPRED: HARRIS, JR et al. (2012) Toward a roadmap in global biobanking for health, *EUR J HUM GENET* 20: 1105-1111
- U-BIOPRED: HONKOOP, PJ et al. (2017) Adaptation of a difficult-to-manage asthma programme for implementation in the Dutch context: a modified e-Delphi, *NPJ PRIM CARE RESP M* 27:
- U-BIOPRED: JAMES, AJ et al. (2016) Increased YKL-40 and Chitotriosidase in Asthma and Chronic Obstructive Pulmonary Disease, *AM J RESP CRIT CARE* 193: 131-142
- U-BIOPRED: KUO, CHS et al. (2017) A Transcriptome-driven Analysis of Epithelial Brushings and Bronchial Biopsies to Define Asthma Phenotypes in U-BIOPRED, *AM J RESP CRIT CARE* 195: 443-455
- U-BIOPRED: LAMBRECHT, BN et al. (2014) Allergens and the airway epithelium response: Gateway to allergic sensitization, *J ALLERGY CLIN IMMUN* 134: 499-507
- U-BIOPRED: LEFAUDEUX, D et al. (2017) U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics, *J ALLERGY CLIN IMMUN* 139: 1797-1807
- U-BIOPRED: LYSENKO, A et al. (2016) Representing and querying disease networks using graph databases, *BIODATA MIN* 9:
- U-BIOPRED: MONTUSCHI, P et al. (2013) The Electronic Nose in Respiratory Medicine, *RESPIRATION* 85: 72-84
- U-BIOPRED: SCHUIJS, MJ et al. (2015) ALLERGY Farm dust and endotoxin protect against allergy through A20 induction in lung epithelial cells, *SCIENCE* 349: 1106-1110

- U-BIOPRED: WHEELLOCK, CE et al. (2013) Application of omics technologies to biomarker discovery in inflammatory lung diseases, *EUR RESPIR J* 42: 802-825
- U-BIOPRED: WOLKENHAUER, O et al. (2013) The road from systems biology to systems medicine, *PEDIATR RES* 73: 502-507
- ULTRA-DD: BARNASH, KD et al. (2017) Discovery of Peptidomimetic Ligands of EED as Allosteric Inhibitors of PRC2, *ACS COMB SCI* 19: 161-172
- ULTRA-DD: BATAILLE, CJR et al. (2017) Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family, *BIOORGAN MED CHEM* 25: 2657-2665
- ULTRA-DD: BAVETSIAS, V et al. (2016) 8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors, *J MED CHEM* 59: 1388-1409
- ULTRA-DD: BOCQUET, N et al. (2015) Real-time monitoring of binding events on a thermostabilized human A(2A) receptor embedded in a lipid bilayer by surface plasmon resonance, *BBA-BIOMEMBRANES* 1848: 1224-1233
- ULTRA-DD: DE FREITAS, RF et al. (2016) Discovery of a Potent Class I Protein Arginine Methyltransferase Fragment Inhibitor, *J MED CHEM* 59: 1176-1183
- ULTRA-DD: DE WITTE, WEA et al. (2016) In vivo Target Residence Time and Kinetic Selectivity: The Association Rate Constant as Determinant, *TRENDS PHARMACOL SCI* 37: 831-842
- ULTRA-DD: ERAM, MS et al. (2016) A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases, *ACS CHEM BIOL* 11: 772-781
- ULTRA-DD: FUJISAWA, T et al. (2017) Functions of bromodomain-containing proteins and their roles in homeostasis and cancer, *NAT REV MOL CELL BIO* 18: 246-262
- ULTRA-DD: GRIEBEN, M et al. (2017) Structure of the polycystic kidney disease TRP channel Polycystin-2 (PC2), *NAT STRUCT MOL BIOL* 24: 114-+
- ULTRA-DD: HAMMITZSCH, A et al. (2015) CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses, *P NATL ACAD SCI USA* 112: 10768-10773
- ULTRA-DD: HATCH, SB et al. (2017) Assessing histone demethylase inhibitors in cells: lessons learned, *EPIGENET CHROMATIN* 10:
- ULTRA-DD: HE, YP et al. (2017) The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex, *NAT CHEM BIOL* 13: 389-+
- ULTRA-DD: HUANG, L et al. (2015) Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids, *NAT MED* 21: 1364-1371
- ULTRA-DD: IGOE, N et al. (2017) Design of a Biased Potent Small Molecule Inhibitor of the Bromodomain and PHD Finger-Containing (BRPF) Proteins Suitable for Cellular and in Vivo Studies, *J MED CHEM* 60: 668-680
- ULTRA-DD: KAGOYA, Y et al. (2016) BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models, *J CLIN INVEST* 126: 3479-3494
- ULTRA-DD: LEE, CF et al. (2017) Oxalyl Boronates Enable Modular Synthesis of Bioactive Imidazoles, *ANGEW CHEM INT EDIT* 56: 6264-6267
- ULTRA-DD: LEITNER, A et al. (2016) Crosslinking and Mass Spectrometry: An Integrated Technology to Understand the Structure and Function of Molecular Machines, *TRENDS BIOCHEM SCI* 41: 20-32
- ULTRA-DD: LINES, KE et al. (2017) Epigenetic pathway inhibitors represent potential drugs for treating pancreatic and bronchial neuroendocrine tumors, *ONCOGENESIS* 6:
- ULTRA-DD: MCALLISTER, TE et al. (2016) Recent Progress in Histone Demethylase Inhibitors, *J MED CHEM* 59: 1308-1329
- ULTRA-DD: MOUSTAKIM, M et al. (2017) Discovery of a PCAF Bromodomain Chemical Probe, *ANGEW CHEM INT EDIT* 56: 827-831

- ULTRA-DD: OSMAN, KT et al. (2017) Discovery and structure activity relationship of the first potent cryptosporidium FIKK kinase inhibitor, *BIOORGAN MED CHEM* 25: 1672-1680
- ULTRA-DD: REYNOIRD, N et al. (2016) Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer, *GENE DEV* 30: 772-785
- ULTRA-DD: ROCKLIN, GJ et al. (2017) Global analysis of protein folding using massively parallel design, synthesis, and testing, *SCIENCE* 357: 168-174
- ULTRA-DD: TUMBER, A et al. (2017) Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells, *CELL CHEM BIOL* 24: 371-380
- ULTRA-DD: VAZ, B et al. (2016) Metalloprotease SPRTN/DVC1 Orchestrates Replication-Coupled DNA-Protein Crosslink Repair, *MOL CELL* 64: 704-719
- ULTRA-DD: WILKES, M et al. (2017) Molecular insights into lipid-assisted Ca²⁺ regulation of the TRP channel Polycystin-2, *NAT STRUCT MOL BIOL* 24: 123-+
- ULTRA-DD: ZHANG, W et al. (2016) System-Wide Modulation of HECT E3 Ligases with Selective Ubiquitin Variant Probes, *MOL CELL* 62: 121-136
- VSV-EBOVAC: HUTTNER, A et al. (2017) A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa, *SCI TRANSL MED* 9:
- VSV-EBOVAC: MOHR, E et al. (2016) Vaccination in early life: standing up to the challenges, *CURR OPIN IMMUNOL* 41: 1-8
- WEB-RADR: LENGSAVATH, M et al. (2017) Social Media Monitoring and Adverse Drug Reaction Reporting in Pharmacovigilance: An Overview of the Regulatory Landscape, *THER INNOV REGUL SCI* 51: 125-131
- WEB-RADR: PIERCE, CE et al. (2017) Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts, *DRUG SAFETY* 40: 317-331
- WEB-RADR: POWELL, GE et al. (2016) Social Media Listening for Routine Post-Marketing Safety Surveillance, *DRUG SAFETY* 39: 443-454
- ZAPI: BECARES, M et al. (2016) Mutagenesis of Coronavirus nsp14 Reveals Its Potential Role in Modulation of the Innate Immune Response, *J VIROL* 90: 5399-5414
- ZAPI: HAAGMANS, BL et al. (2016) An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels, *SCIENCE* 351: 77-81
- ZAPI: LUDLOW, M et al. (2016) Neurotropic virus infections as the cause of immediate and delayed neuropathology, *ACTA NEUROPATHOL* 131: 159-184
- ZAPI: MUTH, D et al. (2015) Infectious Middle East Respiratory Syndrome Coronavirus Excretion and Serotype Variability Based on Live Virus Isolates from Patients in Saudi Arabia, *J CLIN MICROBIOL* 53: 2951-2955
- ZAPI: RISSMANN, M et al. (2017) Vaccination of alpacas against Rift Valley fever virus: Safety, immunogenicity and pathogenicity of MP-12 vaccine, *VACCINE* 35: 655-662
- ZAPI: VERGARA-ALERT, J et al. (2017) Livestock Susceptibility to Infection with Middle East Respiratory Syndrome Coronavirus, *EMERG INFECT DIS* 23: 232-240
- ZAPI: WERNIKE, K et al. (2017) The N-terminal domain of Schmallenberg virus envelope protein Gc is highly immunogenic and can provide protection from infection, *SCI REP-UK* 7:
- Unassigned project: GUTIERREZ-GUTIERREZ, B et al. (2017) Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study, *LANCET INFECT DIS* 17: 726-734
- Unassigned project: VISSCHER, PM et al. (2017) 10 Years of GWAS Discovery: Biology, Function, and Translation, *AM J HUM GENET* 101: 5-22